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Astract 
The DNA information appears nowadays more stratified than it was supposed to be a 
decade before. In this scenario, non coding RNAs have been introduced in the fraction 
of functional RNA, carrying information and underpinning regulatory circuits of 
complex genetic phenomena in eukaryotes. microRNAs are endogenous single 
stranded ~22 nt long transcripts among that unveiled non coding RNA with regulatory 
functions, detected both in animals and plants. Increasing evidence shows that 
deregulation of microRNAs (miRNAs) plays an important role in both solid and 
hematologic malignancies. In this work we considered microRNA non canonical 
functions and involvement in tumours, integrating computational analyses of genome-
wide datasets and targeted experimental results, with a critical approach to the specific 
adopted computational tools. 
First, we studied miRNAs role in myeloproliferative disorders, more specifically in 
primary myelofibrosis, considering also other small RNAs detected in RNA-seq data. 
Myeloproliferative neoplasms are chronic myeloid cancers involving CD34+ 
hematopoietic stem cells alterations, evolving to acute leukemia in the most severe 
forms. This study deals indeed with an Illumina sequencing of small RNAs samples of 
CD34+ hematopoietic stem cells of patients affected by primary myelofibrosis and of 
controls, in order to characterize miRNAs profile and find relevant differentially 
expressed elements, as putative effectors of a disrupted post-transcriptional regulation 
involved in PMF initiation and progression. 
Then, in order to have a better understanding of each step of a computational analysis 
of RNA-seq data, we studied the impact on small RNAs differential expression 
analysis of normalization methods developed for long RNA. We evaluated five 
commonly used normalization methods to pinpoint a procedure to perform a robust 
RNA-seq analysis. We estimated statistical distribution parameters from a real 
microRNA numerous dataset and we simulated a huge number of small RNAs dataset. 
We controlled datasets characteristics in order to generate 9 different testing scenarios 
and measure the normalization impact on differentially expressed elements 
recognition, through ROC and AUC curves. We ascertain that normalization methods 
still need strong efforts in developing new algorithms in order to fill the wide room for 
improvement. 
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Thereafter we evaluated the implication of microRNAs in the gene expression 
changes observed after H-ferritin silencing. We explored whether different FHC 
amounts might modulate miRNA expression levels in K562 cells and we studied the 
impact of miRNAs in gene expression profile modifications. To this aim, we 
performed a miRNA-mRNA integrative analysis in K562 silenced for FHC 
(K562shFHC) comparing it with K562 transduced with scrambled RNA (K562shRNA). 
The remarkable up-regulation of four miRNAs, hsa-let-7g-5p, hsa-let-7f-5p, hsa-let-
7i-5p and hsa-miR-125b-5p, in silenced cells and their down-regulation when FHC 
expression was rescued supported a specific relation between FHC silencing and 
miRNA-modulation. The integration of target predictions with miRNA and gene 
expression profiles led to the identification of a regulatory network. Our data, 
confirmed by an experimental validation, indicate that, FHC silencing may affect 
RAF1/pERK1/2 levels through the modulation of a specific set of miRNAs and they 
add new insights to the relationship among iron homeostasis and miRNAs. 
We further explored a putative non canonical role of microRNAs, more specifically, 
in the context of the always more evident complex cross talk between protein-coding 
and non-protein coding RNAs. We worked on a preliminary study that deals with the 
involvement of microRNAs in the regulation of alternative translation (AT) and thus 
of protein isoform equilibrium. There is an increasing appreciation of the high 
prevalence of alternative translation in mammals. Complex and regulated translation 
pattern are achieved thanks to multiple Open Reading Frame (ORFs) and Translation 
Initiation Sites (TISs) in the same mRNA that can influence each other in different 
ways. miRNAs were recently demonstrated to be involved in modulation of protein 
isoform equilibrium binding to TISs. We provided novel data on the overlap of active 
TISs of mRNAs, experimentally defined using GTI-seq, to miRNA-binding sites, 
experimentally determined using CLASH technique. The genes whose sites were 
recognized are supposed to be involved in miRNA-modulated AT and we modelled 
the interaction mechanism. The miRNA-based regulation of mRNA alternative 
translation surely deserves further investigation to clarify if and how it impacts on cell 
processes and on disease.  
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Sommario 
L’informazione contenuta nel DNA appare oggi sempre più stratificata di quanto non 
si pensasse. In questo scenario, gli RNA non codificanti sono stati riconosciuti come 
RNA funzionali, portatori di informazione e parti fondamentali dei più complessi 
circuiti regolativi negli eucarioti. Tra i più studiati RNA non codificanti con funzioni 
regolative ci sono i microRNA (miRNA), RNA a singolo filamento lunghi circa 22 
nucleotidi, presenti sia in piante che animali. Ci sono prove sempre più evidenti che la 
deregolazione dei miRNA abbia un ruolo fondamentale nei tumori solidi e del sangue. 
In questo lavoro abbiamo preso in considerazione le funzioni non canoniche dei 
miRNA, il loro coinvolgimento nei tumori, integrando analisi computazionali di dati 
genome-wide e dati sperimentali più specifici, con un approccio critico rispetto gli 
strumenti computazionali. 
Abbiamo innanzitutto studiato il ruolo dei miRNA nelle neoplasie mieloproliferative, 
più specificamente nella mielofibrosi, considerando anche altri small RNA presenti 
nei dati RNA-seq. Le malattie mieloproliferative sono tumori cronici della linea 
mieloide che vedono l’alterazione delle cellule emopoietiche CD34+, ed evolvono in 
leucemia acuta nei casi più gravi. In questo studio abbiamo pertanto analizzato dati di 
RNA-seq, prodotti con tecnologia Illumina, di cellule raccolte da pazienti affetti da 
mielofibrosi primaria e da controlli sani, al fine di caratterizzare i profili di microRNA 
e trovare gli elementi differenzialmente espressi, in quanto possibili elementi di 
regolazione post trascrizionale alterata e coinvolti nella genesi e nello sviluppo della 
mielofibrosi. 
Successivamente, al fine di aver piena consapevolezza dei vari passi di un’analisi 
computazionale, abbiamo studiato l’impatto dell’applicazione su dati di RNA corti di 
algoritmi di normalizzazione, sviluppati per RNA lunghi, valutato a livello dei risultati 
dell’analisi differenziale. Abbiamo preso in considerazione cinque tra i più 
comunemente usati algoritmi, per individuare la procedura che permetta di svolgere in 
modo più robusto l’analisi di dati RNA-seq. Abbiamo stimato i parametri della 
distribuzione statistica di un dataset reale di microRNA particolarmente numeroso, e 
abbiamo simulato un numero sostanzioso di dataset. Abbiamo generato nove tipi di 
data set con diverse caratteristiche controllate e abbiamo misurato l’impatto della 
normalizzazione nei vari casi, quantificando l’impatto sull’analisi differenziale 
attraverso curve ROC e AUC. Abbiamo evidenziato la necessità di nuovi algoritmi di 
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normalizzazione, più specifici per i miRNA, in grado di colmare le grosse lacune dei 
metodi attuali. 
Ci siamo in seguito concentrati sul coinvolgimento dei microRNA nei cambiamenti 
dei valori di espressione genica, rilevati in cellule K562 in cui fosse silenziata la 
ferritina FHC. Abbiamo indagato se diversi livelli di FHC potessero modulare i livelli 
di espressione dei microRNA e abbiamo monitorato l’impatto dei miRNAs rispetto le 
modificazioni dei livelli d’espressione dei geni. A tal fine abbiamo, condotto 
un’analisi integrata di miRNA-mRNA in cellule K562 silenziate per la FHC 
(K562shFHC) confrontandole con cellule K562 trasdotte con RNA scrambled 
(K562shRNA). La notevole up-regolazione di quattro miRNA, hsa-let-7g-5p, hsa-let-7f-
5p, hsa-let-7i-5p e hsa-miR-125b-5p, nelle cellule silenziate e il fatto che i loro livelli 
di espressione scendessero quando fosse riattivata l’espressione di FHC, supporta 
l’esistenza di una relazione tra FHC e la modulazione dei miRNA. Integrando le 
informazioni sui target dei miRNA e i profili di espressione dei geni, abbiamo 
identificato dei network regolativi. I nostri dati, confermati con validazioni 
sperimentali, indicano che il silenziamento di FHC potrebbe impattare sui livelli di 
RAF1/pERK1/2 attraverso la modulazione di specifici gruppi di microRNA, fornendo 
nuove informazioni sul rapporto tra omeostasi del ferro e miRNA. 
Infine, ci siamo occupati di un ruolo non canonico dei microRNA, più specificamente 
nel contesto delle sempre più evidenti interazioni tra RNA codificanti e RNA non 
codificanti. Abbiamo condotto uno studio preliminare sul coinvolgimento dei 
microRNA nella regolazione della traduzione alternativa e di conseguenza 
dell’equilibrio delle varie isoforme proteiche. C’è una maggior consapevolezza della 
diffusione del meccanismo della traduzione alternativa nei mammiferi. Si realizzano 
pattern complessi di regolazione delle isoforme grazie alla presenza, nello stesso 
mRNA, di più Open Reading Frame (ORF) e Translation Initiation Sites (TISs) 
utilizzati. Questi sono in grado di influenzarsi a vicenda in maniera diversa. E’ stato 
recentemente dimostrato che i miRNA sono coinvolti nella modulazione 
dell’equilibrio delle isoforme proteiche, legandosi ai TIS. Noi abbiamo individuato la 
corrispondenza di siti TIS attivi nei trascritti di mRNA, trovati sperimentalmente con 
GTI-seq, e siti di legame di miRNA nelle sequenze di mRNA, determinati 
sperimentalmente con tecnica CLASH. Questi geni in cui sono stati riconosciuti siti di 
legame, si suppongono coinvolti in un meccanismo di traduzione alternativa modulata 
da miRNAs. Alcune interazioni miRNA-tis sono state confermate sperimentalmente, 
    5 
ma ulteriori studi sono necessari per valutare se il meccanismo di modulazione della 
traduzione alternativa da parte dei miRNA possa impattare  su processi cellulari e 
nella malattia.  
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Introduction 
The present work aims at exploring multiple aspects of the microRNAs world 
prevalently with a bioinformatics approach. 
We are having an overview on microRNA biogenesis, their biological role and 
mechanism of action, computational tool of analysis. Finally I’ll give you a hint about 
the four main themes we focused on in this thesis. 
 
The non coding small RNA: a focus on 
microRNA 
RNA-seq technologies offer the possibility to investigate in a wide range of biological 
application of interrogating the transcriptome1-­‐3. Many works and ambitious projects 
arose. As such, the Encyclopedia of the DNA Elements (ENCODE)4, 5which 
combined efforts aim to characterize RNAs across 15 different human cell lines. They 
provide new insights into the mechanisms of gene regulation6. Many newly identified 
elements were discovered unveiling the pervasiveness of transcription and many 
noncoding elements were found to control regulatory networks7, 8. Among the non 
coding elements they studied: 
•  Micro-RNAs (miRNAs), which are short RNA fragments known to have a 
role in post-transcription regulation 
• Transfer RNAs (tRNAs), the adapter molecules between mRNA and amino 
acids. 
• Small nuclear RNAs (snRNAs) associated with the spliceosome 
• Small nucleolar RNAs (snoRNAs), which guide chemical modifications 
(methylation and pseudouridylation) of ribosomal and transfer RNAs as well 
as snRNAs. 
 
The DNA information appears nowadays more complex than it was supposed to be a 
decade before. The commonly accepted modular structure of the DNA has been called 
into question: the same genetic sequence does not correspond to a single regulatory 
function or transcript but it is commonly believed that multiple layers of information 
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are embedded in every sequence9. The genome has been compared to a palimpsest by 
Tuck and Tollervey9, as it resembles an overwritten text. In figure 1 you can see their 
interpretation of that concept. 
 
Figure 1: two transcripts from the same locus can use the same sequence to different functional effects. 
The overlapping arrangement of genetic information enables a single sequence to encode multiple 
functions. This principle is embodied at many genomic loci, which generate ensembles of transcripts 
with shared sequences but disparate functions. This raises questions about how a specific function is 
assigned to a transcript, given the numerous possibilities. There are several explanations, illustrated by 
the various ways in which overlapping transcripts are generated: (a) Two transcripts identical in 
sequence and length might function differently, perhaps being translated in alternative reading frames 
(green or purple) to generate distinct proteins. Here, extrinsic factors are responsible for specifying 
which reading frame should be used. (b) Alternative transcription initiation and/or termination generate 
an ensemble of interleaved transcripts from a single genomic locus. Within this ensemble, a shared 
sequence (red) can perform distinct functions, perhaps contributing to an open reading frame (green) in 
one transcript and a structural feature in another. Here, the function of a sequence is governed by its 
context, with the different lengths and orientations of transcripts perhaps affecting their folding or 
recruitment of binding factors. (c) Many classes of transcript might act as precursors to shorter 
fragments, excised by post-transcriptional cleavage. These fragments might function in ways distinct 
from those of their parents. Thus, within the context of the shorter fragment, a shared sequence (blue) 
can perform an alternative role. This indicates that the length of a transcript might contribute to 
specifying which of several possible functions is performed by a particular sequence. Other post-
transcriptional processes (such as splicing) can also generate alternative transcripts, but are beyond the 
scope of this review. Figure adapted from Tuck at al9. 
 
In this complex scenario, non coding RNA must be introduced in the fraction of 
functional RNA, carrying information and underpinning regulatory circuits of 
complicated genetic phenomena in eukaryotes10, 11. microRNAs are endogenous single 
stranded ~22 nt long among that unveiled non coding RNA with regulatory functions, 
detected both in animals and plants12.  They were first revealed during a 
characterization of genes that control the timing of larval development in worm 
Caernorhabditis elegans. This was the case of lin-4 and let-7 13, 14. Soon in other 
bilateral animals including mammals, homologs of let-7 were identified. Their 
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expression followed that observed in C. elegans as if let-7 might be playing 
orthologous roles in different metazoan lineages15. Several thousand of other small 
RNAs were later recognized in worms, flies, plants, green algae, viruses and mammals 
and they were called microRNA16-18. They are evolutionary conserved elements19, for 
example miRNA regulatory system in the floral developmental phase has a well 
conserved patterns for each step of the pathway, suggesting they play important roles 
in the evolution of flower20. 
Salmena et al. 21 proposed a theory that hypothesizes that key elements of multiple 
RNAs communication are microRNAs. All the types of RNA transcripts are supposed 
to exchange information mediated by microRNA-binding sites called “microRNA 
response elements” (MREs). They based their hypothesis on theoretical and 
experimental studies in which “RNAs influences each others’ level by competiting for 
a limited pool of microRNAs”, that’s why they called their theory “competitive 
endogenous RNA” (ceRNA). The actual regulational machinery mechanism is still 
debated but al lot of breakthroughs have been made. 
miRNAs biogenesis 
miRNAs biogenesis starts from RNA polymerase II transcription of several bases long 
primary transcript called pri-miRNAs. These transcripts fold back themselves to form 
hairpin structures12. The pri-miRNA is then cleaved in the nucleus by the Drosha 
RNase III endonuclease22 liberating a ~70 nt long stem loop intermediate, known as 
pre-miRNA23, 24. Secondarily, the pre-miRNA is actively exported to the cytoplasm by 
Ran-GTP and by the export receptor Exportin-5 25, 26, where the RNase III 
endonuclease Dicer lops off the terminal base pairs and the loop of the hairpin 
precursor. This process release a ~22 nt miRNA duplex22. Depending on 
thermodynamic properties of the duplex, one of the two strands is incorporated into 
the Argonaute (Ago) protein27, a component of the ribonucleoprotein complex called 
RNA-induced silencing complex (RISC). This is the effector complex and it guides 
the miRNA incorporated to the targets. The other strand that is not incorporated, 
appears typically to be degraded. It is not clear which are the rules governing strand 
selection. It has been reported that both miRNA strands are functional28 and can be 
both accumulated in specific cell tissues and types.  
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miRNAs can be transcribed as long polycistronic primary transcripts and the first 
experimental confirmation was found in total HeLa cells, with two miRNAs clusters 
transcribed from a transcription unit (TU) 23. They can also be encoded outside a 
cluster, as monocistronic transcripts with their own promoters29, 30. miRNA genes 
structure definition is ongoing and was found in different genomic locations: both 
intronic and exonic. Also a special class of miRNAs has been reported, called 
mirtrons, whose exact sequence of the pre-miRNA31 is an intron. Figure 2 from Olena 
and Patton30 resumes schematically a classification of miRNAs depending on their 
genomic location. 
 
Figure 2. Genomic location of miRNAs. A: Intergenic miRNAs are found in genomic regions distinct 
from known transcription units. These miRNAs can be monocistronic (top part) with their own 
promoters (black arrowhead), or polycistronic, where several miRNAs are transcribed as cluster of 
primary transcripts (bottom part) with a shared promoter (black arrowhead). B: Intronic miRNAs are 
found in the introns of annotated genes, both protein coding and noncoding. These miRNAs can be 
present as a single miRNA (top part) or as a cluster of several miRNAs (bottom part). Intronic miRNAs 
are thought to be transcribed from the same promoter as their host genes (black arrowhead, all parts) 
and processed from the introns of host gene transcripts. In the special case of mirtrons (middle part), the 
intron is the exact sequence of the pre-­‐‑miRNA with splice sites on either side (denoted by white 
asterisks). In this case, the Microprocessor complex is thought to be unnecessary in mirtron maturation 
(Okamura et al., 2007). C: Exonic miRNAs are far more rare than either of the types above and often 
overlap an exon and an intron of a noncoding gene. These miRNAs are also thought to be transcribed 
by their host gene promoter and their maturation often excludes host gene function. Figure adapted 
from Olena and Patton30. 
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Evolutionary conservation of miRNAs 
All miRNAs are characterized by a common biosynthetic pathway and reaction 
mechanism. Many miRNAs sequences are conserved, in their mature form, among 
different organisms. Moreover, the evolutionary appearance of multicellular 
organisms has the same trend of the appearance of the miRNA pathway for regulating 
gene expression. Some miRNA pathways are conserved virtually intact throughout 
phylogeny while miRNA diversity also correlates with speciation. The bigger is 
animal morphological complexity and the growing is the number of miRNA genes, 
expression of miRNAs and diversities of miRNAs targets, corroborating to the idea 
that organismal complexity can be estimated by the complexity of the miRNA 
circuitry. The complexity of the miRNA gene families establishes a link between 
genotypic complexity and phenotypic complexity in animal evolution32. Many works 
in the area of miRNA phylogenetic conservation and diversity suggests that miRNAs 
play important roles in animal evolution, by driving phenotypic variation during 
development19. A well-recognized example of evolutionally conserved miRNA is let-
7. It displays a temporal expression pattern during many organisms development. It 
belongs to a larger gene family that has been amazingly conserved across almost all 
groups of bilaterally symmetrical animals, highly conserving its temporal expression 
pattern, and this is represented in Figure 3. Curiously, let-7 RNA is not found in more 
basal metazoans, including non bilaterians suggesting that acquisition of the let-7 gene 
was an essential step of evolution from lower metazoan to a higher bilaterians19. 
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Figure 3. Acquisitions of miRNAs in metazoan phylogeny. An abbreviated phylogeny is modified 
from earlier studies. Green lines represent animal phyla that do not have let-7 miRNAs. Major 
innovations of miRNA repertoires are represented by magenta arrowheads, which are based on previous 
data. A class of approximately 20 miRNAs, including let-7, is common to all bilaterians except acoels 
(a). The next innovation (b) is the addition of about 56 new families of miRNAs at the branch leading 
to the vertebrates. A third miRNA innovation (c) occurred at the branch leading to the placental 
(eutherian) mammals, at which time about 40 new miRNA families were acquired. Furthermore, a large 
number of primate-specific miRNAs are also identified (d). Each of the nematode and arthropod 
lineages might also have evolved unique miRNA families. Figure adapted from Niwa et al19 
Many miRNAs are highly conserved throughout the animal kingdom, as for example 
mir-1 that is detected from C. elegans to human. It operates during muscle 
development and is essential in maintaining muscle fibers integrity. Moreover, a 
recent comprehensive study of microRNA gene expression in zebrafish, lists 142 
miRNA loci in the genome of Danio rerio that are homologous to more than 100 
different mammalian microRNAs, belonging to almost 100 different families33.  
It is fascinating how episodes of miRNAs innovation correlate with major 
introductions of developmental complexity during evolution. That observation 
suggests that a dramatic expansion of the non coding repertoire, among all miRNAs, 
could represent the mechanism originating the complexity in higher order organisms, 
rather than an increase in protein coding inventory. Supporting that hypothesis, 
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diverse comparative genomic study concluded that both flies and vertebrates witness a 
growth in their respective number of cell types over geologic time, coherently to the 
gaining of their respective number of miRNAs34, 35. It is reasonable to claim that 
miRNAs are active driver of animal evolution over the course of animal phylogeny 
towards gene network complexity, through their regulation of an increasing number of 
targets. It is noteworthy that both DNA and RNA viruses exploit miRNA potential as 
key regulatory elements in the control of gene expression. Viruses indeed have 
evolved mechanisms to degrade, boost, or hijack cellular miRNAs to benefit the viral 
life cycle36. 
Non canonical miRNAs biogenesis 
Canonical biogenesis is not the only mechanism miRNAs are produced with. In the 
last decade, more evidences emerged of alternative biogenesis mechanisms either 
Drosha-independent or Dicer-independent, adding complexity to miRNAs regulatory 
network37, 38. This versatility in miRNA biogenesis may reflect a fine tuned 
regulation mechanism of specific miRNAs expression in different developmental 
stages or altered cell states, in order to achieve differential gene regulation. 
Drosha cleavage is bypassed both during mirtron production, when small RNAs are 
generated through mRNA splicing, lariat debranching and folding as pre-miRNAs, 
and in rare exceptions where small RNAs derive from endogenous short hairpin RNA 
transcription, as the case of the 7-methylguanosine (m7G)-capped pre-mir-320. 
Another example of bypassing Drosha processing is when miRNAs are produced from 
other non-coding RNAs. This is the case of tRNA or tRNA like that can be miRNA 
precursors. Mature miRNAs derived are demonstrated to be functional in modulating 
proliferation and DNA damage response39, 40. Processing of small nucleolar RNAs 
(snoRNAs), as for ACA4541, and small nuclear RNA-like viral RNAs42 can be an 
additional biogenetic pathway.  
Moreover, miRNA biogenesis goes through non canonical miRNA production in 
presence of unusual pri-miRNA structure. If the miRNA precursor has a shorter 3’ 
overhang needs an additional processing step to generate the mature miRNA: it has to 
be monouridylated by the uridylyl transferase for efficient Dicer processing. miRNAs 
characterized by the monouridylation of terminal 3’ are called uridylyl transferase 
(TUTase)-dependent group. 
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Figure 4: The 7-methylguanosine (m7G)-capped pre-mir-320 is directly generated through 
transcription, bypassing Drosha processing, and it is exported to the cytoplasm by exportin 1 (EXP1). 
Mirtron loci produce pre-miRNAs directly through splicing and debranching. Some mirtrons contain 5′ 
or 3′ single-stranded RNA tails that need to be trimmed before Dicer processing. Some small nucleolar 
RNAs (snoRNAs), such as ACA45, and tRNAs (or tRNA-like RNAs) may also be cleaved to produce 
pre-miRNAs. Terminal uridylyl transferase (TUTase)-dependent group II pri-miRNAs produce pre-
miRNAs with a shorter 3′ overhang that is suboptimal for Dicer processing. This means that they need 
to be monouridylated for efficient Dicer processing. In a Dicer-independent pathway, a short pre-mir-
451 is produced by Drosha, exported to the cytoplasm (possibly by EXP5) and loaded on Argonaute 2 
(AGO2) without Dicer processing. AGO2 cleaves ('slices') the stem of pre-mir-451, generating AGO-
cleaved pre-mir-451 (ac-pre-mir-451), which is further trimmed by the 3′–5′ exonuclease poly(A)-
specific ribonuclease PARN. The question marks indicate places in which the depicted action has not 
be fully confirmed. MHV, murine γ-herpesvirus; mmu, Mus musculus; Pol II, polymerase II. Figure 
adapted from Ha et al37 
 
Alternative miRNA biogeneses could be Dicer-independent pathways, as the case of a 
short pre-mir-451 produced by Drosha, exported to the cytoplasm and loaded on 
Argonaute 2. Dicer processing is substituted by a trimming performed by AGO2 and 
the 3′–5′ exonuclease poly(A)-specific ribonuclease PARN. miR-451 is a 
erythropoietic miRNA conserved in vertebrates, in confirmation of the importance of 
its functional role. Figure 4 shows all the different types of alternative miRNA 
biogeneses. 
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IsomiRNAs 
miRNAs are annotated as a single defined sequences but are actually mixture of 
sequences, slightly different from the official mature miRNA. As the case of the most 
part of miRNAs, several length or sequence variants have been detected. These 
variants are called isomiRNAs43. Sequencing-based technology revealed a bona fide 
repertoire of expressed small RNAs, originally dismissed as sequencing/alignment 
artifacts or poor quality RNAs. Nowadays isomiRs are confidently detected and they 
contribute to miRNA expression and qualitative characteristics. They were 
experimentally validated and characterized as tissues, conditions and cell types 
specific44-­‐46. They were demonstrated to vary in response to stimuli, suggesting their 
biogenesis to be dynamic and regulated. IsomiRs are categorized into three main 
classes: 
• 5’isomiRs, with variations at the 5’ end; 
• 3’isomiRs, differing from the canonical miRNA in the 3’ end; 
• Polymorphic isomiRs, harboring distinct nucleotides composition. 
The biological mechanism underlying isomiRs production has not been fully 
elucidated but several lines of evidence suggest that isomiRs could be processed by 
variations in Drosha/Dicer cleavage of the pre-miRNA47-­‐50. Others pri/pre-miRNA 
enzymes processing activities could be source of template miRNA variations. 
Exoribonucleases catalyzed nucleotides trimming, nucleotidyl transferases catalyzed 
nucleotides addition, RNA editing are considered wellspring of variations43, 51. 
Interestingly, a very low frequency of single nucleotide polymorphisms (SNP) has 
been identified in genomic miRNA regions52, 53.  
A growing number of reports suggest that isomiRs are biologically functional and to 
act as canonical miRNAs44,	  46. Also the fact that 5’ isomiRs are also under selection 
during evolution witnesses their functional importance46. 
For example, has-miR-101 has many different 5’-isomiR-101 ubiquitously detected 
and highly abundant that interact with RISC complexes, silencing their target54. 
Cloonan et al.55 biotin-labeled miRNAs and isomiRs to pull down endogenous mRNA 
targets, detecting highly expressed isomiRs incorporated into the RISC complex and 
targeting endogenous mRNAs.  
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Considering that different isomiRs can characterize different tissues or condition, as 
tumor respect to normal tissues, and that diverse isomiRs could impact differently on 
target genes and pathways, isomiRs deregulated expression could be implicated in 
diseases. 
moRNAs 
High-throughput sequencing revealed overlapping reads aligning to hairpins outside 
miRNA loci. That small RNAs were called microRNA-offset RNAs56-58. 
MoRNAs were first reported in a simple chordate, the ascidian Ciona intestinalis, as 
∼20-nt-long RNAs derived from the ends of pre-miRNAs. moRNAs were considered 
as by-products of potentially atypical miRNA processing, possibly generated by 
RNAse III-like processing59. In C intestinalis moRNAs displayed a developmental 
regulated expression. More evidence of moRNAs pervasiveness arrived with 
Langenberger study58. It reported the presence of 78 members of this new class of 
small RNAs, in short RNA sequencing of human prefrontal cortex. For 71 of the 78 
loci, the moRNAs were well-conserved, together with miRNA processed from the 
same hairpin. The 78 moRNAs loci belonged to only 54 distinct families. 
Interestingly, studying the families, Langenberger noted that four families showed 
moRNAs in three or more paralogs, and seven families had two paralogs with 
evidence for moRNA expression. He inferred association of moRNAs with an early 
evolutionary origin, as almost all miRNA families with multiple paralogs are 
evolutionarily old. 
moRNAs sequences partially overlap miRNA regions but generally span the Drosha 
cutting sites, letting us hypothesize a non canonical processing of the hairpin 
precursor in moRNA biogenesis60. However the origin of moRNA is still unclear and 
many hypothesis were generated. They might arise from exonuclease activity on their 
precursor 39, 61or from alternative Drosha processing59, 60, 62. For sure moRNAs are 
detected in different tissues: Taft et al reported moRNAs enriched expression in the 
nucleus in the human leukemia cell line THP-163, Meiri et al detected moRNAs 
expression in solid tumours64while Bortoluzzi and Bisognin in JAK2V617F-mutated 
SET2 cells57. Unfortunately, information about moRNA functional role is still 
fragmentary. They may act as miRNAs but no experimental evidence has been 
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reported. Their need to be further characterized and nowadays their mechanism of 
action remains to be elucidated (Asikainen, personal communication). 
miRNA regulatory function and target 
prediction tools 
When incorporated in the RISC complex, miRNAs are known to target mRNAs by 
imperfect base pairing to the 3’UTR mRNA region. They act to downregulate gene 
expression by either two posttranscriptional mechanism: by irreversibly triggering 
mRNA degradation65-­‐67 or by their translational repression12. Recent works show that 
mRNA destabilization explains most (66%–>90%) miRNA-mediated repression65. 
Plant miRNA target site are located within target genes open reading frames (ORF) 
and miRNAs bind to mRNA by perfect sequence complementarity68.  
It’s more complicated for animals. miRNAs bind to mRNAs by imperfect Watson-
Crick pairing of miRNA nucleotides 2-8, called “seed region”, to a short region of 
mRNA termed miRNA recognition elements (MREs), generally situated at 3’ 
untraslated region (UTR) but also sporadically in the 5’UTR or ORF69. The seed 
region of miRNAs is the most conserved in miRNA sequences70. Not even the 
position of mRNA MRE is easily identifiable along the mRNA sequence and it’s not 
unique for each mRNA: many mRNAs has potential multiple sites for the same 
miRNA71-73, and it has been reported that multiple sites enhance the degree of 
downregulation74. Target sites can be classified in three main groups: 1) canonical, 2) 
3’-supplemetary, 3) 3’-compensatory sites. Among the canonical, three main types 
can be distinguished:  
• the 7mer1A that has an adenine in position 1 at the 5’ end of miRNA; 
• the 8mer having matched adenine in position 1 and an additional match in 
position 8; 
• the 7mer-m8 that has a match in position 8; 
A minor class of canonical sites is represented by 6-nt seed which has a limited impact 
in downregulating targeted mRNA. 
In all the previous cases, there can be an additional binding site at the 3’, the so-called 
3’-supplementary site. It usually has a weaker effect on target recognition and a lower 
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efficiency. 3’ compensatory sites consist in a binding site that has a mismatch in the 
seed but an additional extended pairing at the 3’ of the miRNA that compensates it.  
Figure 5 from Witkos et al75 shows the just described different miRNA-mRNA 
representative interactions. 
 
Figure 5.	  Different classes of miRNA target sites are presented in a schematic way. Vertical dashes 
represent single Watson-Crick pairing. Nucleotides involved in binding have been arbitrarily defined to 
depict positions of required complementarity between miRNA and mRNA. Seed regions of miRNAs 
are marked by red color and the adenine at binding position 1 by green. Interactions between mRNA 
and the 3’ end of miRNA have not been shown because they are sequence-dependent and do not 
significantly contribute to the miRNA downregulation effect. In the case of 3’-suppelmentary and 3’-
compensatory sites two regions of pairing (base pairs colored in blue) force middle mismatches to form 
a loop structure. Additionally, features of particular site types have been listed. Figure adapted from 
Witkos et al.75 
  
The mechanism governing miRNA targeting is poorly characterized76,	  77.  
It is hard to predict which mRNA will be bound by a miRNA also because of the 
numerous predicted MREs sequences that match the complementarity of the short 
miRNA seed region. It is also complicated to predict the effect of miRNA binding78, 
considering that different miRNAs could act cooperatively to the same target, 
increasing the sensitivity of repression and enhancing the regulatory effect71. miRNAs 
themselves are recently supposed to be regulated by target interactions that do not 
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necessarily affect miRNA levels79, entailing that miRNA expression level could not be 
representative of its impact. The complexity of miRNA-mRNA interaction causes 
ambiguity in target prediction results and a high rate of false positive predicted target. 
Target identification is challenging and more rules than sequence complementarity 
need to be taken into account71. Many algorithms have been developed and available 
tools for miRNA target prediction encompass a range of different computational 
approaches, from the modeling of physical interactions to the incorporation of 
machine learning. Well-known methods are miRanda80, DIANA-microT 81, 
RNAhybrid82, MicroInspector83, Target Scan and TargetScans84,	   85, PicTar86, 
MicroTar87, PITA88, RNA2289 .Target prediction algorithms have been extensively 
discussed76,	   90-­‐92 but the debate always ended wishing for powerful predictive 
algorithm. Each method takes into account diverse weighted features to compute a 
score. That score is used to rank predictions and call putative mRNA targets. They 
differently use parameters as free energy of binding, folding energy, the presence of 
multiple binding sites within 3’UTR, secondary structure of 3’UTR that influence 
accessibility, local AU content, pattern recognition, target site accessibility energy. 
Especially, target prediction programs can be divided in two classes, distinguished on 
the basis of the use or not of the information about evolutionary conservation of 
interactions75. miRanda, DIANA-microT, RNAhybrid, MicroInspector, PicTar, 
TargetScan, are all based on conservation criteria, while PITA, MicroTar and RNA22 
are not. 
miRNAs can be grouped depending on their seed sequence, that are supposed to target 
the same mRNAs. miRNAs with same seed sequence are gathered together in the 
same miRNA family. It has been reported that miRNA families are well conserved 
among related species and have the same target. Friedman et al93 gave a 
comprehensive overview of miRNA target conservation: “In total, >45,000 miRNA 
target sites within human 3′UTRs are conserved above background levels, and >60% 
of human protein-coding genes have been under selective pressure to maintain pairing 
to miRNAs. Mammalian-specific miRNAs have far fewer conserved targets than do 
the more broadly conserved miRNAs, even when considering only more recently 
emerged targets. Although pairing to the 3′ end of miRNAs can compensate for seed 
mismatches, this class of sites constitutes less than 2% of all preferentially conserved 
sites detected”.  
    19 
Alternative miRNA localizations and functions 
miRNAs are known endogenous posttranscriptional downregulators of gene 
expression by either irreversibly triggering mRNA degradation or inducing 
translational repression. Proper miRNAs’ functioning requires their assembly into an 
RNA-induced silencing complex (RISC), a multiprotein complex. 
There are increasing evidences that miRNAs can act in a non-canonical way to 
modulate gene expression or to perform different biological effect. This is the case of 
microRNAs found in bloodstream and body fluids, associated with extracellular 
vesicles (EVs), which are small membrane vesicles secreted from various types of 
cells, in cell-free microvesicles (MVs) or in complexes with other factors, such as 
RNA-binding proteins and high-density lipoprotein (HDL) particles. For example, 
EVs released by cells of the immune system can play a regulatory role in the induction 
and suppression of immune responses94. miRNA binding, in that context, was 
hypothesised to act as cell-to-cell communication mediators95. 
Besides posttranscriptional regulation mechanism, by targeting 3’UTR mRNAs, 
microRNAs are transcriptional modulator of epigenetic remodelling events at targeted 
gene promoters, playing a role in a more stable and heritable form of gene 
regulation96. The well conserved miR-10a, for example, targets a homologous DNA 
region in the promoter region of the hoxd4 gene, involved in animal development as 
well as in in tumour invasion and metastasis. microRNA-10a inhibits hoxd4 gene 
expression by targeting the promoter region and mediating chromatin remodelling 
DNA histone methylation, involving Dicer and Ago1-397. 
Similarly, miRNAs can bind to evolutionary conserved loci that are complementary 
genomic seed-matches, corresponding to promoters, lineage-specific transcription 
factors and/or members of their epigenetic machinery. They bind polycomb proteins 
(PcGs) binding sites affecting gene expression at transcriptional level, not only at 
translational mRNA level. They were reported to guide chromatin remodelling 
complexes to specific genome sites in the nucleus98 or promoting de-novo methylation 
of DNA99. 
miRNAs are found to associate with two kind of PcGs, PRC1 and PRC2, that are 
transcriptional repressors, strongly evolutionary conserved, that modify chromatin 
structure by covalent modification of histone proteins. PcGs own RNA binding 
properties and a leading role in PRC promoter targeting is played by microRNAs, as 
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the part of policomb-RNA complex that modulates PcG-promoter pairing100. The 
polycomb-microRNA complex catalyzes the histone H3 trimethylation or histone 
H2A monoubiquination of the “bivalent domain" of the NFI-A promoter, modulating 
NFI-A expression. Upregulation of NFI-A levels in primary hematopoietic 
stem/progenitor cells (HSC/HPCs) induces differentiation along the erythroid lineage, 
while downregulation leads toward the granulocytic linage. More specifically miR-
223 was identified to target NFI-A promoter, thus mediating cell-lineage faith through 
PcGs recruitment101. 
A non-canonical miRNA function more related to miRNA-based post-transcriptional 
silencing can be related to the control of alternative translation. 
There is a growing appreciation of widespread of alternative translation (AT) in 
mammals102-107. It’s a fine regulated mechanism and many mRNAs display a complex 
translation pattern, having multiple open reading frames (ORFs). ORFs can be 
mutually alternative, influence each other and/or the formation of secondary structures 
that can modulate ribosome activity, giving birth to alternative protein isoforms108, 109. 
miRNAs were reported to bind 5’UTR110 and coding sequences (CDS) regions of 
mRNAs111-113. A recent work of Sonda et al114 demonstrated that C/EBPβ mRNA 
alternative translation is regulated by miR-142-3p. The miRNA binds to non canonical 
site of the mRNA coding sequence, in a region including one of three in frame 
translation initiation site (TIS). The miRNA binding changes the ratio between protein 
isoforms with different properties, thus impacting on the cell phenotype. 
This is just a short list of non canonical miRNA functions and this is an area of active 
ongoing study. 
miRNAs deregulation and cancer 
It is well known that gene expression is intricately regulated and there are multiple 
layers of expression level controls. microRNAs are active player of gene post 
transcriptional regulation and cellular homeostasis. They play important roles in many 
biological processes including cell differentiation, organogenesis, development, 
regulation of cell cycle and apoptosis. Dysregulation of miRNAs has been observed in 
many diseases but the cause-effect mechanism has not always been established, nor 
their role in tumour initiation and progression115. Moreover, dysregulated miRNAs of 
a tumour expression profile are not necessary pathogenetic and needlessly activate a 
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specific mechanism of action in oncogenesis116. So that dysregulation detection 
constitutes only the starting point for disease-relevant studies117. The deregulation of 
miRNAs in cancer can be due to epigenetic changes, as altered DNA methylation or 
histone acetylation, to defect in miRNAs biogenesis, as altered Dicer or Drosha 
activity, or to chromosomal abnormalities118. They can act either as tumour suppressor 
genes, promoting cancer cell death and/or to inhibit cancer cell growth, or as 
oncogenes, actively contributing to cancer cell proliferation. The first evidence of 
miRNA involvement in human cancer derived from studies on chronic lymphocytic 
leukemia (CLL). They were studying a deleted region in CLL at chromosome 13q14. 
They were expected to find a tumour suppressor gene, being the region deleted in 
tumour phenotype. They rather detected the miR-15a and miR-16-1 loci, transcribed 
from the same polycistronic RNA. These miRNAs target several factors that promote 
cell-cycle progression, as CDK6, CARD10 and CDC27. Lacking miRNAs post 
transcriptional regulation of these factors, due to deletion in haematopoietic and solid 
malignancies, there is an enhanced proliferative response of cancer cells to a variety of 
mitogenic stimuli116. In this case miRNAs influence tumour biology through their 
action as signal modulators along cancer-relevant pathways. Another way miRNAs 
can be involved in disease is through the increased or decreased activity of their 
transcription factors at the promoter. The well-known p53 tumour suppressor gene 
directly transactivates the miR-34a, miR-34b and miR-34c family transcription units, 
which are able to mediate some aspects of the cellular response to p53 activation, 
including cell-cycle arrest and apoptosis119-121.  Another miRNA able to impair cell 
proliferation or induce apoptosis through oncogenes targeting is let-7, targeting RAS 
and MYC122, 123, while opposite effect has miR-21 targeting tumour suppressor 
proteins in breast cancer, glioblastomas and pancreas118, 124-126. A number of 
microRNAs, that Hurst et al called metastamir, are demonstrated to play a role in the 
metastatic program, both displaying a pro- and anti-metastatic effects127. They showed 
involvement in epithelial-mesenchymal transition, migration and angiogenesis. miR-
10b for example, is highly expressed in ~50% of metastatic tumours. It suppresses the 
homeobox D10 expression, leading to an increase in RHOC, a pro-metastatic gene, 
and initiation of breast cancer invasion and metastasis. miR-373 and miR-520c were 
studied by Agami et al128, found to promote migration and to increase in vivo 
metastasis at least in part by targeting the adhesion molecule, CD44. On the other 
hand, miR-373 showed higher expression in lymph-node metastasis compared with 
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the primary tumours. Conversely,	  miR-146 family of miRNA could profoundly inhibit 
invasion and metastasis of MDA-MB-231 human breast carcinoma cells, similarly to 
miR-126 and miR-335 that are active regulators of tumour invasion and metastasis in 
human breast cancer. 
The list of validated microRNAs involved in tumour development and progression is 
still long, acting through a huge variety of mechanisms. Although significant advances 
have been made so far, only fewer success in the development of miRNAs for use in 
therapy have been reported. A great step forward will be the use of circulating 
miRNAs in body fluids are accessible and allow a non invasive inquiry. They have 
already been detected in serum of women characterized of being expected and 
disappeared after the baby birth, as proof of pregnancy status. Circulating miRNAs 
expression level was further used to monitor the existence of cancer cell in patients95, 
129, as for early diagnosis with serum miRNAs in colorectal adenocarcinoma130or lung 
cancer131. Indeed, human body fluids, as blood, urine, saliva amniotic fluid, colostrum, 
breast milk, bronchial lavage, cerebrospinal fluid, peritoneal fluid, pleural fluid, tears 
and seminal fluid, have been shown to harbour extracellular miRNAs that are 
emerging as effective biomarkers for detection of diseases132, 133. However, the entire 
spectrum of miRNAs in the fluids has not been fully characterized. 
More efforts must be put in that issue for an effective translation of miRNAs 
knowledge into clinical practices. 
 
Aim of the work 
In this work we considered different aspect of the microRNA word, integrating 
computational analyses of genome-wide datasets and targeted experimental results.  
First, we studied miRNA role in myeloproliferative disorders, more specifically in 
primary myelofibrosis, considering also other small RNAs detected in RNA-seq data. 
This study deals indeed on a Illumina sequencing of small RNAs samples of CD34+ 
hematopoitic stem cells of patients affected by primary myelofibrosis and of controls, 
in order to characterize miRNA profiles and find relevant differentially expressed 
elements. 
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Then, in order to have a better understanding of each step of a computational analysis 
of RNA-seq data, we studied the impact on small RNAs differential expression 
analysis of long RNA-contrived normalization methods. 
Thereafter we evaluated the implication of microRNAs in the gene expression 
changes observed after H-ferritin silencing in K562 cells. 
The last part of this thesis report a preliminary study of the involvement of 
microRNAs in the regulation of alternative translation and thus of protein isoform 
equilibrium.  
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Chapter 1 
We expanded the knowledge of miRNAs and moRNAs expressed by CD34+ cells, we 
identified and validated a few elements that can contribute to PMF pathogenesis. We 
considered small RNA sequencing data of 6 CD34+ cells, including 3 samples 
collected from 3 pools of bone marrow CD34+ cells of healthy subjects, and 3 
samples of circulating CD34+ cells of patients affected by primary myelofibrosis 
(PMF), two of which were from a single patient and one was from a pool of 4 patients. 
In addition to 784 miRNAs annotated in miRBase, our in-house pipeline miR&moRe 
let us discover 34 new miRNAs expressed in our samples. miRNAs are de facto 
mixtures of isomiRs, specific variations of isomiRs expression impact also on 
miRNAs expression. Thus, we considered isomiR counts for miRNA expression 
calculations, recognizing that most of miRNAs detected are expressed in their isoform 
variants, not as the annotated sequence. We also detected in our samples sequences 
aligning to hairpins outside known and novel miRNAs that correspond to expressed 
microRNA-offset RNAs, called moRNAs. Myeloproliferative disorders are clonal 
hematopoietic stem cell neoplasias, miRNA and moRNA deregulation can be implied 
in tumor physiopathology. We then looked for differentially expressed small RNAs in 
PMF CD34+ samples respect to control samples. We recognized 37 sRNAs with 
significant differentially expressed (DE) in patient respect to control CD34+. 
Noteworthy, among the differentially expressed sRNAs, 2 moRNAs are included. hsa-
3’-moR-128-2 was highly expressed in normal CD34+ cells and dramatically 
downregulated in PMF patients: the moRNA was not detected in considered PMF 
samples. We excluded multiple matching loci and ruled out mapping or annotations 
artifacts and made sure that the detected small RNA was a moRNA derived from the 
non-canonical processing of the human mir-128-2 hairpin. moRNA biological roles 
and mechanisms of function still deserve investigation. Very likely, moRNAs can 
function as miRNAs in post-transcriptional gene silencing, guiding RISC to 
complementary target mRNAs. Six of the selected small RNAs differentially 
expressed in PMF considering small RNA sequencing data in CD34+ resulted 
significantly differentially expressed, also in PMF granulocytes samples, we thus 
validated the differential expression of miR-10b-5p, miR-19b-3p, miR-29a-3p, miR-
379-5p, miR-543 and moR-128-2. Target predictions of these validated small RNA 
were performed by using two different programs, miRanda and PITA. A functional 
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enrichment analysis, based on Reactome annotation maps, of targets predicted by both 
methods was obtained using a hypergeometric test. miRNA targets are enriched in 
many interesting pathways involved in tumor development and progression, as 
signaling by FGFR, DAP12 and Oncogene Induced Senescence. Hopefully identified 
and validated elements will help in the understanding the mechanisms that contribute 
to PMF pathogenesis and in formulate new targeted therapies.  
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Abstract 
Myeloproliferative neoplasms are chronic myeloid cancers involving CD34+ 
hematopoietic stem cells alterations. They include essential thrombocythemia (ET), 
polycythemia vera (PV) and myelofibrosis (MF). MF is the most severe form and can 
evolve in acute leukemia. Increasing evidence shows that deregulation of microRNAs 
(miRNAs) plays an important role in both solid and hematologic malignancies. 
Moreover, previous studies showed that microRNA-offset RNAs (moRNAs) could be 
expressed by processing of miRNA precursors. To attain deeper knowledge of small 
RNAs expressed in CD34+ cells and of the possible miRNA/moRNA-mediated post-
transcriptional regulation in PMF, we sequenced with Illumina HiSeq2000 technology 
CD34+ cells from healthy subjects and from of patients affected by primary 
myelofibrosis (PMF).  
We detected the expression of 784 known miRNAs, discovered 34 new miRNAs and 
99 new miRNA-offset RNAs (moRNAs), expressed in in CD34+ cells. We then 
identified 37 small RNAs (DEMs) differentially expressed in patients respect to 
healthy subjects, with a prevalence of miRNA up-regulation in the disease. Six of the 
37 identified small RNAs resulted significantly differentially expressed also in PMF 
granulocytes samples, we thus validated the differential expression of miR-10b-5p, 
miR-19b-3p, miR-29a-3p, miR-379-5p, miR-543 and moR-128-2. Target predictions 
of these validated small RNA and a functional enrichment analysis were performed. 
miRNA targets are enriched in many interesting pathways involved in tumor 
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development and progression, as signaling by FGFR, DAP12 and Oncogene Induced 
Senescence. 
In this study, we expanded the knowledge of miRNAs and moRNAs expressed in 
CD34+ cells, identified and validated a few elements that can contribute to PMF 
pathogenesis. Hopefully this information will help in the understanding the 
mechanisms that contribute to PMF pathogenesis and in formulate new targeted 
therapies.  
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Background 
Philadelphia-negative chronic myeloproliferative neoplasms (MPNs) are a 
heterogeneous group of clonal hematopoietic stem cell (HSC) disorders associated 
with overproduction of mature myeloid cells1, 2.  
MPNs are chronic myeloid cancers that include essential thrombocythemia (ET), 
polycythemia vera (PV) and primary myelofibrosis (PMF). MPNs can be complicated 
by thrombosis and/or hemorrhage and they may evolve into acute myeloid leukemia.  
MF, the most serious MPN form, can arise primarily (PMF) or follow PV and ET 
onset (post-PV/ET MF). In primary myelofibrosis (PMF) the abnormal proliferation 
of megakaryocytes is accompanied by deposition of fibrous connective tissues in the 
bone marrow, abnormal stem cell trafficking, and extramedullary hematopoiesis 
(myeloid metaplasia).1, 2  
PMF is associated with marked hepatosplenomegaly, anemia and profound 
constitutional symptoms including fatigue, weight loss, cachexia, pruritus, night 
sweats, low-grade fever, and bone and joint pain. Treatment, apart from 
“conventional” allogeneic stem cell transplantation (SCT), is guided by risk 
stratification and the patient’s clinical needs.2-4 
In 2005 the first mutation related to MPNs was identified in the Janus Kinase 2 
(JAK2)5-9. 
The JAK2 V617F mutation is present in approximately 95% of patients with PV, and 
in 50% to 60% of those with ET or primary MF (PMF). Additional mutations have 
been identified in patients who have myeloproliferative neoplasms with or without 
JAK2 mutations: in particular a signaling mutation that activates the thrombopoietin 
receptor (MPL) and in epigenetic regulators, but also chromosomal aberrations.2, 10-12 
In 2013, somatic mutations of CALR, the gene encoding calreticulin, have been found 
in 20% to 25% of patients with essential thrombocythemia (ET) or PMF. Like JAK2 
and MPL mutations, somatic mutations of CALR behave as driver mutations 
responsible for the myeloproliferative phenotype. 
Despite the fact that the mutational landscape of MPNs has been extensively 
investigated, the molecular etiology of the disease has not been fully elucidated. 
Indeed several lines of evidence indicate that the identified mutations are not 
sufficient for disease initiation and progression. Although murine models have 
provided unequivocal evidence that JAK2V617F is able to cause MPNs13, disease 
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phenotype is significantly heterogeneous between different murine lines and even 
within the same line, suggesting that disease phenotype is affected by other unknown 
genetic or epigenetic factors14.  
MicroRNAs are endogenous small non-coding RNAs, approximately 22 nt in length, 
crucial for post-transcriptional gene regulation. They are loaded into the RNA-induced 
silencing complex (RISC), directing the complex (including Argonaute proteins) to 
downregulate target mRNA expression by either triggering mRNA degradation or 
translational repression.15 Recent studies show that mRNA destabilization explains 
most (66%–>90%) miRNA-mediated repression16. 
It is known that that deregulation of miRNAs plays an important role in both solid and 
hematologic malignancies17, 18. Indeed, hematopoietic differentiation is tightly 
governed by gene expression that is strictly regulated at multiple cell-fate decision 
levels. miRNAs regulate hematopoiesis acting both in HSC and in committed 
progenitor cells18-20. At the stem cell level, some miRNAs evolutionally conserved are 
responsible for expanding HSCs by inhibiting apoptosis21-23. At the progenitor cell 
level, miRNAs regulate the developmental fate of the megakaryocyte-erythroid 
progenitor (MEP) cell, the common progenitor of the erythroid and megakaryocytic 
lineages24, 25. At the more committed hematopoietic cell level, specific miRNAs are 
expressed in different blood cell lineages and in different stages of hematopoietic 
differentiation. For example Chen et al.26 reported that miR-142s expression was 
lower in the erythroid and T-lymphoid lineages and higher in B-lymphoid and 
myeloid lineages, while miR-223 expression was confined to myeloid lineages, with a 
very low detectable expression in T- and B-lymphoid and erythroid lineages. 
miRNAs have an important role in regulation of hematopoiesis27-30. miR-16, miR-451 
upregulation and miR-150, miR-155, miR-221 and miR-222 downregulation are 
associated with different stages of erythropoiesis31, 32. miR-223 expression level, 
determined by two regulatory regions on its gene, fine-tunes lineage commitment of 
myeloid precursor33. miR-181 family was detected during granulocytic and 
macrophage-like differentiation and its level decrease along the hematopoietic lineage. 
They modulate differentiation by targeting and negatively regulating PRKCD mRNA, 
an upstream regulator of a pathway of the myeloid differentiation, and CAMKK1 
mRNA, involved in the granulocytic and PMA-induced macrophage-like 
differentiation34, 35.  
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Recent studies highlighted aberrant miRNA expression in MPNs, and specific miRNA 
signatures that distinguish MPN granulocytes from those of healthy donors18, 36.  
A recent study characterized both gene and microRNA (miRNA) expression profiles 
in CD34+ cells from PMF patients37. It identified several biomarkers and putative 
molecular targets such as FGR, LCN2, and OLFM4. By means of miRNA-gene 
expression integrative analysis, the study suggested that JARID2 downregulation, 
mediated by miR-155-5p overexpression, might contribute to MK hyperplasia in 
PMF. 
High-throughput analysis of miRNA expression levels in MPN CD34+ cells were 
previously reported only by Lin et al.35,38 and by Zhan et al.26.  
In a preliminary study, we performed short RNA massive sequencing and extensive 
bioinformatic analysis in the JAK2V617F-mutated SET2 cell line39, detected and 
quantified 652 known mature miRNAs, of which 21 were highly expressed, thus being 
responsible of most of miRNA-mediated gene repression. In the same study, we 
showed that the majority of miRNAs were mixtures of sequence variants (isomiRs) 
and we identified 78 novel miRNAs. Indeed, we discovered that SET2 cells express a 
number of miRNA-offset RNAs (moRNAs), short RNAs derived from genomic 
regions flanking mature miRNAs, whose biological role needs to be elucidated.  
In this study, we characterized miRNA and moRNA expression in CD34+ stem cells 
using massive small RNA-seq. The observed specificities in small RNAs expression 
of PMF CD34+ cells were subsequently confirmed considering granulocytes from 
PMF, PV and ET patients and from healthy controls. We thus provided new 
information regarding the possible role of miRNAs and new moRNAs in the disease.  
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Materials and Methods 
Small RNA-seq library construction and sequencing 
We deep-sequenced small RNAs libraries using Illumina HiSeq2000 technology, 
single reads from 49 to 57 bp. We sequenced 3 samples of pooled CD34+ bone 
marrow cells from healthy subjects (unknown genders) and 3 samples of circulating 
CD34+ cells of patients affected by primary myelofibrosis (PMF), a 
myeloproliferative neoplasm, two of which were from a single patient and one was 
from a pool of 4 patients, for a total number of 6 sequenced samples. All samples and 
raw reads information are summarized in Supplementary Table 1. 
  
Small RNA data analysis: preprocessing 
First step of data analysis is data preprocessing. The starting point is adapter removal. 
Reads “adapter-only”, too short or unclipped have been discarded. Unclipped reads 
are discarded because they can't represent miRNA or miRNA like short RNAs. 
We admitted a read length range between 15 and 30 nt, slightly wider than the human 
annotated miRNAs length in miRBase to conserve also possible new longer isomiRs. 
We therefore discarded raw reads out of the range 15-30 bps in length. We then 
filtered out low quality reads, keeping all that reads displaying a base mean quality 
higher than 30, and allowing no more than 2 nucleotides per read with quality under 
20. To complete data preprocessing we eliminated ground noise, considered as reads 
belonging to unique sequences with less than 10 reads counts each.  
 
Small RNA data analysis: reads mapping and comparative 
filtering 
Reads have been mapped using Bowtie v. 1.1.0 both to the GRCh38 genome assembly 
and the known hairpins sequences extended in both directions by additional 30 bp to 
accommodate moRNAs mapping at the extremities of known hairpins. Reads mapping 
to more than 5 different loci on the genome, out of miRNA hairpins, are unlikely to be 
real miRNAs, and they have been thus discarded. 
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Barplot on Supplementary Figure 1 shows filtering effects on absolute reads counts 
for each sample. 
We processed each sample data with our in-house pipeline miR&more. The output 
consists of lists of known miRNA read counts, lists of new miRNAs and moRNAs 
and lists of variants (isomiRs) for all the small RNAs found in each sample.  
 
Expression data normalization and sample cluster analysis   
Sample merging and carefully conducted steps of data normalization and 
transformation are needed to guarantee the comparability of samples, to allow 
descriptive unsupervised analyses and differential expression tests. We performed 
normalization using R/Bioconductor package DESeq. Inference of differential 
expression in DESeq relies on the estimation of the typical relationship between the 
data variance and their mean, or, equivalently, between the data dispersion and their 
mean. Variance dependence to the mean can be modeled following different ways 
using DESeq, with several algorithms and very different results. The selection of the 
method used is crucial, since variance estimation influences unsupervised 
classification, differential expression and all following analyses. We tried two 
different methods for fitting data variance: 1) a parametric model, 2) a local regression 
model. 
The first is the recommended default but in some data sets could fail to give optimal 
results. Sum of square of residuals for local regression is 15311.52 whereas for GLM 
is 156849.3, so we can conclude that local regression fits better our data. 
We performed cluster analysis using R to check whether samples were correctly 
classified in their own biological class. We clustered samples using both full small 
RNAs expression matrix (904 small RNAs) and filtered, computing euclidean distance 
and complete linkage as clustering method. 
To filter the expression matrix at different levels of small RNAs expression we 
calculated, for each small RNA in the matrix, the sum of expression vector values. 
Then we performed clustering analysis under the following conditions 1) considering 
all the small RNAs found 2) selecting only small RNAs over the median (430 
miRNAs and 22 moRNAs), 3) filtering only small RNAs over the third quartile (219 
miRNAs and 7 moRNAs).  
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Differentially expressed sRNAs 
We performed a differential expression analysis using DESeq R/Bioconductor 
package. We considered those short RNAs that had a total expression throughout all 
samples higher than the median. We performed a multiple test correction according to 
the Benjamini Hochberg (FDR). We considered a corrected p-value of 0.05 as 
threshold to identify differentially expressed elements. 
 
Validation of differentially expressed sRNAs 
We performed Real-time PCR (RT-PCR) assays on granulocytes using single TaqMan 
MicroRNA Assay (Applied Biosystem). These were carried out in an independent 
cohort of normal controls (n=10) and patients with PMF (n=50), polycythemia vera 
(PV)(N=30) and essential thrombocythemia (ET)(n=30).  
 
Target prediction of validated small RNAs and functional 
enrichment 
The complexity of miRNA-mRNA interactions causes ambiguity in target prediction 
results. Target genes identification is indeed challenging and many algorithms have 
been developed. Target prediction programs can be divided in two classes, 
distinguished on the basis of the use or not of the information about evolutionary 
conservation of interaction68.  We chose to perform a target prediction using two 
different programs, miRanda55 and PITA63, which implement orthogonal target 
prediction strategies. Our choice was determined also by code availability that allowed 
us to make custom predictions using as query sequences also isomiRs and moRNA 
sequences. 
We performed a target prediction using both miRanda 3.3a and PITA executable 
version 6 (31-Aug-08). We applied default parameters of miRanda to predict target of 
selected small RNA sequences since these settings are reported to optimize the 
dynamic programming miRanda algorithm. We used default parameters for PITA 
target prediction too. According to PITA documentation, we considered a binding site 
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with score <= -10 likely to be functional in endogenous microRNA expression levels. 
We performed a hypergeometric test using an in-house modified version of the R 
Category package of Bioconductor that supports Reactome annotation maps via the 
reactome.db R package. 
Results and Discussion 
sRNA sequencing libraries 
Small RNA libraries were prepared from 1 µg of total RNA according to TruSeq 
Small RNA kit. 
Quality control was performed on a high sensitivity DNA chip (Agilent).  
The purified cDNA libraries was used for cluster generation on Illumina's Cluster 
Station and sequenced on an Illumina HiSeq2000 instrument.  
 
small RNA expressed in and PMF CD34+ cells and in PMF 
patients 
We considered small RNA sequencing data of 6 CD34+ cells, including 3 samples 
collected from 3 pools of bone marrow CD34+ cells of healthy subjects (CTR; 
unknown gender), and 3 samples of circulating CD34+ cells of patients affected by 
primary myelofibrosis (PMF), two of which were from a single patient and one was 
from a pool of 4 patients.  
The Illumina 2000 sequencing produced a total of 787,913,722 raw reads 
(131,318,954 per sample mean). After a stringent filtering during the preprocessing 
and quality control steps (Supplementary Figure 1), 349,372,534 were aligned to 
GRCh38 genome “extended” hairpins. Aligned reads corresponded to 44.3% of initial 
raw reads, but due to high sequencing depth, the number of considered reads was still 
high. 
Table 1 reports a summary of different types of small RNAs detected in the 
considered samples, according to current miRNA annotations.  
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 CTR ONLY CTR PMF ONLY PMF ALL 
known miRNAs 568 24 760 216 784 
new miRNAs 20 3 31 14 34 
moRNAs 52 3 96 47 99 
Total new 
sRNAs 
72 6 127 61 133 
Total sRNAs 640 30 887 277 917 
Table1 Summary of small RNAs expressed in considered CD34+ cells. 
We detected a total of 917 small RNAs expressed in at least one of the 6 considered 
CD34+ samples, including 784 know miRNAs. Notably, 8 known miRNAs are highly 
expressed and contribute to the total miRNA expression throughout all samples from 
2.5% to 25%, representing all together the 80% of the total expression. Moreover, we 
detected 133 new small RNAs, including 34 new miRNAs produced from known 
hairpins and 99 microRNA-offset RNAs (moRNAs). 
Descriptive sample clustering analysis was conducted to check if differences in 
mapped read numbers across samples may affect expression estimation and small 
RNAs profile sample characterization. Cluster analysis and heatmaps are represented 
in Supplementary Figure 2. Two heatmap plots were generated, by considering 
normalized expression profiles of all the small RNAs expressed and considering only 
those expressed over the median level. Both unsupervised analyses show the same 
result: samples are correctly clustered, with CTR samples clustered together and 
separately from PMF samples. Looking at the distances, CTRs are closer to each other 
than the MFs in their group pointing out an increased variability of small RNA 
expression profiles in patient samples respectively to controls. 
Cluster analyses and heatmaps demonstrate that patients and controls small RNAs 
profiles are significantly different from each other and highlight a characteristic 
miRNA and moRNA expression profile in PMF. 
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New miRNAs 
In addition to 784 miRNAs annotated in miRBase, our in-house pipeline miR&moRe 
let us discover 34 new miRNAs expressed in our samples (Supplementary Table 2).  
To find new miRNAs, we considered all the hairpins precursors annotated in 
miRBase, to be used as reference for read mapping and small RNA detection and 
quantification. Some of the known hairpin precursors were known to only generate 
one mature miRNA with only a handful of reads reported in mirBase across all NGS 
experiments surveyd. After identifying the hairpin region that would most likely pair 
with annotated mature we classify as new miRNAs all the clusters of reads that map 
there. A consistent number of reads were attributed to new miRNAs. Since these reads 
passed stringent quality filtering and mapping criteria, it is improbable that they could 
be sequencing errors. Furthermore, two of these new miRNAs: hsa-miR-2110* and 
hsa-miR-548ag-2* are highly expressed and show a mean expression over the median 
of the mean expression values distribution calculated on all the detected small RNAs.  
 
miRNAs are mixtures of isoforms contributing to miRNAs 
expression 
Our and other previous studies showed that miRNAs are mixtures of sequences, 
slightly different from the official mature miRNA, called isomiRs 39, 40. Microarray 
technology, relying on sequence hybridization to appropriately designed annealing 
probes, can only detect annotated miRNA sequences. Sequencing-based technology 
reveals instead all the repertoire of expressed small RNAs, both the unknown and the 
annotated miRNAs, and is able to detect isomiRs, that contribute to miRNA 
expression and qualitative characteristics.  
In our dataset, miRNA expression counts indeed consider for each miRNA a group of 
reads that not only perfectly match the annotated miRNA (“exact”), but also match the 
precursor with a 1-2 nt shorter or longer sequence than the mature miRNA in the 3’ 
region (“shorter or longer at 3’ ”), in the 5’ end (“shorter or longer at 5’”) or at both 
the ends (“both”). 
Expressed miRNAs with unique sequence are very few, only 165 out of the 784 
annotated miRNAs detected (21%). Unique sequence miRNAs are in general weakly 
expressed: they were detected at level under the median of the mean expression values 
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distribution. Notably, the remaining 619 expressed miRNAs have more than one 
isomiR. We also detected reads aligning to hairpins precursor with one or two 
mismatches but we excluded these reads from the total miRNAs expression 
estimation.  
  
Figure 1 Distribution of reads per category across sample. “Exact” reads are identical to the mature 
miRNA sequence annotated in miRBase, whereas “mismatch” reads present respectively one or two 
nucleotides different from the annotated sequence but identical length; the last category includes reads 
perfecly matching the miRNA precursor (and genomic) sequence but shorter or longer than the 
annotated mature miRNA. “Exact” reads are rare, while shorter or longer are very abundant. 
 
Figure 1 and Supplementary Table 3 show that the annotated sequence, called “exact” 
isomiR, rarely is the dominantly expressed form, while most of the total expression 
contribute is given by shorter or longer isomiR sequences. Reads aligning with 
mismatches are also represented in display items for comparison. These 
considerations are based on statistics considering all expressed miRNAs. Looking at 
singular miRNAs, the ratio between isomiR types changes. For example miR-10b-5p 
is mainly detected in its “shorter or longer” variant (Figure 2).  
We considered the possibility that peculiar genetic characteristics of the considered 
PMF cells would result in specific isomiR sequences, or can be related to variations of 
isomiRs expression level in disease. Our results did not identified isomiRs expressed 
exclusively in PMF samples. Anyway, since miRNAs are de facto mixtures of 
isomiRs, specific variations of isomiRs expression impact also on miRNAs 
    47 
expression. Thus, we considered isomiR counts for miRNA expression calculations 
and for the following analyses. 
 
 
Figure 2. Abundance of reads falling in different isomiR types fro hsa-miR-10b-5p. Reads different 
from the annotated mature miRNA sequence are the most abundant. 
 
moRNAs discovery 
As anticipated, we also detected in our samples sequences aligning to hairpins outside 
known and novel miRNAs, that correspond to expressed microRNA-offset RNAs, 
called moRNAs (Table 1).  
moRNAs sequences partially overlap miRNA regions but generally span the Drosha 
cutting sites, letting us hypothesize a non canonical processing of the hairpin 
precursor in moRNA biogenesis.39  
A complete list of all the detected moRNAs is in Supplementary Table 4. Noteworthy, 
28 moRNAs were highly expressed, 26 of them over the median of the short RNAs 
expression values distribution and 12 of them even over the third quartile (Table 2).   
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name CTR MF strand position seq 
hsa-moR-128-2-3p 2493 0 + 
chr3:35744548-
35744568 
CCCTACTGTGTCACA
CTCCTA 
hsa-moR-21-5p 2946 2437 + 
chr17:59841243-
59841271 
ACATCTCCATGGCTG
TACCACCTTGTCGG 
hsa-moR-24-2-5p 5971 1719 - 
chr19:13836350-
13836376 
TGCCTGGCCTCCCTG
GGCTCTGCCTCC 
hsa-moR-27a-5p 1752 312 - 
chr19:13836510-
13836534 
CGAAGCCTGTGCCTG
GCCTGAGGAG 
hsa-moR-3651-5p 0 1266 - 
chr9:92292537-
92292565 
ATGGACAGCTCTCCA
GTGGATTCGATGGG 
hsa-moR-421-5p 848 2784 - 
chrX:74218449-
74218472 
CCTAATCCGGTGCAC
ATTGTAGGC 
hsa-moR-6724-1-5p 683 280 + 
chr21:8205298-
8205332 
TGTGGGGGAGAGGC
TGTCGCTGCGCTTCT
GGGCCC 
hsa-moR-6724-2-5p 683 280 + 
chr21:8249488-
8249522 
TGTGGGGGAGAGGC
TGTCGCTGCGCTTCT
GGGCCC 
hsa-moR-6724-3-5p 683 280 + 
chr21:8388345-
8388379 
TGTGGGGGAGAGGC
TGTCGCTGCGCTTCT
GGGCCC 
hsa-moR-6724-4-5p 683 280 + 
chr21:8432513-
8432547 
TGTGGGGGAGAGGC
TGTCGCTGCGCTTCT
GGGCCC 
hsa-moR-941-4-5p 6564 2531 + 
chr20:63919746-
63919768 
CACCCGGCTGTGTGC
ACATGTGC 
hsa-moR-941-5-5p 9780 3800 + 
chr20:63919858-
63919880 
CACCCGGCTGTGTGC
ACATGTGC 
Table 2. List of most abundant moRNAs in considered CD34+ samples, which are expressed over the 
third quartile of all sRNAs expression. 
We classified moRNAs on the basis of the hairpin precursor arm they where 
processed from: 5’-moRNAs mapping to the 5’ hairpin arm, and 3’-moRNAs 
spanning over the 3’ hairpin arm. 5’-moRs were significantly more abundant respect 
to 3’-moRs. Out of 99 moRNAs expressed in considered samples, only 16 (16.2%) 
were processed from the 3’ hairpin arm, while 83 (91.1%) were 5’-moRs. According 
to our data, seven hairpins were processed producing two moRNAs each 
(Supplementary Table 4). 
5’-moRs estimated expression values were 10 times higher than 3’-moRs, ranging 
from summed up normalized values over all samples of 5 to 40,739, compared to a 3’-
moRs range of 6 to 7,478. Both 3’-moRs and 5’-moRs are more expressed in controls 
than in PMF patient samples.  
Considering all the small RNAs processed from the same hairpins precursors from 
which the 9 most expressed moRNAs are derived, we see that whereas miRNAs are 
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more expressed in PMF samples compared to CTRs, the relation is flipped in 
moRNAs, that are more expressed in normal CD34+ than in PMF samples (Figure 3). 
For the same set of moRNAs, Figure 4a shows in detail all the expressed small RNAs 
that are produced from the same hairpins precursor. 
 
Figure 3. Expression of miRNAs and moRNAs produced from the same hairpin, considering the 
hairpins expressing most abundant moRNAs considered separately (A) and together (B). 
 
We observed that moRNAs sequences partially overlap mature miRNA regions and 
generally span the Drosha cutting sites, with moRNAs protruding from the canonical 
hairpin precursor.  
  
Identification of sRNA differentially expressed in PMF vs 
CTR 
Since myeloproliferative disorders are clonal hematopoietic stem cell neoplasias, 
miRNA and moRNA deregulation can be implied in tumor physiopathology. We then 
looked for differentially expressed small RNAs in PMF CD34+ samples respect to 
control samples. We recognized 37 sRNAs with significant differentially expressed 
(DE) in patient respect to control CD34+ (Table 3). 
name CTR PMF log2(FC) P value P-val-adj 
hsa-miR-1185-5p 0 136 15.00 1.24E-05 6.98E-04 
hsa-miR-127-5p 0 317 15.00 4.66E-07 7.01E-05 
hsa-miR-1277-5p 0 98 15.00 1.53E-04 6.28E-03 
hsa-miR-299-3p 0 210 15.00 1.78E-04 6.69E-03 
hsa-miR-323a-3p 0 121 15.00 5.34E-03 7.29E-02 
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hsa-miR-377-3p 0 206 15.00 9.34E-04 1.92E-02 
hsa-miR-377-5p 0 155 15.00 8.32E-06 6.25E-04 
hsa-miR-379-3p 0 89 15.00 2.76E-04 9.56E-03 
hsa-miR-382-5p 0 205 15.00 2.97E-04 9.56E-03 
hsa-miR-431-3p 0 80 15.00 1.72E-03 3.11E-02 
hsa-miR-490-3p 0 719 15.00 2.48E-03 3.99E-02 
hsa-miR-539-3p 0 204 15.00 1.37E-03 2.58E-02 
hsa-miR-543 0 262 15.00 4.64E-04 1.40E-02 
hsa-miR-654-5p 0 99 15.00 6.37E-04 1.60E-02 
hsa-miR-656 0 78 15.00 8.90E-04 1.91E-02 
hsa-miR-665 0 317 15.00 2.67E-03 4.15E-02 
hsa-miR-758-3p 0 171 15.00 3.04E-03 4.56E-02 
hsa-miR-873-5p 0 211 15.00 6.57E-04 1.60E-02 
hsa-miR-25-3p 37 226192 12.59 2.85E-27 1.29E-24 
hsa-miR-29a-3p 206 44817 7.77 6.73E-04 1.60E-02 
hsa-miR-136-5p 34 1516 5.47 1.24E-04 5.57E-03 
hsa-miR-495-3p 8 281 5.09 6.43E-04 1.60E-02 
hsa-miR-873-3p 7 239 5.04 5.15E-03 7.27E-02 
hsa-miR-485-5p 12 353 4.84 1.17E-03 2.30E-02 
hsa-miR-19b-3p 3795 99173 4.71 7.13E-07 8.03E-05 
hsa-miR-432-5p 14 343 4.62 2.09E-03 3.62E-02 
hsa-5'-moR-542 9 232 4.62 6.72E-03 8.66E-02 
hsa-miR-379-5p 31 561 4.16 7.86E-03 9.58E-02 
hsa-miR-19a-5p 15 265 4.16 5.16E-03 7.27E-02 
hsa-miR-33b-5p 26 394 3.90 6.09E-03 8.08E-02 
hsa-miR-1307-5p 779 10914 3.81 8.23E-04 1.86E-02 
hsa-miR-142-3p 5954 33867 2.51 7.73E-03 9.58E-02 
hsa-miR-3150b-3p 196 7 -4.90 2.23E-03 3.73E-02 
hsa-miR-10b-5p 119504 2855 -5.39 2.15E-08 4.84E-06 
hsa-3'-moR-128-2 2489 0 -15.00 1.15E-05 6.98E-04 
hsa-miR-128-2* 102 0 -15.00 1.87E-05 9.36E-04 
hsa-miR-5008-3p 149 0 -15.00 4.17E-06 3.76E-04 
Table 3. List of 37 most expressed miRNAs  
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Figure 4A shows the logarithm of the mean expression ratio in PMF and control cells 
for DE miRNAs and moRNAs. As shown in Figure 4A, the most part of DE sRNAs 
are upregulated in patients, while only five small RNAs are downregulated.  
Noteworthy, among the differentially expressed sRNAs, 2 moRNAs (hsa-5’-moR-542 
and hsa-3’-moR-128-2) are included.  
hsa-5’-moR-542 results up-regulated in PMF with a log2FC of 3.5. 
hsa-3’-moR-128-2 highly expressed in normal CD34+ cells (at levels over the third 
quartile of the overall small RNA expression distribution) and dramatically 
downregulated in PMF patients: the moRNA was not detected in considered PMF 
samples. We mapped hsa-3’-moR-128-2 sequence to the whole human genome to 
exclude multiple matching multiple loci and to rule out mapping or annotations 
artifacts. We can thus exclude that moRNA-associated reads could come from 
different or contaminating RNAs. An additional UCSC Blat41 analysis confirmed that 
the moRNA sequence only aligned to chr3:35786042-35786062. We are therefore 
confident that the detected small RNA is a moRNA derived from the non-canonical 
processing of the human mir-128-2 hairpin.  
 
Figure 4. Differential expression of small RNAs in PMF vs CTR CD34+. A) Log2 FC of small RNA 
differentially expressed considering PMF vs CTR CD34+, according to RNA-seq data. When a small 
RNA was not expressed in one sample category, the ratio was infinite and we represent it as the 
arbitrary maximum value of 15. B) RT-PCR expression calculation in granulocytes collected from an 
independent and sizeable cohort of normal controls (n=10) and of PMF (50), PV (30) or ET (30) 
patients. 
Validations confirmed 6 differentially expressed sRNAs 
We selected the most significantly deregulated and highly expressed detected 
differentially expressed miRNAs for further analysis. Specifically, we considered 21 
A B 
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small RNAs among the 37 differentially expressed for a quantification with Real-time 
PCR (RT-PCR) in granulocytes collected from an independent and sizeable cohort 
(total n=120) of normal controls and PMF, PV or ET patients. 
Six of the selected small RNAs differentially expressed in PMF considering small 
RNA sequencing data in CD34+ resulted significantly differentially expressed, also in 
PMF granulocytes samples: miR-10b-5p and moR-128-2 from RT-PCR, and miR-
19b-3p, miR-29a-3p, miR-379-5p, miR-543 from a previous study of Norfo et al37 
(Figure 4B). 
For these small RNAs the evidence of differential expression in PMF was robust, 
since it was detected by NGS and also validated technically (by qRT—PCR) and 
biologically (in independent samples). For the remaining miRNAs, the observed 
differences were not confirmed by PMF granulocytes analysis. 
Of the sRNAs for which DE in PMF was detected both in CD34+ cells and in 
granulocytes, all resulted to follow the same trend also in PV or ET granulocytes 
(Data not shown). Considering the significance of the observed variation, we would 
like to mention that miR-10b-5p is down regulated both in PV and ET samples (with a 
significant p-value, not reaching significance when the p-value is adjusted), whereas 
miR-19b-3p and miR-543 are respectively down and up regulated only in ET. 
Regarding the moR-128-2, very downregulated in PMF CD34+ and granulocytes, it 
decreases, but at a lower extent, without reaching statistical significance, also in PV 
and ET granulocytes. 
miR-10b-5p, downregulated both in PMF CD34+ and granulocytes, has been 
previously reported to be deregulated in breast cancer42-44and involved in 
chemoresistance related pathway45 . It has been validated as downregulated in 
endometrial carcinoma46, bladder cancer 47, in advanced stage of small cell carcinoma 
of the cervix (SCCC)48 and in clear cell renal cell carcinoma (ccRCC) and its 
expression level has been also included in a linear model that capture the metastatic 
tumor signature and patient prognosis49. 
We found miR-29a-3p upregulated in patients CD34+ respect to controls. Han et 
al.50previously demonstrated that miR-29a is downregulated in hematopoietic 
progenitors respect to lineage-committed progenitors, including granulocytes. That 
means that its expression level grows along the committed lineage. In our validation 
set of granulocyte cells, we recognized miR-29a as significantly downregulated in 
patients compared to controls. It results therefore deregulated in the validations too, 
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but it reversed the direction of differential expression in the committed granulocytes 
of the validation set, respect to the HSCs of sequencing set. Assuming that miR-29a 
expression in controls follows the highlighted trend reported by Han et al., in our 
patient data it results highly expressed in HSC when it should have a low expression 
level, while it has a low expression level in committed granulocytes when it should be 
highly expressed. We can thus classify miR-29a as a deregulated small RNA, which 
expression is modulated along differentiation. Figure 5 shows miR-29a trend in 
different cell and sample types. 
 
 
Figure 5. Schematic trend of miR-29a in CD34+ and granuocytes 
 
Coherently with our finding, Han et al also showed that sustained expression of miR-
29a-3p in mouse HSC/progenitors leads myeloid progenitors to self-renewal capacity, 
to biased myelopoiesis and myeloproliferative disorder that progress to acute myeloid 
leukemia. Additional data supporting miR-29a-3p deregulation comes from a previous 
study by Norfo et al.37, in which miRNA expression profiling was obtained by 
Affymetrix miRNA 2.0 array analysis on a cohort of 42 PMF patients CD34+ cells 
and 31 healthy donors. In the same study, miR-29a-3p was found upregulated in 
CD34+ patients, in agreement with our findings in PMF CD34+ patients. miR-29a-3p 
upregulation in PMF CD34+ cells was validated by RT-PCR (with TaqMan probes) in 
an independent set of CD34+ cells from 10 PMF patients and 8 healthy subjects.  
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In the same study, also the upregulation of miR-379-5p, miR-543 and miR-19b-3p 
were validated in PMF CD34+. Our validations on granulocytes do not confirm a 
statistically significant upregulation of these miRNas in PMF, showing only a trend 
toward, but we are confident that the validation of Norfo et al. on CD34+ is solid, 
considering that they were carried out on our same cell type. Interestingly Norfo et al. 
validated microarray data using two sets of experiments, conducted on CD34+ cells 
and on granulocytes, that showed that PMF-specific variations of a few miRNAs are 
observed in CD34+ and not in granulocytes.  
Indeed miR-486-3p was significantly downregulated in PMF granulocytes and 
upregulated in PMF in CD34+. 
The 3’-moR-128-2, a newly annotated small RNA, results expressed in CD34+ and is 
not detected in PMF. It is also downregulated in PMF granulocytes respectively to 
controls.  
Supplementary Figure 3 shows the expression profiles in considered RNA-seq 
samples, of all the detected sRNAs expressed from mir-128-1 and mir-128-2 loci: of 
them, the unique miRNA expressed from 128-1 hairpin is equally expressed in PMF 
and normal samples, 3’-moR-128-2 is highly expressed in normal stem cells and down 
regulated in PMF, whereas miR-128-3p (miR-128-2-3p) is weakly expressed.  
In Figure 6 we show additional information regarding miR-128-3p and 3’-moR-128-2. 
The moRNA sequence is not contained in the canonical hairpin (Figure 6A). Thus, the 
moRNA probably derives from the processing of an alternative hairpin precursor. In 
Figure 6B we show the RNAfold predicted minimum free energy (MFE) folding 
structure of the canonical hairpin and of the longer one from which the moRNA is 
derived. 
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Figure 6. The 3’-moR-128-2 is produced by the precursor sequence of miR-128-3p. Panel A) shows 
that the moRNA is derived from a region of the primary miRNA sequence exceeding the canonical 
hairpin precursor sequence, and that the moRNA is not exaclty adjactent to the annotated miRNA. 
Panel B) shows the minimum free energy (MFE) folding structure predicted  by RNAfold  for the 
canonical hairpin seqeunce and for the longer one, from which the moRNA is probably derived. Panel 
C) shows that the considered small RNAs are conserved in evolution through vertebrates. 
Figure 6C shows that mir-128 locus is inside an intron of ARPP21 gene, and displays 
that the genomic region encoding the 5’ region of the moRNA is as conserved as that 
corresponding to the miRNA, according to Vertebrate and Mammals UCSC base-wise 
conservation score. 
moRNA biological roles and mechanisms of function still deserve investigation. Very 
likely, moRNAs can function as miRNAs in post-transcriptional gene silencing, 
guiding RISC to complementary target mRNAs. This was first demonstrated by 
Umbach and colleagues, that used a luciferase-based indicator assay to demonstrate 
that a viral moRNA (moR-rR1-3-5p) has inhibitory activity against an artificial 
mRNA bearing a perfect target site 51, 52. Beyond this proof of principle experiment, a 
recent study reported moRNA specific expression in human embryonic stem cells 
(hESCs; Asikainen et al., personal communication, 2015). In the same study, moRNA 
and miRNA transfection experiments and microarray quantification of gene 
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expression were conducted and identified gene silenced by moR-103a-2-3p, one of the 
most abundantly expressed moRNAs in hESCs, and by miR-103a.  
In line with these previous studies, we assumed that 3’-moR-128-2 can act as a 
miRNA, and investigated its possible impact on target gene silencing and on specific 
pathways or biological processes.  
We conducted a preliminary functional characterization of the possible biological role 
of sRNAs DE in PMF, by a double strategy.  
First we investigated possible target genes and pathways of the group of validated DE 
sRNAs, considered as a whole. 
Then, we focused more on one of the most novel elements emerged by our results, 3’-
moR-128-2, to get specific insights on its possible functions in CD34+ and, in turn, in 
PMF disease. 
 
Genes and pathways targeted by the sRNAs deregulated in 
PMF 
Target predictions of miR-10b-5p, miR-19b-3p, miR-29a-3p, miR-379-5p, miR-543 
and of moR-128-2 were performed by using two different programs, miRanda53 and 
PITA54, which implement orthogonal target prediction strategies, and for which the 
code availability allowed us to make custom predictions of possible miRNAs and 
moRNA target genes, by using as query sequences the identified isomiRs and 
isomoRs sequences. 
Among different isomiRs detected for each considered miRNA, we considered the 
most expressed, even if it was different from the annotated sequence (Supplementary 
Table 6). We also considered those isomiRs that were significantly contributing to 
miRNA total expression, and which were differently expressed in patients respect to 
controls (t-test<0.05 and |log2FC| > 1). Accordingly, both isomoRs were considered 
for moR-128-2.  
A functional enrichment analysis, based on Reactome annotation maps, of targets 
predicted by both methods was obtained using a hypergeometric test. 
Supplementary Table 6 includes details on considered sequences and on the number of 
identified target genes per sequence. It lists the significantly (p-value <= 0.05) 
enriched pathways, and the number of distinct genes represented in small RNAs 
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targets. We choose to include in the table only those pathways that appear enriched in 
targets of at least half of the small RNAs.  
miRNA targets are enriched in many interesting pathways involved in tumor 
development and progression, as signaling by FGFR, DAP12 signaling and Oncogene 
Induced Senescence.  
Human fibroblast grow factor receptors (FGFRs) are a family of four tyrosine kinase 
receptors (FGFR1–4) involved in a variety of cellular processes. They are indeed key 
regulators of fibrogenesis, embryogenesis, angiogenesis, metabolism, and many other 
processes of proliferation and differentiation55, 56. Deregulation of FGFR signaling has 
been observed in numerous tumors.57, 58 
DAP10 is an immunoreceptor tyrosine-based activation motif (ITAM)-bearing 
transmenbrane adapter molecule and it is reported to be signaling partner of activating 
natural killer receptors. DAP12 complex to TREM-1 and MDL-1 receptors to form 
receptor complexes involved in macrophage differentiation59 and apoptosis in M1 
leukemia cells60, significant monocytic activation of myeloid cell, calcium 
mobilization  and inflammatory response61, 62. Its elevated expression levels are 
associates with enhanced cytotoxic characteristics in large granular lymphocyte 
leukemia63. 
Senescence is the stable cell growth arrest. Oncogene senescence (OIS) occurs when 
the activation of an oncogene is triggered, in this case it is termed oncogene-induced 
senescence. OIS acts as a barrier against tumour progression by driving stable growth 
arrest of cancer progenitor cells 64-66. 
3'-moR-182-2 
Intrigued by the striking expression pattern of the newly discovered 3'-moR-182-2 we 
looked in details into sequence, structure, expression and functional differences of 3'-
moR-128-2 and miR-128-3p.  
First we considered how sequence variants (isomiRs) of these two small RNAs relate 
to each other (Figure 7). For miR-128-3p, we identified 7 variants expressed in 
considered CD34+ samples: one exact isomiR, corresponding to the miRBase 
annotated mature form, and 6 “shorter or longer” variants (miR-128-3p-SL-1 to miR-
128-3p-SL-6), whereas only 2 3'-moR-128-2 isomoR were found out (3'-moR-182-2-1 
and 3'-moR-182-2-2)(Figure 7A). 
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Figure 7. Origin, sequence variability, and relations beween 3’-moR-128-2 and the adjacent miR-128-
3p. Panel A) shows that 3’-moR-128-2 and miR-128-3p map to the same locus and that both shows 
sequence variability (isomiRs and isomoRs). Both the major and the minoR isomoRs are found in 
normal CD34+ cells and not in PMF samples. Red and blue colors indicate isomiR and isomoR groups 
that can be produced with an unique sequence cutting sites. The most expressd isomoR is not associated 
to the corresponding most expressed isomiR. Moreover, expression levels, in CTR and PMF samples, 
of isomiRs and isomoRs are poorly correlated intragroup. These observations, point against the 
moRNA being simply a by-product of the miRNA biogenesis. A similar indication is given by the fact 
that some abundant isomiRs are not associated to detected isomoR sequences. Panel B) shows that 3’-
moR-128-2 and miR-128-3p have different, poorly overlapping, sets of predicted targets.  Panel C) 3-
moR-128-2 can stably bind RAN 3’UTR, schematic representation of the binding.  
 
According to the conservative hypothesis that interprets moRNA as byproducts of 
Drosha cleavage 67, one should expect comparable mean levels of miRNA and 
moRNA cognate variants (i.e. obtained from a single endonucleolytic cleavage cut) in 
control and PMF samples. 3'-moR-182-2-1, the most abundant isomoR, is expressed 
only in control samples and its only viable cognate partner is the miR-128-3p-exact 
variant that is highly and nearly equally expressed in control and PMF samples (with 
3,739 and 2,256 normalized reads, respectively)(Figure 7A). This observation does 
not point in this direction. Neither do the poor correlation of expression levels, in CTR 
and PMF samples, of cognate isomiRs and isomoRs, the fact that some abundant 
isomiRs are not associated to detected isomoR sequences, the good conservation of 
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moRNA sequence (Figure 6C), and the previously reported observation that both 
isomoRs are not contained in the canonical hairpin (Figure 6A). 
At the functional level, we predicted the targets of most expressed miR-128-3p 
isomiRs (miR-128-3p-exact, miR-128-3p-SL-2, miR-128-3p-SL-3, and miR-128-3p-
SL-4) and targets of the two 3'-moR-182-2 isomoRs (3'-moR-182-2-1 and 3'-moR-
182-2-2) assuming that they would act as miRNA, as indicated by the available 
experimental data51. 
We compared the union of predicted targets of miR-128-3p variants and the union of 
predicted targets of of 3-moR-128-2 variants, to understand how the moRNA function 
can be related to that of the cognate miRNA, as previously supposed (Asikainen 
personal communication). As shown in the Venn diagram in Figure 7B, only a small 
fraction of 3-moR-128-2 target genes, less than 17%, is putatively targeted also by at 
least one of the miR-128-3p isomiRs. 
According to Reactome-based functional enrichments, performed as explained in the 
previous paragraph, different pathways are enriched in predicted targets of 3-moR-
128-2 and of miR-128-3p. miR-128-3p targets are enriched in genes that are part of 
cellular pathways for the most part related to NGF, FGFR, ERBB4, ERBB2 signaling 
and transduction and to calcium ion homeostasis and signal transduction. 
Targets of 3-moR-128-2 are enriched too in genes part of several, distinct, pathways 
related to cellular signaling in growth and proliferation as “Signaling by Notch“, 
“Signaling by ERBB4”, “Signaling by FGFR in disease” but also, quite interestingly, 
in genes part of the “Post-transcriptional silencing by small RNAs” and of the more 
general “Regulatory RNA pathways”. Remembering that 3-moR-128-2 is highly 
expressed in normal and not detected in PMF CD34+, it is worth notice that, 4 out of 7 
genes of the “Post-transcriptional silencing by small RNAs” path, namely AGO1, 
AGO3, TNRC6A, and TNRC6B can be targeted by at least one isomoR of 3-moR-
128-2. Moreover, both considered 3-moR-128-2 isomoRs can also target RAN, the 
RAS-related nuclear protein, member of the RAS Oncogene Family, that is required 
for RNA export from the nucleus. Table 4 shows regulatory pathways identified for 
the two expressed moR-128 variants. 
 
Short RNA Variant Regulatory RNA pathways targets 
3'-moR-128-2 3'-moR-128-2-1 AGO3, RAN, POLR2H 
 3'-moR-128-2-2 AGO1, RAN, TNRC6A, TNRC6B 
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Table 4. regulatory RNA pathways of moR-128 predicted target 
In principle 3-moR-128-2, where it is expressed, as in CD34+ hematopoietic stem 
cells, could affect the expression of genes important for the entire process of miRNA-
based silencing. It can indeed target genes essential for post-transcriptional silencing 
both by translation repression, as AGO1/3, and by mRNA degradation, as 
TNRC6A/B. AGO1 and AGO3 are required for post-transcriptional translation 
repression activity; AGO1 is also involved in transcriptional silencing of promoters 68, 
and AGO3 is additionally putatively involved into the modulation of mature miRNA 
incorporation to the RISC complex, thus controlling the ratio between microRNA 
guide and passenger strand 69.  
TNRC6A, and TNRC6B play a role in miRNA-dependent translation repression and 
endonucleolytic cleavage, by recruiting specific deadenylase complexes. 
Moreover, 3-moR-128-2 can stably bind RAN 3’UTR. RAN is a multifunctional 
protein, involved in many processes and diseases. RAN controls cell cycle progression 
and it is a potential therapeutic target for treatment of cancers with activation of the 
PI3K/Akt/mTORC1 and Ras/MEK/ERK pathways 70. 
Specifically in relation to the above mentioned findings, as known, RAN play a key 
role in RNA export from the nucleus and for the biogenesis of all miRNAs. Thus, 
RAN silencing by 3-moR-128-2 can impair pre-miRNA transportation to the 
cytoplasm and output a reduction of miRNA biogenesis, a situation someway similar 
to that documented by a recent study that identified, in B. mori, a virus-encoded 
miRNA that suppresses the host miRNA biogenesis exactly by targeting the host 
exportin-5 RAN cofactor 71. 
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Conclusion 
In this study, we characterized miRNA and moRNA expression in CD34+ stem cells 
using massive small RNA-seq. The observed specificities in small RNAs expression 
of PMF CD34+ cells were subsequently confirmed considering granulocytes from 
PMF, PV and ET patients and from healthy controls. We thus provided new 
information regarding the possible role of miRNAs and new moRNAs in the disease. 
An interesting findings is the validated differentially expressed 3-moR-128-2 that we 
suppose could affect the expression of genes important for the entire process of 
miRNA-based silencing. It can indeed target genes essential for post-transcriptional 
silencing both by translation repression, as AGO1/3, and by mRNA degradation, as 
TNRC6A/B. It can also stably bind RAN 3’UTR that controls cell cycle progression 
and it is a potential therapeutic target for treatment of cancers with activation of the 
PI3K/Akt/mTORC1 and Ras/MEK/ERK pathways. Hopefully this information will 
help in the understanding the mechanisms that contribute to PMF pathogenesis and in 
formulate new targeted therapies. 
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Chapter 2 
In order to have more awareness in applying normalization methods when managing 
RNA-seq data of small RNA dataset, we evaluated the performance of normalization 
algorithms formulated for long RNAs, applied to human small RNA datasets. We 
simulated multiple matrixes with a controlled number of differentially expressed 
elements. We chose five normalization methods among the most cited and widespread, 
implemented in R packages: DESeq, edgeR, Quantile, NBPSeq, TBT. Each algorithm is 
based on different hypothesis on statistical shape and characteristics of data and we tested 
their impact on the downstream analysis in a differential expression test. To quantify 
normalization algorithms performances we calculated ROC curves and AUC curves. In 
this way we could compare the power of discovery differentially expressed small RNAs 
under different dataset characteristic, even when the assumption each method makes were 
violated. ROC curves showed that algorithms do not perform significantly differently 
applied to the same simulated scenarios and we are not able to definitively prefer a 
normalization algorithm as the best. The most successful situation for all the algorithm 
was when small RNAs strongly differentiate between the two groups. That coincides with 
a simulation scenario with the widest generated mean fold change. All the algorithms 
produced a high false positive rate and AUC curves showed us only small differences in 
the performances. We are far from reaching the consensus on the best normalization 
algorithm and there is still room to improve normalization methods for RNA-seq analysis. 
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Abstract 
RNA-seq technologies are useful for a wide range of biological investigations. While 
providing the highest throughput and the biggest discovery potential than ever, count data 
analysis is getting always more challenging. Many normalization methods have been 
developed to manage massive RNA-seq datasets and draw the information encrypted. All 
methods rely on statistical assumptions on data characteristics but no one of them has 
been specifically full-fledged for small RNAs. We comprehensively evaluated five 
commonly used normalization methods to pinpoint a procedure to perform a robust RNA-
seq analysis. We thus considered DESeq, edgeR, Quantile, NBPSeq and TBT algorithms. 
We simulated a huge number of small RNAs dataset with controlled characteristics in 
order to generate 9 different testing scenarios. With the aim of constructing a scenario the 
more realistic as possible, we estimated the distribution parameter of small RNA profiles 
from a real small RNAs dataset. We paid attention to choose a numerous real dataset to 
have an estimated value as representational of the reality as possible. We introduced in 
the simulated distribution a fixed number of differentially expressed elements and we 
applied five normalization methods. We evaluated the impact of the algorithms as the 
ability to recognize differentially expressed elements, conducting a differential expression 
analysis to all the normalized datasets. 
Our results show that there is not yet a performing algorithm to use and there is an 
impelling need for more powerful normalization methods. Appropriate statistical and 
computational methods could improve the accuracy of results that still include a high 
number of false positive elements. 
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Introduction 
 
High-throughput technologies are today in common use in biology. In the last decade we 
witnessed a very quick transformation in the methods for studying the transcriptome, 
offering a growing spectrum of applications. RNA-seq technology is the innovative 
element and since the very first papers in which it was applied1-­‐3, the potentials to 
understand the transcriptome have been appreciated. The evolution started from the 
relative low throughput sequence-based approach of Sanger sequencing of cDNA or EST 
libraries4-­‐7 and led to tag-based methods that improved the throughput, as serial analysis 
of gene expression (SAGE)	   8,	   9, cap analysis of gene expression (CAGE)	   10-­‐12 and 
massively parallel signature sequencing (MPSS)	   13-­‐15. These technologies were still 
expensive and the true revolutionary tool for transcriptomics was the advent of RNA-
seq16, performed by the Illumina technologies17-­‐21, the Applied Biosystems SOLiD22 and 
by Roche 454 Life Science23-­‐25. The use of these new technologies slushed the 
sequencing costs and improved the throughput, opening the doors to a wide application 
field. Examples of the use of NGS are chromatin immunoprecipitation coupled to 
sequencing (ChIP-seq), whole genome genotyping, genome wide structural variation, de 
novo assembling and re-assembling of genome, mutation detection and carrier screening, 
detection of inherited disorders and complex human diseases, paired ends and genomic 
captures, sequencing of mitochondrial genome, personal genomics26 and post-
transcriptional gene regulation27. 
Regarding transcriptome characterization, RNA-seq has a huge discovery potential that 
previous microarray technology or PCR missed. Indeed, it does not depend on prior 
knowledge about genome or transcriptome sequence. In addition, differently from 
microarray technology, RNA-seq is not affected by background noise nor by signal 
saturation signal1, it has a wide dynamic range of expression estimations, enabling the 
detection of weakly expressed genes27. Datasets produced are so heavily large and 
complex that the information contained is not clear-cut. Millions of short reads are 
produced from an RNA-seq experiment and a computational pipeline is always necessary 
to manage raw-data and to draw out information. Processing methods to extract and to 
release the information are pivotal. As well elucidated by Oshlack at al. 28	   	  28, a typical 
pipeline is organized in three main different steps: 1) Reads mapping to reference genome 
or transcriptome; 2) Summary of mapped reads at gene-level or transcriptome-level 
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depending on the experiment; 3) Data normalization, to compare different biological 
samples. The previous steps are always preliminary respect to further and more specific 
applications of methods that are determined by the experiment aim and scientific question 
of interest. A common issue in RNA-seq experiments is to determine differentially 
expressed (DE) elements among compared samples, generally two or more conditions or 
treatments. The goal is hence to identify genes or small RNAs that have changed 
significantly across samples and that can characterize distinct experimental groups of 
samples. In these specific applications of RNA-seq experiment, the normalization step is 
critical. It affects the good performance of the issue and DE genes could not actually be 
recognized due to an inadequate normalization29-­‐31. Its aim is to correct for technical bias 
that affect data and make multiple samples comparable, while maintaining true biological 
signal32. Bias have impact upon between-sample distributional differences in read 
counts29,	  33.  These bias are due to differences in sample preparation, in library size (or in 
sequencing depth) 1, in variable GC contents34, in gene length or in relative abundances of 
the genes35, 36. Despite many efforts to develop and evaluate normalization methods, there 
is not a recognized gold standard procedure. Many statistical methods have been 
formulated and discussed for microarray data analysis37. Due to the different principle of 
functioning upon which RNA-seq and microarray rely, and to deep differences in the 
distributions of expression data obtained with the two methods, microarray normalization 
algorithms cannot be applied to RNA-seq data. Microarrays record intensities as 
continuous measurements, assumed to follow a logarithmic or Gamma distribution38-40, 
while RNA-seq data are count, and thus discrete, values. Many algorithms have been 
devised to achieve normalisation of RNA-seq-derived long RNA expression data but no 
one has been developed specifically for small RNA. There are only few statistical studies 
evaluating normalization methods on mRNA-seq29,	   35,	   41-­‐44. Only one focus on 
normalization methods applied specifically to small RNAs dataset45 but Zhou et al. 32 
took a dig at it. All the procedures that deal with undesired variations among samples 
make assumption about true shape of data, in order to correct for differences in data 
shapes respect to the assumption. The most commonly used statistical models for RNA-
seq are Negative Binomial and Poisson distributions46-49, while more frequently they used 
a beta-binomial distribution50. It is also accepted that the fraction of deregulated mRNA 
respect to the total mRNAs expressed is negligible and that the deregulation is equally 
arranged between up-regulation and down-regulation41, 49. mRNA data and small RNA 
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data are somehow different in their expression and it not guarantee that normalization 
methods conceived for mRNA fit also for small RNA data. More specifically microRNAs 
(miRNA) are small RNA ~22 nt long51, post-transcriptional regulator of gene 
expression52. Their deregulated expression is implicated in tumour onset and 
progression53-55 and recognizing differentially expressed miRNAs can thus be crucial. 
Although many relevant normalization methods for RNA-seq have been generated, there 
is no guidance about how each algorithm impacts on the downstream analysis of 
microRNA data, as differentially expressed elements detection. The aim of this study is to 
evaluate normalization effect on DE downstream analysis in microRNA datasets. 
Materials and Methods 
In this section we describe the normalization methods considered, the real dataset used 
and the statistical model adopted in the simulation model. We performed a systematic 
analysis in order to test the robustness of normalization algorithms when their 
assumptions on data distribution are violated. 
Normalization methods 
We chose five normalization methods among the most cited and widespread, 
implemented in R packages: DESeq56, edgeR57, 58, Quantile59, NBPSeq60, TBT61. Each 
algorithm is based on different hypothesis on statistical shape and characteristics of data 
and we briefly describe their assumptions.  
 
DESeq   
It considers RNA-seq count data to follow a negative binomial distribution of witch 
parameters are variance and mean. It differentiates from other normalization methods 
because of its data-driven relationships of variance and mean. DESeq is based on the 
hypothesis that the majority of genes are not differentially expressed and that the 
proportion of up-regulated and down-regulated genes is equal. Differentially expressed 
elements impact on statistical data distribution is then negligible and they do not hence 
change the assumed regular negative distribution. It is implemented in the DESeq 
Bioconductor package and is easily applicable for R programming language users. 
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edgeR  
As DESeq, edgeR methods considers data to have a negative binomial distribution and 
the most part of it to be not DE. This information is taken into account to model the 
overdispersion parameter relative to the Poisson distribution, and uses a conditional 
weighted likelihood to moderate the level of overdispersion across genes. To achieve the 
moderation, they share information over all reads and the most evident effect is to 
stabilize dispersion estimation in small samples. The normalization methods implements 
the Trimmed Mean of M values (TMM) 31 method to calculate a scaling factor as a 
weighted trimmed mean of the log ratios between two classes of samples. 
Quantile 
The Quantile normalization method was developed for microarray data and it has been 
later applied to RNA-seq count data too. Its aim is to make two data distribution identical 
in their statistical properties and it works modifying data to the mean of the 
corresponding ranked values. It makes hypothesis neither on the proportion of up 
regulated and down regulated genes nor on a specific statistical distribution shape. It just 
assumes data to have the same distribution across samples. It is implemented in the R 
Bioconductor Limma package. 
 
NBPSeq 
NBPSeq has been formulated for RNA-Seq data normalization of DE analysis 
experiments. Di et al.60, 62  claim this method to be a parameterized negative 
binomial distribution based. It was derived from Robinson and Smyth algorithms57 
and it is asserted to solve edgeR inappropriate estimation of data overdispersion. 
Di et al model has indeed an additional parameter to allow the dispersion parameter to 
depend on the mean. Their parametric method complements nonparametric regression 
approaches for modelling the dispersion parameter. 
 
TBT  
TBT is developed by Kadota et al. and consist of a double normalization step of Trimmed 
Mean of M values (TMM) 31 algorithm alternated by the baySeq procedure62. They start 
normalizing data with a first run of TMM normalization. Then they estimate the 
percentage of DE using the empirical Bayesian method implemented in baySeq and they 
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exclude the corresponding DE for the last step that is a second TMM normalization. In 
that way they eliminate DE elements for TMM normalization that have been 
demonstrated to shift the median log-ratio of data from the expected zero mean61.  In this 
manner they do not need to make assumption on the proportion of up/down regulated 
elements. On the other hand, they consider a negative binomial statistical model for 
RNA-seq count data. 
 
Real Dataset 
We downloaded and considered a real data set from the Sequence Read Archive (SRA) 
database. It is a microRNA high throughput sequencing dataset of 63 head and neck 
squamous cell carcinoma, submitted by the French National League Against Cancer - 
Research Dept. It is a part of an integrative study of the Cartes d'Identité des Tumeurs 
(CIT) project (Accesion Study ERP001908). 
We chose this public dataset because of its large number of samples of Human tissue, 
belonging all to the same biological type, all sequenced with high depth. We indeed 
needed the more samples as possible in order to have the more representative statistical 
population of small RNA expression profiles. In the 63 high throughput samples we 
found 970 small RNAs expressed, more precisely annotated microRNAs, new 
microRNAs and new moRNAs. We assume data to have a negative binomial distribution 
with an overdispersed variance. The head and neck tumour count data allowed us to make 
a realistic estimation of distribution parameters of a miRNA expression profile. 
 
Comparison procedure 
The aim was to evaluate the performance of normalization algorithms formulated for long 
RNAs, applied to human small RNA datasets. We simulated multiple matrixes with a 
controlled number of differentially expressed elements, keeping track of them with a flag 
on data. We then measured the impact of normalization methods as the ability to 
recognize differentially expressed elements in a differentially expressed analysis, after the 
normalization step. To this aim we applied the normalization methods and performed the 
same differential expression analysis to all the normalized data. The analysis had 
identified some elements as differentially expressed and, knowing the truth about the 
nature of elements, we easily determined how many true positive, true negative, false 
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positive and false negative elements each test produced, when applied to a datasets 
normalized with a specific method. 
From these values we derived measures of the goodness of normalization algorithms in 
maintaining the intrinsic information the data contain. To quantify normalization 
algorithms performances we calculated ROC curves and AUC curves. In this way we 
compared the power of discovery differentially expressed small RNAs under different 
dataset characteristic, even when the assumption each method makes were violated.  
Simulation model 
In order to significantly assess the impact of the normalization methods on small RNAs 
downstream analysis, we simulated many groups of small RNAs dataset, each made up of 
1000 simulated datasets of 1000 small RNAs expression valules (Ngenes=1000) in 10 
normal samples compared against 10 treated samples (Nsamples=20). Each group of 
datasets has specific and controlled statistical distribution of small RNA expression 
values.  
In the “head and neck squamous cell carcinoma” small RNAs dataset, we detected 970 
small RNAs (Ngenes=970) in the 63 samples (Nsamples=63). The dataset can thus be 
represented as a matrix 970x63, with sample values on the columns and gene values 
across samples on the rows. We started from the evaluation of the mean and the 
dispersions of small RNA expression values across samples, drawing two vectors of 970 
values (970 means and 970 dispersions). To this aim, we used both a customized version 
of the Bioconductor DESeq package and the standard Bioconductor edgeR package.  
The function “estimateTagwiseDisp.R” implements the empirical Bayes strategy 
proposed by Robinson and Smyth57 for estimating the tagwise negative binomial 
dispersions. The empirical Bayes method is based on a weighted conditional maximum 
likelihood.  
In the DESeq package, the dispersion is considered as the square of the coefficient of 
biological variation, and additive weighted component of the variance, together with the 
uncertainty in measuring a concentration by counting reads. The function 
“estimateDispersions” performs three steps: it first estimate a temporary dispersion value 
for each gene, then it fit a curve for each group and then it assign a final estimated 
dispersion value. It implicitly normalizes data and we modified it in order to pass over 
this step. 
In Figure 1 we compared the estimated dispersion 
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Figure 1. Comparison of estimated dispersion with different methods, a 
customized version of DESeq and the edgeR tagwise dispersion. 
 
We then fitted the relationship between all the couples mean-variance. It is a 
characteristic parameter of small RNAs dataset56, 58and we considered the fitted 
distribution function rather than directly the mean-variance couples values, in order to be 
able to sample as many couples mean-variance as we wanted. We therefore needed a 
multiple datasets owing the same characteristic to have a representative population and 
give a statistical significance to the results. We chose the custom DESeq values as 
estimated variance because we could more easily fit the relation between data dispersion 
and mean. The fitted variance-mean relationship is represented in Figure 2. 
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Figure 2. Fitted relation of estimated mean and dispersion values 
 
To create a matrix 1000x20 (Ngenes=1000, Nsamples=20) with realistic expression 
values, we sampled 1000 times from the quartile of the distribution of the estimated 
means. Having estimated the relation with dispersion, for every sampled mean value, we 
calculated the related dispersion, finding 1000 couples of mean and dispersion values, 
corresponding to the parameters of 1000 small RNAs expression values of the assumed 
binomial negative distributions. Having fixed 1000 corresponding distributions, we 
sampled from each distribution 20 values, drawing a matrix 1000x20. We repeated the 
sampling of 20 expression values 1000 times, obtaining 1000 matrixes of 1000x20. 
After that, we have always considered the same 1000 matrixes 1000x20 and we always 
introduced a 20% of elements differentially expressed in one of the two classes of 10 
samples, modifying the 20% of small RNA expression values in 10 of the 20 samples. We 
implicitly assume that differentially expressed elements are in a relative small number, 
more specifically the 20% of the total. To choose which small RNA should be 
differentially expressed we randomly sampled 200 indexes of the matrix, for each matrix. 
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Every normalization method assumes data to respond to some specific statistical 
characteristics but actually, in most cases, we do not know which is the truth about data. 
To this aim we tuned the proportion of up/down regulated small RNA (respectively 
upregulated-downregulated: 50%-50%, 70%-30%, 90%-10%) and the mean extent of the 
shift from normal values, measured as fold change (FC: 2, 4, 8). 
The combination of different values of the parameters FC and up/down differentiated our 
dataset in 9 groups of 1000 matrixes each.  
Each count data matrix was then normalized using all the normalization algorithms 
chosen: DESeq, edgeR, quantile, NBPSeq, TBT. 
 
Differential expression analysis 
To assess the impact of normalization methods we performed a differential expression 
analysis for each normalized matrix.  
To test which small RNAs were recognized as differentially expressed, we proceeded in a 
similar way the “nbinomTest” DESeq package does. Unlike it, we did not normalize data 
in the testing for differentially expressed genes. We indeed similarly calculated the mean 
expression value for each small RNA, both considering all the classes and individually 
for every class of samples. Then we computed the fold change for each small RNA, as the 
logarithm to basis 2 of the ratio for the first to the second condition values, and a t-test to 
get the statistical significance for the change. Since we worked with matrixes of 1000 
miRNAs, it is necessary to control the false discovery rate (FDR). Raw P-values were 
thus adjusted for multiple testing with the Benjamini-Hochberg procedure63. 
We considered as differentially expressed all the small RNAs with an adjusted P-value < 
0.05.  
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Results and discussion 
We aimed to investigate the impact of the five chosen normalization methods on small 
RNA downstream analysis. All the normalization methods were developed for count data 
of long RNA transcripts. Small RNA dataset exhibit a negative binomial distribution with 
an overdispersed variance. In order to measure the performances of different 
normalization algorithms we simulated different population of small RNA count data. All 
the populations have the same dimensions: they are all composed by 1000 elements and 
each of it is a matrix of count expression values. The matrixes are all made up of two 
groups of samples of 10 members each, the groups corresponding to the classes we 
compare in the differential analysis. For each member we measure the expression values 
of 1000 small RNAs. 
All the populations have the 20% of differentially expressed small RNAs in one of the 
two groups, with controlled characteristics. They indeed vary in the proportion of 
up/down regulated and in the mean fold change. The ratio of up/down regulated small 
RNA let us investigate the robustness of the normalization methods respect to the 
assumption that there are the same proportion of up/down regulated small RNAs. 
Introducing a high mean fold change in the differential expressed elements, we can 
analyse differences in normalization methods in presence of high count small RNAs.  
The goal of a differential expression analysis is to assess whether two groups of sample 
belong (null hypothesis) or not (reject the null hypothesis) to the same population, in that 
sense the test is a binary classifier. Formally an instance is mapped to one element of the 
set {p,n} of positive and negative class labels. A classifier is a mapping from instances to 
predicted classes. We label as positive all the instances that belong to different population 
(differentially expressed elements) and negative all the elements that confirm the null 
hypothesis of belonging to the same population. 
The performance of a binary classifier can be measured with the power of the test: it’s the 
test’s probability to correctly rejecting the null hypothesis, called also “sensitivity”, 
“recall” or “true positive rate” (TPr). In our scenario it corresponds to the correct 
classification of a small RNA as differentially expressed. We are also interested in the 
false positive rate (FPr), or “false alarm rate”, that means the probability of error in 
rejecting the null hypothesis. In other word, how often we classify as differentially 
expressed small RNAs that are not. Testing for differentially expressed small RNAs in a 
simulated scenario where we know the truth about belonging to differentially expressed 
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elements or not, let us evaluate the effective false positive rate and false positive rate in a 
representative situation of the reality. 
We proceeded with a first qualitative evaluation of the impact of normalization methods, 
drawing Receiver Operating Characteristics (ROC) curves. ROC graph shows TPr on Y 
axis and FPr. Every point of the graph correspond to a pair of TPr and FPr varying the 
threshold of the scoring that we use to assign a label {p,n} to an instance. We can see all 
the curves in Figure 3.  
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Figure 3. ROC graph in 9 different scenarios, ROC graph shows TPr on Y axis and FPr. Every point of the 
graph correspond to a pair of TPr and FPr varying the threshold of the scoring. 
We can see that the algorithms do not perform significantly differently applied to the 
same scenarios and we are not able to definitively prefer a normalization algorithm as the 
best. They all have the same trends, varying the fold change value and the ratio between 
up regulated and down regulated small RNAs. More specifically we can see that an 
unbalanced proportion of up-regulated small RNAs respect to the down regulated small 
RNAs worsen the performance. As previously mentioned, an imbalance of up- and down-
regulated miRNAs is very likely to occur in many real word datasets. 
Considering a up-down regulated ratio of 50%, independently from the fold change value, 
the methods led to the same condition. The choice of the normalization procedure in that 
scenario does not weigh on DE recognition.  
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Fold change differentiate a little how the normalization methods have a bearing on DE 
test and we decided to quantify the performance by comparing the values of areas under 
the ROC curves. To compare classifier we may want to reduce ROC performances to a 
single scalar value. It is commonly accepted to calculate the Area Under the ROC Curve 
(AUC) that is equivalent to the probability that the classifier will rank a randomly chosen 
positive instance higher then a randomly chosen negative instance. The higher the AUC 
value is and better is the classifier performance. 
In Tables 1A, 1B, 1C are represented all the mean values of the areas under the curves 
that we draw for each TPR-FPR pair, varying the p-values threshold.  
The most successful situation is when small RNAs strongly differentiate between the two 
groups. That coincides with a simulation scenario where a mean fold change is equal to 8. 
Considering that the attainment falls short when the proportion of up regulated small 
RNAs grows, it is not surprising that the best performance is achieved in case of fold 
change equal to 8 and 50% of proportion. The normalization algorithm that allows the 
best compromise between TPr and FPr is edgeR but it does not move far away from other 
methods. 
To have a dimension of the differences, we arbitrary considered as threshold a p-value 
adjusted of 0.05 and in Table 2A, 2B, 2C we gathered a complete calculation of TPr and 
FPr for each of the 9 scenarios. We can see that all the normalization algorism produce a 
high false positive rate and this strengthen the needs of experimental validation in case of 
biological data. 
 
 FC2UP0.5 FC2UP0.7 FC2UP0.9 
auc_deseq 0,8059 0,7974 0,7677 
auc_edger 0,8060 0,7981 0,7693 
auc_quantile 0,8037 0,7948 0,7631 
auc_tbt 0,7918 0,7861 0,7638 
auc_nbpseq 0,8044 0,7944 0,7590 
Table 1A AUC  (area under ROC curves) values of  FC=2 and proportion of up regulated=50%, 70%, 90%  
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 FC4UP0.5 FC4UP0.7 FC4UP0.9 
auc_deseq 0,9386 0,9331 0,9109 
auc_edger 0,9391 0,9341 0,9165 
auc_quantile 0,9362 0,9284 0,8945 
auc_tbt 0,9397 0,9391 0,9363 
auc_nbpseq 0,9380 0,9305 0,9043 
Table 1B AUC  (area under ROC curves) values of  FC=4 and proportion of up regulated=50%, 70%, 90% 
 
 FC8UP0.5 FC8UP0.7 FC8UP0.9 
auc_deseq 0,9674 0,9647 0,9505 
auc_edger 0,9683 0,9664 0,9538 
auc_quantile 0,9664 0,9585 0,9231 
auc_tbt 0,9622 0,9625 0,9613 
auc_nbpseq 0,9678 0,9643 0,9458 
Table 1C AUC  (area under ROC curves) values of  FC=8 and proportion of up regulated=50%, 70%, 90% 
  
 
FC2UP05 FC2UP07 FC2UP09 
TPR FPR TPR FPR TPR FPR 
deseq 0,3505 0,8200 0,2766 0,7789 0,4088 0,7800 
edger 0,3656 0,7850 0,2396 0,7100 0,4492 0,8050 
quantile 0,2638 0,7650 0,3717 0,7588 0,3292 0,6750 
tbt 0,1691 0,6133 0,1100 0,6111 0,1397 0,6270 
nbpseq 0,3304 0,7850 0,3108 0,7286 0,3922 0,7550 
Table 2A. TPR, FPR of FC=2 and proportion of up regulated=50%, 70%, 90% p-value adjusted = 0.05.  
 
 
FC4UP05 FC4UP07 FC4UP09 
TPR FPR TPR FPR TPR FPR 
deseq 0,4313 0,9296 0,4593 0,9500 0,5859 0,9400 
edger 0,5670 0,9600 0,5788 0,9500 0,6349 0,9700 
quantile 0,4020 0,9548 0,5144 0,9246 0,6851 0,9300 
tbt 0,2382 0,9293 0,2434 0,9184 0,3945 0,9694 
nbpseq 0,3497 0,9450 0,4862 0,9300 0,5551 0,9347 
Table 2B. TPR, FPR of  FC=4 and proportion of up regulated=50%, 70%, 90% p-value adjusted = 0.05.  
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FC8UP05 FC8UP07 FC8UP09 
TPR FPR TPR FPR TPR FPR 
deseq 0,3108 0,9700 0,3852 0,9450 0,7009 0,9949 
edger 0,3484 0,9700 0,5038 0,9849 0,6270 0,9850 
quantile 0,3568 0,9450 0,5707 0,9747 0,7997 0,9849 
tbt 0,2808 0,9444 0,2831 0,9646 0,2886 0,9596 
nbpseq 0,1541 0,9750 0,3509 0,9497 0,7186 0,9450 
Table 2C. TPR, FPR of  FC=8 and proportion of up regulated=50%, 70%, 90% p-value adjusted = 0.05.  
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Conclusions 
In this study, we systematically evaluated the impact of five normalization algorithms 
formulated to manage RNA count data, when applied to small RNA count data. 
To this aim we simulated nine different realistic scenarios of 1000 data set each, each 
scenario differing in the proportion of up and down regulated small RNAs and in the 
extent of deregulation.  
We have not been able to identify a method that was robust respect to the diverse 
characteristics of the datasets. All the algorithms produce a high false positive rate and 
AUC curves show us only small differences in the performances. 
We are far from reaching the consensus on the best normalization algorithm and there is 
still room to improve normalization methods for RNA-seq analysis. 
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Chapter 3 
We were later interested in studying whether different intracellular amounts of FHC 
might affect gene expression profile. As first step toward the dissection of the molecular 
basis of FHC-modulated gene expression, we performed an integrated analysis of miRNA 
and mRNA expression patterns in K562 FHC-silenced cells. We used K562 cells in 
which the expression of FHC has been stably knocked-down by shRNA interference and 
whose transcriptome profile was already established. By using a microRNA PCR Panel, 
we found that 4 out of 84 analysed miRNAs, namely hsa-let-7g-5p, hsa-let-7f-5p, hsa-let-
7i-5p and hsa-miR-125b-5p, were consistently and significantly up-regulated in 
FHCsilenced K562 cells compared to control cells. The correlation among FHC amounts 
and the expression of the four miRNAs was further supported by the transient silencing 
and the reconstitution experiments. The profile of the four up-regulated miRNAs has been 
integrated with the transcriptome analysis by combining data obtained from the 
microRNA targets prediction software with a correlation-based approach. This test is 
based on the assumption that, since miRNAs tend to down-regulate the expression of 
their targets, the expression profiles of miRNAs are expected to be inversely related with 
those of their true target genes. This analysis led to the identification of 91 down-
regulated genes, the majority of whom appear to be candidate targets of a single miRNA, 
while 15 are subjected to multiple miRNA regulation. IPA revealed that the highest 
scored pathways in which these genes are involved are: “Cell Death and Survival, 
Hematological System Development and Function, Hematopoiesis” and “DNA 
Replication, Recombination and Repair, Cell Cycle, Cancer”. We believe that the 
identification of FHC-dependent miRNA/mRNA networks implies that different amounts 
of the ferritin subunit contribute, in K562 cells, to the remodelling of gene expression 
taking place during these cellular processes through the action of let-7g, let-7f, let-7i and 
miR-125b. This observation is further strengthened by the comparison of the miRNAs-
regulated pathways, reported in this work. It is interesting to note that, among the 
common pathways, “Cell Death and Survival” and “Hematological System Development 
and Function” rely on the ERK1/2 activation that our results demonstrate to be severely 
affected by FHC modulation. In conclusion, the data presented in this study add a further 
level of complexity to the relationship among iron and miRNAs, since it appears that the 
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intracellular amounts of FHC subunit are able to regulate let-7g, let-7f, let-7i and miR-
125b expression, as well as the repertoire of their down-stream genes. Recent reports 
suggest that the redox state of the cell might influence Let7 and 125-b levels, but 
certainly the FHC interference on miRNA expression deserves further analysis. 
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Abstract 
In a previous study, we showed that the silencing of the heavy subunit (FHC) of ferritin, 
the central iron storage molecule in the cell, is accompanied by a modification in global 
gene expression. In this work, we explored whether different FHC amounts might 
modulate miRNA expression levels in K562 cells and studied the impact of miRNAs in 
gene expression profile modifications. To this aim, we performed a miRNA-mRNA 
integrative analysis in K562 silenced for FHC (K562shFHC) comparing it with K562 
transduced with scrambled RNA (K562shRNA). Four miRNAs, namely hsa-let-7g, hsa-
let-7f, hsa-let-7i and hsa-miR-125b, were significantly up-regulated in silenced cells. The 
remarkable down-regulation of these miRNAs, following  FHC expression  rescue, 
supports a specific relation between FHC silencing and miRNA-modulation. The 
integration of target predictions with miRNA and gene expression profiles led to the 
identification of a regulatory network which includes the miRNAs up-regulated by FHC 
silencing, as well as 91 down-regulated putative target genes. These genes were further 
classified in 9 networks; the highest scoring network, “Cell Death and Survival, 
Hematological System Development and Function, Hematopoiesis”, is composed by 18 
focus molecules including RAF1 and ERK1/2. We confirmed that, following FHC 
silencing, ERK1/2 phosphorylation is severely impaired and that RAF1 mRNA is 
significantly down-regulated. Taken all together, our data indicate that, in our 
experimental model, FHC silencing may affect RAF1/pERK1/2 levels through the 
modulation of a specific set of miRNAs and add new insights in to the relationship among 
iron homeostasis and miRNAs. 
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Introduction 
A tight regulation of iron homeostasis is essential for life in eukaryotic cells. The 
availability of iron is required for critical pathways such as ATP generation and DNA 
synthesis. Deregulated iron levels contribute indeed to the generation of free radicals that, 
in turn, damage cellular proteins and nucleic acids [1]. Ferritin, a 24-mer protein, is 
devoted to keep intracellular iron in a bio-available and non-toxic form [2], thus playing a 
central role in intracellular iron equilibrium. 
The nano-cage of the ferritin molecule is composed by a well-defined array of heavy-type 
(FHC) and light-type (FLC) subunits, coded by two different genes [3] that share both 
extensive aminoacid sequence (55%) and structural similarity. The two subunits perform 
different functions in iron metabolism: FHC is involved in rapid iron uptake and release 
and it has ferroxidase activity, while FLC, devoid of enzymatic activity, essentially 
contributes to long-term iron storage [4]. Recently, several lines of evidence have 
demonstrated that FHC is a multi-functional protein, that might play a central role in 
proliferation [5], angiogenesis [6], chemokine signalling [7] and neoplastic 
transformation [8]. FHC expression is modulated, at transcriptional level, by proteins 
involved in tumorigenesis; among them, E1A [9], p53 [10], and c-Myc [11] act as 
repressors, while c-Jun is an inducer [12]. FHC itself binds to p53 and is able to activate 
p53 transcription under oxidative stress conditions [13]. Moreover, FHC transcription is 
activated by TNFα and interleukin 1α (IL-1α) [14], suggesting that pathways related to 
inflammation and stress can impact on ferritin regulation. The ferritin H subunit also 
physically interacts with, and regulates the activity of the chemokine receptor CXCR4 
[7], highly expressed in a variety of human malignancies. FHC down-regulation by 
shRNA interference strongly modifies, in vivo and in vitro, the proliferation of human 
melanoma cells [15].  
This scenario is even more complicated when considering the relationship between 
ferritin and cellular proliferation. FHC up-regulation has been associated with induction 
of differentiation and growth arrest in hematopoietic systems [16], differentiation of the 
Caco-2 enterocytic cell line [17] and switch from pre-adipocytes to adipocytes [18]. 
The last decade has witnessed a tremendous increase of knowledge on the role of 
microRNAs (miRNAs) in regulating gene expression in normal and pathological 
conditions. These non-coding RNAs, with an average length of 19-25 nucleotides, are 
able to modulate the expression of thousands of genes by inhibiting translation or 
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inducing degradation of transcripts. Moreover, one target transcript can be controlled by 
more than one miRNA [19]. It has been suggested that miRNAs might regulate more than 
60% of the protein coding genes [20]. Key functional roles for miRNAs have been 
demonstrated in development, organogenesis and cell differentiation [21]. In 
hematopoietic stem and progenitor cells miR-221, miR-222, miR-223 and miR-150 act as 
master regulators, contributing to the hematopoietic development and the lineage 
specification [22, 23].  
The role of miRNAs in cancer has been deeply investigated. Specific patterns of miRNA 
expression (miRNome) and variations have been established in different tumour stages 
and subtypes. miRNAs can play oncogenic (oncomiRNAs) and/or tumor suppressive role 
in almost all the aspects of cancer biology [24]. Moreover, a specific miRNA can play 
opposite roles in different contexts: for example, miR-29 acts as a tumor-suppressor in 
lung cancer, while it plays oncogenic functions in breast cancer [25]. Like virtually all 
other cellular processes, also iron homeostasis is regulated by specific miRNAs. miR-210 
acts on the transferrin receptor and is involved in iron acquisition. Iron storage and 
utilization are controlled by miR-200b, targeting FHC, while iron release is regulated by 
miR-485-3p, through its action on ferroportin (Fpn) [26]. 
We have recently found that, in a metastatic melanoma cell line [15] and in the K562 
erythroleukemia cell line [27], the silencing of FHC subunit is accompanied by profound 
modifications of gene expression. The molecular basis of the link among FHC levels and 
gene expression profile in these cells have not been established yet. 
In this study, we profiled both mRNA and miRNA expression in K562 cells silenced for 
the ferritin H subunit and compared these expression profiles with that of control cells. 
We identified specific miRNAs and genes differentially expressed upon FHC-knock 
down and studied the relations thereof. 
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Materials and Methods  
miRNA isolation and quantitative real-time PCR 
miRNA-enriched total RNA was extracted from cultured FHC-silenced K562 (K562shFHC) 
cells and K562 transduced with scrambled RNA (shRNA) using miRCURYTM RNA 
Isolation Kit Cell and Plant (EXIQON, Woburn, USA) following the manufacturer’s 
protocol. The concentration of RNA and the RNA quality (260/280 and 260/230 
absorbance ratios) of the samples were measured using Nanodrop (Thermo SCIENTIFIC, 
Waltham, MA, USA). We designed a double-step analysis for identification and 
quantification of abnormally expressed miRNAs in K562 shFHC compared to K562 
shRNA cells. The first was a “panel” procedure that simultaneously evaluated expression 
level of different mature miRNAs by quantitative real-time PCR (qRT-PCR); the second 
was performed on individual miRNAs, which eventually resulted differentially expressed 
in panel experiments. For panel analysis, we used Cancer Focus microRNA PCR Panel 
that assesses the expression levels of 84 onco-miRNAs.  
Each sample was assayed in triplicate, and the experimental data were normalized to the 
expression levels of the housekeeping small nuclear RNA,U6. 
 
Identification of differentially expressed miRNAs 
The fold change of miRNAs expression among the tested samples was calculated using 
2−ΔΔCt formula. Differences among the two sets of samples were analyzed by the Student 
t-test. Those differences with a p<0.05 were considered statistically significant.  
From this first analysis we decided to focus on those miRNAs that were found to be up-
regulated in K562 shFHC compared to K562 shRNA cells. cDNA synthesis, was 
performed using  TaqMan® MicroRNA Reverse Transcription Kit (Life Technologies, 
Carlsbad, CA, USA) containing microRNA-specific RT primers and Taqman miRNA 
assay. To measure miRNAs expression levels, 1.33 µL of each cDNA was added to the 
specific TaqMan microRNA Assay (20X) and TaqMan 2X Universal PCR Master MiX 
(Life Technologies, Carlsbad, CA, USA). The amplification conditions for miRNA qRT-
PCR were the following: 10 min at 95 °C, 40 cycles at 95 °C for 15 s, and 60 °C for 60 s. 
The experiments were performed in duplicate and the analysis was performed using the 
2−ΔΔCt formula. 
    98 
Transfection of K562 cells 
K562 cells were transfected using electroporation. In particular, over-expression of FHC 
was performed using the expression vector containing the full length of human FHC 
cDNA (pc3/FHC); transient silencing of K562 cells was obtained using a homemade 
FHC siRNA, kindly provided by Prof. Sonia Levi from the Vita-Salute San Raffaele 
University Milano, Italy. For rescue of FHC expression, approximately 6×106 K562-
silenced cells (K562shFHC) were resuspended in 600µL of Opti-MEM (Gibco BRL). 
Subsequently, 3×106 of cell suspension was mixed with 30 µg of pc3/FHC 
(K562shFHC/pc3FHC). The remaining 3×106 of cell suspension was mixed with the 
control plasmid, pcDNA™3.1 (K562shFHC/pcDNA™3.1). For transient silencing of 
FHC, 6x106 K562 cells were resuspended in 600µL of Opti-MEM and then, half was 
mixed with 15µg of a GFP-positive control siRNA (K562 Ctrl siRNA) and half with 
15µg of FHC siRNA (K562 FHC siRNA). After 15 minutes of incubation at room 
temperature, each sample was electroporated in a sterile electroporation cuvette (Bio-Rad 
Gene Pulser cuvette, 0.4 cm) using Gene Pulser Xcell Electroporation System (Bio-Rad). 
Electroporation was performed at 285V and 975µFa. After electroporation, cell 
suspensions were centrifugated at maximum speed and the pellets were left at room 
temperature for 20 minutes. Then, fresh complete medium was added to the pellets and 
cells were further incubated at 37°C in a humidified atmosphere supplemented with 5% 
CO2. Transfection efficiency was measured after 72h using real-time PCR. 
 
Identification of differentially expressed genes 
Genes modulated after FHC silencing have been identified using Limma package [28]. 
Differential expression analysis was obtained by a t-statistic, which is computed for each 
gene and for each contrast, with standard errors moderated across genes, exploiting the 
Empirical Bayes shrinkage method to stabilize the variance estimate. 
Only genes with absolute log(FC) of at least 1 and a FDR q-value lower than 0.1 have 
been considered differentially expressed. 
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Identification of anticorrelated predicted targets of miRNAs 
We identified the predicted regulatory relations significantly supported by expression 
data, integrating target predictions with miRNA and gene expression profiles in silenced 
and un-silenced cells. Only differentially expressed miRNAs were considered. Target 
predictions were computed with TargetScan. 
Pairwise Spearman correlations between miRNA and predicted target gene expression 
profiles were calculated. The supported relationships associated to statistically significant 
correlations (r<= -0.81 and p-value <=0.05) were selected. 
 
Pathways visualization 
Network visualization and annotation have been performed using Cytoscape [29]. 
  
Functional analysis of target genes  
In order to infer the potential functions of the differentially expressed miRNAs, we 
performed the functional analysis of their target genes using Ingenuity Pathway Analysis 
(IPA) database. IPA maps each gene within a molecular network and defines it as “focus 
molecule”. Ingenuity Pathway Analysis (IPA) software program was used as described 
elsewhere [30]. Following IPA analysis, Panther (Protein ANalysis THrough 
Evolutionary Relationships) was used to also classify genes in specific signalling and 
metabolic pathways (http://www.pantherdb.org/).  
 
RNA extraction and quantitative real-time PCR for FHC and 
c-Myc and RAF1 detection 
Total RNA was extracted from two distinct batches of K562 shRNA and K562 shFHC 
cells using the Trizol method (Life Technologies, Carlsbad, CA, USA). Real-time PCR 
was performed using 10X SYBR Green PCR Master mix (Life Technologies, Carlsbad, 
CA, USA), 400 nM of each primer pair, 20 ng of cDNA (total RNA equivalent) and 
nuclease-free water. The thermal profile consisted of 1 step at 95 °C for 10 min followed 
by 45 cycles at 95 °C for 30 s, 60 °C for 60 s. Human glyceraldehyde 3-phosphate 
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dehydrogenase (GAPDH) was used as housekeeping. Each reaction was performed in 
duplicate. The primer sequences for FHC and GAPDH have been already published (27). 
The primer sequences for RAF1 and c-MYC were as follow: 
RAF1 FW: TGCTGCGTCTTTGATTGGAG 
RAF1 REV: TGGTGCTACAGTGCTCATGA 
c-MYC FW: CCTCGGATTCTCTGCTCTCC 
c-MYC REV: TGTGAGGAGGTTTGCTGTGG 
Protein Extraction and Western Blotting Analysis 
K562 shRNA and K562 shFHC cells were lysed in the following buffer [20 mM Hepes 
pH 7.9, 420 mM NaCl, 1% Triton X-100, 1 mM EDTA, 25% glycerol, 1 mM PMSF, 1 
mM Na3VO4, 1 mM DTT, 1 µg/ml aprotinin, 1 µg/ml leupeptin] for 30 min on ice. After 
removal of the cell debris by centrifugation (12,000 ×g, 30 min), the concentration of 
proteins in the supernatant was measured by the Bio-Rad protein assay according to the 
manufacturer's instructions (Bio-Rad Laboratories, Hercules, CA, USA) [31]. A total of 
50 µg protein extract was boiled for 10 min in SDS sample buffer, separated by 12% 
SDS-PAGE and the proteins were transferred to a nitrocellulose membrane by 
electroblotting. Non-specific reactivity was blocked by incubating the membrane in 
nonfat dry milk in TPBS [5% (w/v) milk in PBS (pH 7.4) and 0.005% Tween 20] for 2 h 
at room temperature. The membrane was incubated with primary mouse anti-Phospho-
p44/42 MAPK (Erk1/2) (Thr202/Tyr204) antibody (1:1000; Cell Signaling Technology, 
Danvers, MA, USA) overnight at 4°C. Being washed in TPBS, the membranes were 
subsequently incubated with anti-mouse secondary antibody (1:3000 Cell Signaling 
Technology, Danvers, MA, USA) for 2 hours. The membrane was developed by ECL-
Western blot detection reagents according to the manufacturer's instructions (Santa Cruz 
Biotechnology, Texas, USA). γ-Tubulin was used as a loading control. 
 
Assessment of cell proliferation 
3-[4,5-Dimethylthiaoly]-2,5-diphenyltetrazolium bromide (MTT) assay was performed to 
detect proliferation of K562 shRNA and K562 shFHC cells. The experiments were 
performed on starved cells that were obtained culturing proliferating cells with RPMI 
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1640 without FBS for 24h. A total of 4.5X104 cells/well were seeded into 96-well plate 
and let to grow for 72h in RPMI medium. There were octuplicates for each cell type. 
Fresh MTT (Sigma Aldrich, Saint Louis, MO, USA), re-suspended in PBS was added to 
each well. After 2h incubation, culture medium was discarded and replaced with 200µL 
of DMSO. Optical density was measured at 570 nm in a spectrophotometer. Each 
experiment was performed in triplicate.  
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Results 
miRNA and transcriptome analysis in K562 cells 
Our main goal in the past years has been the identification and classification of genes 
whose expression is directly or indirectly modulated by FHC in different human cell 
lines. In the present study, we evaluated if the silencing of FHC may also alter 
oncomiRNAs expression in the K562 erythroleukemic cell line with the aim of 
identifying the potentially regulated genes. To this, we utilized a cell clone, already 
described, in which FHC expression has been knocked-down with specific shRNA [27]. 
Using Cancer Focus microRNA PCR Panel, we have identified 59 miRNAs, 12 of which 
were up-regulated and 3 down-regulated, with an absolute Log fold-change (LogFC) 
greater than 1, in K562 cells silenced for H ferritin (shFHC) versus K562 cells transduced 
with scrambled RNA (shRNA) (Table S1). The analysis was performed in triplicate from 
both cell types using quantitative real-time PCR (qRT-PCR). Four miRNAs namely hsa-
let-7g-5p, hsa-let-7f-5p, hsa-let-7i-5p and hsa-miR-125b-5p resulted significantly up-
regulated, with LogFC variation of at least five  and a t-test p-value <0.05, after FHC 
knock-down (Table 1). 
 
microRNA 
LogFC 
(shFHC vs shRNA) 
p-value 
hsa-let-7g-5p 7.38 0.0133 
hsa-let-7f-5p 5.47 0.0218 
hsa-let-7i-5p 4.95 0.0340 
hsa-miR-125b-5p 5.82 0.0470 
Table 1 .Four miRNAs are significantly up-regulated after H ferritin silencing 
 
The expression of these four miRNAs was assessed by TaqMan assay in an independent 
set of RNA obtained from silenced cells and from K562 cells in which the expression of 
FHC has been restored. The results of a duplicate set of experiments are shown in Panels 
A and B of Figure 1. Panel A shows the extent of FHC-silencing and reconstitution. In 
Panel B are reported the expression levels of the four miRNAs in the silenced and 
reconstituted K562 cells. It appears that the four miRNAs are indeed up-regulated in the 
cells in which the FHC subunit was present at a significantly lower level (FC= 0.3) 
    103 
compared to shRNA cells (p-value<0.05) and down-regulated in the cells where FHC 
expression levels were rescued.  
 
Figure 1. Four miRNAs are significantly modulated by FHC amounts. A) Real-time PCR 
analysis of FHC mRNA performed on total RNA from K562 shRNA, K562 shFHC and 
K562shFHC/pc3FHC . Results are representative of two different experiments. B) TaqMan 
analysis of hsa-miR-125b, hsa-let-7f, hsa-let-7g, hsa-let-7i in K562 shRNA, K562 shFHC 
and K562shFHC/pc3FHC. Results are representative of two different experiments. N.S.: Not 
Significant 
 
According with the microRNA PCR panel, the greatest increase was observed for hsa-let-
7g, whose expression is about 14-fold higher in the silenced cells compared to the 
control. We also transiently trasfected K562 cells with a homemade FHC siRNA kindly 
provided by Professor S. Levi, and compared the expression levels of the four miRNAs 
with those of control cells. In two independent experiments, a different silencing 
efficiency, in the order of about 20 and 40%, was obtained. Panels A and B of Figure 2 
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show that, in both samples, FHC silencing is accompanied by an up-regulation of hsa-let-
7g-5p, hsa-let-7f-5p, hsa-let-7i-5p and hsa-miR-125b-5p. 
 
Figure 2. Transient silencing of FHC induce up-regulation of hsa-miR-125b, hsa-let-7f, hsa-let-7g, hsa-let-
7i. A transient silencing of FHC of about A) 20% and B) 40% is accompanied by the up-regulation of hsa-
miR-125b, hsa-let-7f, hsa-let-7g, hsa-let-7i. Results are representative of two different experiments 
performed by TaqMan analysis. *p value<0.05 
 
The gene expression profile of FHC-silenced versus un-silenced K562 cells has been 
already determined in a previous work [27]. Here, in order to integrate miRNA and 
mRNA transcriptome findings, we have re-analyzed the raw microarray data. The Limma 
differential expression analysis identified 219 transcripts with a significantly altered 
expression in the FHC-silenced cells, including 64 up- and 53 down-regulated genes with 
an absolute LogFC greater than 2. The full cast of the FHC-dependent mRNAs is reported 
in Supplementary Table 2 (Table S2). 
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miRNA-mRNA regulatory network 
Next, for differentially expressed miRNAs, we integrated target predictions with miRNA 
and gene expression profile, to identify the regulatory relationships significantly 
supported by expression data. Combining TargetScan predictions of miRNA-target 
interactions with a correlation-based analysis of miRNA and transcript expression 
profiles (see Materials and Methods), we obtained 108 interactions supported by 
expression data, involving hsa-let-7g-5p, hsa-let-7f-5p, hsa-let-7i-5p and hsa-miR-125b-
5p and 91 down-regulated genes. In particular, the expression of hsa-let-7i resulted to be 
negatively correlated with that of 13 transcripts; hsa-let-7f and hsa-let-7g with that of 20 
transcripts and 25 transcripts, respectively; finally, hsa-miR-125b negatively correlated 
with 50 transcripts. As shown in the reconstructed regulatory network (Figure 3), the 
majority of these genes were supported targets of only one miRNA, whereas 15 genes 
were putatively regulated by two or more  up-regulated miRNAs. 
The list of the 91 down-regulated transcripts with their cognate miRNAs is reported in 
Supplementary Table 3 (Table S3). 
 
Figure 3. miRNA-mRNA interaction networks. miRNA-mRNA interaction networks built by Cytoscape. 
We identified a total of 108 miRNA-mRNA significantly negatively correlated interaction. The four up-
regulated miRNAs are colored in red and the 91 down-regulated target mRNAs are in green. let-7i is 
correlated with 13 transcripts; let-7f and let-7g with 20 and 25 transcripts, respectively; miR-125b 
negatively correlates with 50 transcripts. The majority of genes are supported targets of only one specific 
miRNA, whereas 15 genes are putatively regulated by two or more distinct up-regulated miRNAs.  
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miRNAs modulated by FHC silencing impact on specific 
pathways  
The 91 down-regulated supported target genes of hsa-let-7g-5p, hsa-let-7f-5p, hsa-let-7i-
5p and hsa-miR-125b-5p were studied with two knowledge-based approaches  to better 
characterize the networks potentially modulated by FHC silencing. Ingenuity Pathway 
Analysis tool (IPA) highlighted the 9 networks reported in Table 2; of them, the highest 
scoring is “Cell Death and Survival, Hematological System Development and Function, 
Hematopoiesis” with a significance score of 37 and 18 focus molecules (Panel A of 
Figure 4), followed by “DNA Replication, Recombination and Repair, Cell Cycle, 
Cancer” with a significance score of 32 and 16 focus molecules (Panel B of Figure 4). 
The significance scores of these networks (estimating the probability that a collection of 
genes equal to or greater than the number in a network can be achieved by chance alone) 
are very high, since a score of 3 indicates a 1/1000 chance that the focus genes are in a 
specific network due to random chance.  
 
Figure 4. The two highest scoring networks identified by IPA, that correlate genes target of the miRNAs 
differentialy expressed after FHC silencing. Ingenuity Pathway Analysis was used to investigate the 
networks potentially affected by the down-regulated genes. (A) Cell Death and Survival, Hematological 
System Development and Function, Hematopoiesis” is the highest scoring network with a significance 
score of 37 and 18 focus molecules (B) DNA Replication, Recombination and Repair, Cell Cycle, Cancer” 
has a significance score of 32 and 16 focus molecules. The target down-regulated genes are shaded in 
green. Intensity of shading correlates with the degree of down-regulation. A solid line represents a direct 
interaction between two genes, while a dotted line indicates an indirect interaction.  
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Table 2 Top 9 molecular networks predicted by IPA, by analysis of genes with expression profiles 
significantly negatively correlated with that of miRNAs differentially expressed after FHC silencing 
 
Molecules in Network Score Focus 
Molecules 
Top Diseases and Functions 
BMF, CD69, GIPC1, GJC1, GNPDA1, 
ICAM2, IRS2, PAG1, PPAT, PPP2CA, 
RAF1, RDX, SEMA3E, SOCS1, 
ST6GAL1, TGFBR3, UTRN, VEGFB 
37 18 Cell Death and Survival, 
Hematological System 
Development and Function 
ABHD6, ARL6IP4, ASXL2, CMTM6, 
CRCP, GALNT1, GANAB, HIST2H2BF, 
NXT2, OSBPL3, PARP8, PSTPIP2, RMI2, 
TMEM87A, WDR73,XRCC3 
32 16 DNA Replication, 
Recombination and Repair, Cell 
Cycle, Cancer 
DDX26B, GXYLT1, PHF23, QSOX2, 
RAB43, SLC46A3, SNX22, SNX24, 
SNX25, SZRD1, TMEM50A, VSTM4, 
ZNF10 
24 13 Cancer, Gastrointestinal disease, 
Cell death and Survival 
ADRBK1, ARHGEF2, ARRB1, ATP5G2, 
AZI2, HAND2, HBEGF, P2RX4, P2RX6, 
SFMBT1, SLC25A12, UBA52, USP24 
23 13 Cardiovascular system 
development and function, 
Developmental disorders, Organ 
morphology 
AMT, DLGAP4, ELF4, EPB41L4A, 
FAM214B, MEGF9, SEMA4F, SPRTN, 
USP32, ZNF263 
16 10 Cancer, Gastrointestinal disease, 
Cell to cell signaling and 
interaction 
CCDC126, FAM118A, FAM53C, GALE, 
GJC1, GPR153, GPR160, MAN2A2, 
NEO1, PPARGC1B,  
16 10 Cancer, Cellular Movement, 
Tissue Morphology 
CTPS1, HABP4, NAGA, PSMD7, 
SEC14L1, TDG, TRIM5, WARS, LIPT2 
13 8 Carbohydrate Metabolism, 
Developmental Disorder, 
Hereditary Disorder 
LIPT2 2 1 Organ,  Morphology, 
Riproductive System 
Development and Function, 
Endocrine System Development 
and Function  
ATP8B4 2 1 Cancer, Organismal Injury and 
Abnormalities, Reproductive 
System Disease 
    108
In parallel, ANalysis THrough Evolutionary Relationship (PANTHER) showed that hsa-
let-7g, hsa-let-7f, hsa-let7i and hsa-miR-125b up-regulation might determine changes in 
29 metabolic pathways 18 of which are signalling pathways (Figure 5) mostly involving 
RAF1. Notably, RAF1 is one of the 18 focus molecules identified by IPA in the network 
reported in Figure 4A. 
. 
Figure 5. Pathway analysis performed using PANTHER. Panther gene ontology (GO) 
analysis for the 91 down-regulated target genes. Several metabolic pathways are 
affected, the majority of them is represented by signalling pathways , shaded in blue. 
 
RAF1, pERK1/2 and c-Myc expression in K562 FHC-silenced 
cells 
We noticed that, in the “Cell Death and Survival, Hematological System Development 
and Function, Hematopoiesis” network (Figure 4A), the 18 focus molecules potentially 
modulated by hsa-let-7g-5p, hsa-let-7f-5p, hsa-let-7i-5p and hsa-miR-125b-5p, converge 
on a central hub represented by the ERK1/2 kinase. In particular, 6 of them directly 
impact on this kinase; RAF-1, VEGFB, CD69 and IRS2 are known activators, PPP2CA 
acts as inhibitor, while SOCS1 might act either as inhibitor or activator depending on the 
cellular context. The potential involvement of ERK1/2 is further supported by the 
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observation that the pathways identified by PANTHER analysis all depend on the 
activation of this molecule. Thus, we decided to investigate RAF1 expression and 
ERK1/2 activation in the FHC-silenced cells by real-time PCR and western blot analysis, 
respectively. The experiments were performed in duplicate on RNAs and protein extracts 
from two independent sets of cells.. 
 
Figure6. FHC silencing in K562 cells reduces proliferation rate via RAF1/MAPK pathway inhibition and is 
associated with  c-Myc down-regulation. A) Real-time PCR of RAF1 mRNA performed on K562 shRNA, 
K562 shFHC and K562shFHC/pc3FHC. Results are representative of two different experiments B) Western Blot 
analysis for pERK1/2 was performed on 50µg of total protein extract from K562shRNA and K562shFHC 
cells. Total ERK1/2 was used as loading control. Results are representative of three different experiments. 
C) Western Blot analysis for pERK1/2 and FHC was performed on 50µg of total protein extract from 
K562shRNA and K562 shRNA+FHC. Total ERK1/2 and γ-Tubulin were used as loading controls. Results 
are representative of two different experiments. D) Equal number of starved silenced and un-silenced cells 
were plated into a 96-well plate, incubated for 72 h and analysed by MTT assay. Proliferation of FHC-
silenced cells is reduced of about 35% compared to controls. Data are presented as mean ± standard 
deviation. E) Real-time PCR of c-Myc mRNA performed on K562 shRNA, K562 shFHC and 
K562shFHC/pc3FHC . Results are representative of two different experiments. 
 
Panel A of Figure 6 shows that RAF1 levels are significantly altered by FHC silencing, 
thus confirming the microarray data. Panel B shows that ERK1/2 phosphorylation is also 
severely impaired in the silenced cells compared to control. To further correlate ERK1/2 
phosphorylation and FHC expression levels, we analysed pERK1/2 after FHC over-
expression. Panel C of Figure 6 shows that, in the control cells, an FHC over-expression 
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of the order of about 37% is accompanied by an increased ERK1/2 phosphorylation. The 
role of ERK1/2 in the control of cell proliferation has been largely demonstrated [32]. 
Therefore, we analysed the proliferation rate of the silenced and un-silenced K562 cells 
by MTT assayThe experiments were performed in triplicate and the results, reported in 
Panel D of Figure 6, indicate that the proliferation of FHC silenced cells is reduce of 
about 35% compared to the controls It has been reported that in the 3’ untranslated region 
of c-Myc mRNA there are multiple potential binding sites for Let-7 miRNAs family 
members. Moreover, the overexpression of Let-7 in cell cultures is accompanied by a 
decrease in c-Myc mRNA levels. Consequently, we determined by qRT-PCR the amounts 
of c-Myc mRNA in K562 cells silenced or not for FHC, finding that c-Myc mRNA was 
down-regulated to an extent of about 35% following FHC-silencing (Panel E of Figure 6).  
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Discussion 
While the biochemical bases of ferritin function in iron uptake and deposition have been 
clearly established, and the respective roles of the two subunits determined, other aspects 
of its biological functions still remain to be clarified. Since the middle of last century, a 
robust body of data indicates that intracellular FHC is not only essential for iron 
metabolism but is also involved in critical metabolic pathways from the signalling 
cascades of CXCR4 [7] and G-CSFR [33] to Apo-B biogenesis [34].  
We are interested in studying whether different intracellular amounts of FHC might affect 
gene expression profile of a given cell; proteome and transcriptome analysis has already 
revealed that the silencing of FHC is accompanied, in different cell types, by profound 
modifications in the steady-state amount of key proteins and transcripts [15, 27]. This 
phenomenon can be at least partially attributed to perturbations of the oxidative state of 
the cell induced by FHC-silencing, but the type and the amount of transcripts potentially 
regulated by FHC suggest the existence of additional mechanisms that still require to be 
investigated. In this work, as first step toward the dissection of the molecular basis of 
FHC-modulated gene expression, we performed an integrated analysis of miRNA and 
mRNA expression patterns in K562 FHC-silenced cells.  
We have utilised K562 cells in which the expression of FHC has been stably knocked-
down by shRNA interference and whose transcriptome profile is already established [27]. 
By using a microRNA PCR Panel, we found that 4 out of 84 analysed miRNAs, namely 
hsa-let-7g-5p, hsa-let-7f-5p, hsa-let-7i-5p and hsa-miR-125b-5p, are consistently and 
significantly up-regulated in FHC-silenced K562 cells compared to control cells. The 
correlation among FHC amounts and the expression of the four miRNAs is further 
supported by transient silencing and reconstitution experiments. 
The Let-7 human miRNA family is composed by 14 members widely considered as 
tumor suppressors. Let-7 miRNAs regulate, among others, the expression of the 
oncogenes Ras [35], Myc [36, 37] and HMGA2 [38]; accordingly, we found that, in FHC-
silenced K562 cells, the up-regulation of Let7-g, -f and -i, is accompanied by an 
important reduction of Myc expression.  
Different members of the Let-7 family regulate highly overlapping set of genes, thus 
suggesting a redundant function. On the other hand, the regulation of their expression is 
elicited at multiple levels, and, in certain cancers, only specific members appear to be 
deregulated [39]. Therefore, an emerging question is whether different members of a 
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miRNA family undergo a differential regulation within the same cell. Our data point in 
this direction, since FHC-silencing is accompanied, in K562 cells, by a selective up-
regulation of three out of 9 Let-7 miRNAs analysed. 
miR-125b, a member of the miR-125 family, is an intriguing molecule, acting either as 
tumor suppressor or as an oncogene in different cancer types [40, 41]. Recently, miR-
125b has been utilized as biomarker to distinguish cell lines derived from acute (HL60) 
and chronic (K562) myeloid leukemias and it has been proposed that in K562 it may act 
as a tumor promoting agent [42].  
Our results demonstrate that RAF1, one of the target genes of miR-125b, is down-
regulated in the FHC-silenced K562 cells. Moreover, we have shown, in these cells, a 
reduced activation of pERK1/2, that plays a central role in all the pathways in which the 
miRNA-regulated genes are involved. ERK1/2 MAP kinases regulate growth, survival 
and cell cycle progression in mammalian cells upon phosphorylation-induced activation 
[43]. Our data show that FHC knock-down may negatively regulate, through the 
modulation of miR-125b expression, the ERK activation thus suggesting that, in our 
experimental model, hsa-miR-125b may prevalently act as tumor suppressor molecule. 
Consistent with this hypothesis is also the significant reduction in proliferation rate of 
FHC-silenced cells. A correlation among FHC levels, has-miR-125b and ERK1/2 
activation is further supported by the decreased miRNAs amount (data not shown) and 
the augmented phosphorylation of the MAPK in FHC over-expressing cells (Panel C of 
Figure 6). 
In this study, the profile of the four up-regulated miRNAs has been integrated with the 
transcriptome analysis by combining data obtained from the microRNA targets prediction 
software with a correlation-based approach. This test is based on the assumption that, 
since miRNAs tend to down-regulate the expression of their targets, the expression 
profiles of miRNAs are expected to be inversely related with those of their true target 
genes. This analysis led to the identification of 91 down-regulated genes, the majority of 
whom appear to be candidate targets of a single miRNA, while 15 are subjected to 
multiple miRNA regulation. IPA revealed that the highest scored pathways in which these 
genes are involved are: “Cell Death and Survival, Hematological System Development 
and Function, Hematopoiesis” and “DNA Replication, Recombination and Repair, Cell 
Cycle, Cancer”. The role of FHC in the processes of cell differentiation and neoplastic 
transformation has been investigated for a long time, starting from the observation that its 
intracellular amounts can significantly vary when comparing differentiated with 
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undifferentiated cells, or transformed versus non transformed cells [44, 5]. Both the 
central role of FHC in iron homeostasis and its ability in modulating different 
transduction pathways, are consistent with its increased expression during differentiation 
and neoplastic transformation. We believe that the identification of FHC-dependent 
miRNA/mRNA networks implies that different amounts of the ferritin subunit contribute, 
in K562 cells, to the remodelling of gene expression taking place during these cellular 
processes through the action of let-7g, let-7f, let-7i and miR-125b. This observation is 
further strengthened by the comparison of the miRNAs-regulated pathways, reported in 
this manuscript, with those highlighted in our previous work on FHC-silenced K562 
undergoind differentiation [27]. It is interesting to note that, among the common 
pathways, “Cell Death and Survival” and “Hematological System Development and 
Function” rely on the ERK1/2 activation which is severely affected by FHC silencing. 
In conclusion, the data presented in this study add a further level of complexity to the 
relationship among iron and miRNAs, demonstrating that the intracellular amounts of 
FHC subunit are able to regulate let-7g, let-7f, let-7i and miR-125b expression, as well as 
the repertoire of their down-stream genes. Even though an increasing body of evidence 
suggests that the redox state of the cell might significantly influence Let7 and 125-b 
levels [45, 46], we believe that the FHC interference on miRNA expression deserves 
further analysis.  
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Chapter 4 
The hypothesis that miRNAs could regulate alternative translation of many mRNAs is 
indirectly supported by the integration of the two types of evidence: the multiple and non-
canonical active ORFs in human mRNAs, provided by GTI-seq data, and miRNA-mRNA 
binding outside 3’UTRs thanks to CLASH technique. Looking for overlapping region 
identified in both the experimental evidences, we identified many genes in which one or 
more miRNAs could interfere with translation of main annotated ORF or with ORFs 
located in the 5’ UTR respectively to the annotated ORF, or even downstream it. These 
regions are evolutionary conserved and the miRNA footprints tend to overlap mRNA 
regions involved in RNA fold stabilization. We selected most significant cases of genes 
and we provided experimental evidence of TIS activity. We obtained direct evidence of 
miRNA-TIS interaction causing suppression of protein expression in 60% of tested cases. 
This non canonical miRNAs function surely deserve further investigation, to better 
characterize the mechanisms of AT regulation, more specifically we need to understand if 
and how the miRNA-based regulation of mRNA alternative translation impact on cell 
processes and on disease.  
 Nowadays multiple proofs of functional and regulatory role of the non coding have been 
adduced and it is always more evident that there are a huge redundancy of control 
throughout all the different steps of extended variety of biological networks. miRNAs 
appear key modulators of information and understanding the interplay of miRNAs and 
DNA, coding RNA or other targeted elements is crucial. Further studies need to be 
performed to elucidate post-transcriptional and transcriptional role of miRNAs. Profiling 
miRNAs that are bound to their target have already been useful, as we discovered 
potential new miRNAs function thanks to the integration of data from CLASH technique 
and from GTI-seq. Further experimental data on active miRNA binding, as HITS-CLIP or 
PAR-CLIP, would adduce proof of their functionality and would not be mere prediction, 
rather experimental evidences. Experimental evidences of new functions would drive to 
targeted sequencing experiments and, improving the technique potential. 
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Abstract 
We previously demonstrated that non-canonical binding of a miR-142-3p to a translation 
initiation site of C/EBPβ multi-ORF mRNA is able to change the ratio between protein 
isoforms with different properties, thus impacting on the cell phenotype. There is an 
increasing appreciation of the high prevalence of alternative translation in mammals. 
Complex translation patterns are known, with multiple ORFs in the same mRNA that can 
influence each other in different ways. New evidence indicates that miRNAs can 
frequently bind 5’UTR and coding regions of mRNAs. We provide novel data on the 
overlap of active translation initiation sites (TISs) of mRNAs, experimentally defined 
using GTI-seq, with miRNA-binding sites, experimentally determined using CLASH 
technique. We identified many genes in which one or more miRNAs could interfere with 
translation of the main annotated ORF, or with ORFs starting in the 5’ UTR and 
downstream the main TIS. We propose a new mechanism relevant to increase our 
understanding of the complex cross talk between protein-coding and non-protein coding 
RNAs. We model how the binding of a miRNA to a TIS can produce different regulatory 
effects, according to the involved ORF types coexisting in mRNAs, and to their 
regulatory relations. Increased evolutionary conservation of miRNA footprints 
overlapping TISs, their propensity to fall in regions stabilizing mRNA fold, as well as 
direct experimental evidence of miRNA-mRNA interactions corroborate the proposed 
hypothesis. The miRNA-based regulation of mRNA alternative translation surely 
deserves further investigation to clarify if and how it impacts on cell processes and on 
disease. 
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ABBREVIATIONS LIST 
 
5’TIS: 5’ Translation Initiation Site 
AT: Alternative Translation 
aTIS: annotated Translation Initiation Site 
BP: Biological Process (Gene Ontology) 
CC: Cellular Components (Gene Ontology) 
CDS: Coding Sequence 
CLASH: Cross Linking Ligation And Sequencing of Hybrids 
CLIP: Cross Linking Immuno Precipitation 
dTIS: downstream Translation Initiation Site 
GTI-seq: Global Translation Initiation sequencing 
IRES: Internal Ribosome Entry Site 
LRS: Leak Ribosomal Scanning 
MF: Molecular Function (Gene Ontology) 
miRNA: microRNA 
NMD: Nonsense Mediated Decay 
ORF: Open Reading Frame 
PIC: Pre Initiation Complex 
TIS: Translation Initiation Site 
uORF: upstream Open Reading Frame 
UTR: Untraslated Region 
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Introduction 
Non-canonical binding of a miRNA to the translation initiation site is able to change 
isoforms ratio of an mRNA whose alternative translation can generate multiple protein 
isoforms with different properties. This equilibrium consequently determines cell fate and 
ultimately induces phenotype changes relevant to cancer-induced immune tolerance 
(Sonda et al., 2013).  
There is an increasing appreciation of the high prevalence of alternative translation (AT) 
in mammals (Kochetov, 2008;Menschaert et al., 2013;Smith et al., 2005;Vanderperre et 
al., 2013;Wang et al., 2004). The importance of protein synthesis studies is increasing, 
with the growing list of genetic diseases caused by mutations that affect mRNA 
translation (Valasek, 2012). The emerging scenario shows complex translation patterns of 
many mRNAs, in which multiple ORFs influence each other and/or the formation of 
secondary structures that can modulate ribosome activity (Morris and Geballe, 
2000;Skabkin et al., 2013). On the other hand, new data indicate that miRNAs act in a 
non-canonical ways to regulate gene expression at different levels (Kosaka et al., 
2013;Mittal and Zavolan, 2014) and they can bind more frequently 5’UTR and coding 
sequences (CDS) regions of mRNAs than 3’UTR, where canonical target sites are 
expected.  
In this manuscript we discuss whether and how much miRNAs can contribute to the 
regulation of AT and we provide new data supporting the pervasiveness and perhaps the 
biological significance of this intriguing miRNA function. 
 
AT: a widespread post-transcriptional regulation mechanism 
with underappreciated complexity 
Proteome complexity in terms of multiplicity of different functional protein isoforms 
emerges not only from alternative splicing of RNA transcripts and the use of alternative 
promoters, but also from use of alternative translation initiation sites (TIS). The 
importance of AT in eukaryotes, both in terms of prevalence and functional relevance, is 
becoming apparent from recent studies, which added considerable evidence to earlier 
reports on AT in either specific genes or gene categories.  
Translation can be divided mechanistically into three steps: initiation, elongation and 
termination. As the rate-limiting step of translation, initiation involves ribosome loading, 
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scanning, and TIS selection before elongation commitment. Normally, translation 
initiation requires the pre-initiation complex (PIC) assembly and recruitment to the 
mRNA, which is a CAP-dependent process. The PIC then scans the 5’ UTR of the mRNA 
until it encounters a start codon. Normally it is assumed that the first AUG encountered 
by the ribosome serves as TIS. However, one or more potential initiation sites could exist 
upstream of the main ORF, forming uORFs. Likewise, TIS downstream the main start 
codon could also potentially serve as initiators.  
After the elongation step, the translation stops when the ribosome encounters a stop 
codon, and termination occurs with the concerted action of release factors, that triggers 
peptide release, tRNA dissociation and ribosome separation. In some cases, the 40S 
subunit remains associated with the mRNA and could re-initiate translation from a 
downstream TIS (re-initiation).  
Inefficient recognition of a TIS can lead to initiation downstream (leaky ribosomal 
scanning; LRS). On the basis of LRS model, the presence of uORFs in mRNAs (at least 
one uORF was reported in 50% of mammalian transcripts), can suppress the translation 
efficiency of the main ORF. In other cases, the uORF translation could also stimulate the 
translation of the main ORF (ATF4) (Kochetov et al. 2008). 
According to the LRS model, the TIS sequence context is deemed to be important in 
determining the strength of a given AUG codon, with optimal (GCCRCCAUGG) and 
suboptimal consensus sequences known. Bioinformatic analyses showed that downstream 
alternative TIS (dTIS) following a suboptimal TIS are under negative selection in 
vertebrates, with stronger selection in genes with weaker primary TIS (Bazykin and 
Kochetov, 2011). Moreover, the authors of this study noticed that genes with multiple 
conserved TISs are enriched for olfactory receptors and transcription factors. It was also 
proposed that other mRNA features, such as stable secondary structures over or near the 
TIS, could also influence AUG recognition. In addition to these cis sequence elements, 
the stringency of TIS selection is also subject to regulation by trans-acting factors such as 
eIF1 and eIF1A.  
Apparently, different ORFs of the same mRNA can regulate or influence each other in 
complex ways.  
By definition, uORFs encode peptide different from that encoded by the main ORF, 
whereas alternative overlapping ORFs can be in frame or out of frame. According to the 
leaky ribosomal scanning model, suboptimal 5’ TIS are not used with 100% efficiency 
and the ribosome goes ahead to start translation from downstream TIS. Different in frame 
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ORFs (with shorter ORFs being suffixes of the longer ORF) can generate proteins sharing 
the C-terminal part and differing in the N-terminal domains. The alternative inclusion of 
functional domains in different isoforms may differentiate, to some extent, their 
functional activity. For instance, two isoforms (Ora1α and Ora1β) arising from in frame 
alternative translation of the plasma membrane store-operating channel Ora1 mRNA 
display distinct plasma membrane mobility, since the shorter isoforms lack the 
phospholipid-binding domain (Fukushima et al., 2012). Recently, PTENα, a N-terminal 
extended isoform of PTEN, translated through alternative initiation at an upstream in 
frame TIS was discovered (Liang et al., 2014). Isoforms with different N-terminal signals 
can be targeted to distinct cell compartments: RNase Z isoforms display dual 
nuclear/mitochondrial targeting since the shortest isoform does not include the 
mitochondrial targeting sequence.  
Moreover, ORFs in different frames may produce, by AT of the same mRNA, proteins 
with completely different sequences and functions. A relevant example is AltPrP, a 
protein produced by alternative use of a downstream out of frame TIS of the PrP (prion 
protein) mRNA, with a different amino acid sequence from the PrP (Vanderperre et al., 
2011). AltPrP is a protein integrated in the outer mitochondrial membrane. AltPrP 
expression from PrP cDNA is constitutively negatively regulated and it is increased by 
proteasome inhibition and endoplasmic reticulum stress.  
Recently, it was shown that cells proteome includes many previously disregarded small 
peptides (Slavoff et al., 2013) and the products of AT were directly detected by proteomic 
studies (Slavoff et al., 2013; Vanderperre et al., 2013), thus supporting the high 
prevalence of AT in Eukaryotes. 
Many human genes undergoing alternative translation play important roles in tumorigenesis 
and development. Notable examples include OCT4, a transcription factor with a pivotal 
role in embryonic stem cells self renewal (Cao et al., 2009;Gao et al., 2012;Wang et al., 
2009), and the massively regulated, multi isoform, and multi functional P53 gene 
(Candeias et al., 2006).  
It is worth notice also that intronless genes cannot use alternative splicing to generate 
multiple proteins and AT is used instead as main mechanism for diversity generation. 
Many human genes as histone genes and G-protein-coupled receptor genes are 
predominantly intronless (Grzybowska, 2012). Besides, about 70% of single-copy, 
primate-specific human transcriptional units are intronless (Tay et al., 2009). 
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As anticipated, another important mechanism of AT is re-initiation (Jackson et al., 2012). 
Translation can be described as a cyclical process, consisting of initiation, elongation, 
termination, and ribosome recycling. In some cases, the recycling of post-translation 
complexes is incomplete: the 40S ribosomal subunit remains bound to mRNA, and 
termination is followed by re-initiation, usually downstream of the stop codon (Skabkin et 
al., 2013). In yeast, eIFs binding to the large ribosomal subunit lasts for several rounds of 
elongation and critically enhances the re-initiation capacity of post-termination 40S 
ribosomes (Szamecz et al., 2008;Valasek, 2012). In this view, the translation of small 
upstream ORFs (uORFs) can modulate the efficiency of use of downstream start sites. 
The uORFs are translated using TISs located 5’ (5’ TIS) to the main/annotated TIS 
(aTIS). As many as 44% of human mRNAs 5’UTRs include one or more uORFs 
(Kochetov et al., 2008). An uORFs shorter than 30 codons and the intercistronic distance 
(between uORF and the next TIS) longer than 37 nucleotides have been shown to favor 
efficient re-initiation (Luukkonen et al. 1995).  
The uORFs are quite common in certain classes of genes, including two-thirds of 
oncogenes and many other genes involved in the control of cellular growth and 
differentiation. They can influence the translation of downstream ORFs with different 
mechanisms (Morris and Geballe, 2000). At least three possible fates are available to a 
ribosome after translating an uORF: 1) The ribosome may remain associated with the 
mRNA, continue scanning, and re-initiate further downstream, at either a proximal or 
distal AUG codon; 2) Another option for the ribosome is to stall during either the 
elongation or termination phase of uORF translation, creating a blockade to additional 
ribosome scanning (in the known cases, ribosome stalling is mediated by the peptide 
structure encoded by the uORF); 3) In addition to influencing the action of ribosomes 
during and after termination, uORFs may affect gene expression by altering mRNA 
stability. 
Translation can be also initiated in a 5’-CAP recognition-independent way by the usage 
of secondary structures known as internal ribosome entry sites (IRES). IRES sequence 
elements form complex secondary structures that directly recruit ribosomes and drive 
translation particularly in special conditions as cellular stress, apoptosis or hypoxia (Liu 
and Qian, 2014).  
After the use of an IRES, both LRS and re-initiation are possible, in principle (Kochetov 
et al., 2008). In addition, non AUG codons can be used for TIS, and they are frequently 
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used in 5’TIS (Touriol et al., 2003), an example being the extended-C/EBPα isoform, 
which is translated from a non-AUG codon  (Muller et al., 2010). 
A prediction of all possible short and long ORF for each mRNA produced by the human 
genome is feasible, but is expected to result in a massive number of putative AUG and 
non-AUG TISs, including an exceedingly large proportion of false positives. A recent 
study exploited global translation initiation sequencing (GTI-seq), to achieve detection of 
alternative translation initiation in mammalian cells with single-nucleotide resolution 
(Lee et al., 2012). This study used cycloheximide (CHX) and lactimidomycin (LTM) to 
selectively inhibit ribosome translocation and thus capture initiation events by deep 
sequencing of ribosome-protected mRNA fragments (RPF). RPF reads alignment to 
mRNA sequences defined read peaks pinpointing 16,863 active TIS in about 10,000 
human transcripts and showed that 50% of the transcripts contain multiple TISs, 
supporting the idea of AT prevalence. In addition, 42% of transcripts showed an inactive 
aTISs, with translation initiating from different TISs, at least in cells considered in the 
study. Translation initiation downstream the aTIS was observed in 27% of transcripts 
with TIS peaks, with upstream TIS associated to suboptimal consensus sequences when 
both 5’TIS and aTIS were active. Besides, increasingly stable folded structures, shortly 
after the 5’TIS of transcripts with repressed aTIS initiation, were observed. In particular, 
more stable structure were present in correspondence of suboptimal 5’TIS codons, 
indicating the correlation of TIS selection with the sequence context of an optimal 5’TIS 
or with the intervention of secondary structures in TIS selection. 
 
miR-142-3p non-canonical binding on a TIS controls AT of the 
C/EBPβ mRNA, thus promoting macrophage differentiation 
and acquisition of immunosuppressive function in cancer. 
In a recent work, we identified a mini-circuit involving miR-142-3p, which is activated 
by tumor-released IL-6 family cytokines during tumor-induced myelopoiesis (Sonda et 
al., 2013). We demonstrated that miR-142-3p downregulation eventually promotes 
macrophage differentiation and acquisition of an immunosuppressive function in the 
tumor environment. The circuit includes the C/EBPβ intronless transcription factor gene. 
C/EBPs are a family of transcription factors that regulate the expression of tissue specific 
genes during differentiation of many cell types (Morris and Geballe, 2000).  
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The C/EBPβ mRNA is a known example of in frame AT. It encodes three protein 
isoforms that are produced by alternative use of aTIS and in-frame dTISs. These isoforms 
have different molecular weight and transcription activity: LAP* and LAP are considered 
to act as activating proteins, whereas the truncated LIP isoform, lacking the transcription 
activation domain is deemed an inhibitory isoform (Abreu and Sealy, 2010;Albergaria et 
al., 2013;Park et al., 2013). Indeed, the C/EBPβ mRNA presents a small out-of-frame 
regulatory uORFs immediately upstream the major TIS, modulating the ratio of isoforms 
produced by AT of in-frame ORFs (Morris and Geballe, 2000).  
The miR-142-3p downregulates gp130 (the common subunit of the interleukin-6 cytokine 
receptor family involved in signaling after ligand interaction) by canonical binding to its 
mRNA 3' UTR and impacts on the ratio of the three C/EBPβ transcription factor 
isoforms, mainly by moving the equilibrium towards LIP. In turn, miR-142-3p 
transcription is controlled by the isoforms ratio, with LIP acting as transcriptional 
inducer.  
A peculiar characteristic of this regulatory circuit is that miR-142-3p exerts its regulatory 
activity on C/EBPβ by a non canonical binding to the mRNA coding sequence, in a 
region including one of three in frame TIS (aTIS an dTIS1-2) of the C/EBP mRNA. The 
RNA duplex is stabilized by an imperfect pairing, involving 17/23 nt of the miRNA, with 
two bulges in the so-called seed region in the 5’ of the miRNA. In this way, miR-142-3p 
interferes with a complex equilibrium of regulated re-initiation, possibily involving, 
secondary structures and other modulator factors such as eIF2, and it plays a key role in 
the activation the macrophage differentiation and the acquisition of their 
immunosuppressive functions in cancer. 
We asked whether this non-canonical function of a microRNA was a special case or 
rather the regulation of pervasive AT by miRNAs was a more widespread phenomenon. 
In this paper, we present new data supporting the latter hypothesis, suggesting that novel, 
non-canonical regulatory roles for miRNA related to AT regulation are possible. 
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miRNAs regulate gene expression at different levels with 
diverse mechanisms and they frequently bind mRNAs before 
3’UTR 
Several, non-canonical miRNA functions have been discovered in last years in terms of 
target recognition mode and regulatory actions. Regarding unusual regulatory actions, it 
is known that miRNAs can be imported in a signal-dependent way into the nucleus (Liao 
et al., 2010) and subsequently guide chromatin remodeling complexes to specific genome 
sites, eventually silencing gene transcription (Zardo et al., 2012) or promoting de-novo 
methylation of DNA (Sinkkonen et al., 2008). Furthermore, miRNAs may act as cell-to-
cell communication mediators through exosomal vesicles, which are delivered to other 
cells and are detectable in body fluids (Chiba, 2012).  
Regarding target recognition, it is generally accepted that miRNAs usually bind to the 
3’UTR sequence of their mRNA targets, but targeting 5’ untranslated regions (5’UTR) 
(Lytle et al., 2007) and CDS regions (Helwak et al., 2013;Huang et al., 2008;Tay et al., 
2008) has been reported. Moreover, microRNA targets containing simultaneous 5'-UTR 
and 3'-UTR interaction sites are also known (Lee et al., 2009).  
Anyway, the majority of characterized miRNA target sites are in the 3’UTRs of mRNAs, 
and large-scale studies examining the effects of either introducing or deleting a miRNA 
have shown that sites in 3’UTRs generally are more effectively suppressor of target 
expression than those in either 5’UTRs or CDS (Bartel, 2009). Besides, highly repetitive 
ORFs containing many miRNA sites can generally be subject to significant and, in some 
cases, substantial repression by the cognate miRNA and that repeats occur frequently 
within families of paralogous C2H2 zinc-finger genes (Schnall-Levin et al., 2011), 
suggesting the potential for their coordinated regulation.  
Recent reports support that miRNA binding outside the 3’UTR is more common than 
previously expected. Liu et al. (2013) (Liu et al., 2013) used crosslinking 
immunoprecipitation (CLIP) for identification of a conspicuous number of argonaute-
bound target sequences that contain miRNA binding sites. They described sequences, 
thermodynamic and target structure features essential for target binding by miRNAs in 
the 3' UTR, CDS and 5' UTR regions of target messenger RNA (mRNA) and showed 
that, out of 6,666 AGO tags, 61% mapped to 3′ UTRs, 37% to CDS, and 2% to 5′ UTRs.  
In a recent seminal study, Helwak et al., 2013 (Helwak et al., 2013) exploited 
crosslinking, ligation, and sequencing of hybrids (CLASH) technique to unveil miRNA-
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target pairs as chimeric reads in deep-sequencing data. More than 18,000 high-confidence 
miRNA-mRNA interactions were reported; around 60% of seed interactions are non-
canonical, containing bulged or mismatched nucleotides. Overall, 60% of all target sites 
were mapped to the CDS, whereas 35% and 5% were mapped to the 3’UTR and to the 
5’UTR, respectively. The proportions of miRNA targets associated by CLASH to the 
CDS are slightly higher compared to previous CLIP-seq experiments, likely because in 
this study the mapping of sequencing reads to a transcriptome database can consider 
target sites overlapping splice junctions. Notably, different miRNAs vary in the relative 
proportions of targets in 5′ UTRs, coding sequences, and 3′ UTRs. Targets in CDSs were 
shown to be significantly up-regulated upon miRNA depletion, and up-regulation of sites 
in the CDS is about half of that in 3′ UTRs (Helwak et al., 2013). 
These reports suggest that miRNA binding outside the 3’UTR allow a miRNA-target 
interaction, which is non-canonical in terms of the mRNA region involved but canonical 
in terms of functional consequences, i.e. suppression or negative regulation of target 
expression. Interesting exceptions are provided by the previously cited study by (Sonda et 
al., 2013), that indicated a miR-142-3p-based isoform ratio regulation of the target gene 
and by Orom et al. (2008) (Ørom et al., 2008), who showed that miR-10a binds a TOP 
motif in the 5′UTR of ribosomal protein mRNAs and alleviates its translational repression 
during amino acid starvation, exerting eventually a positive control of global protein 
synthesis. In this case, the miRNA contributes to a complex translational regulatory 
system, and acting together with other, less characterized, regulators (Miloslavski et a., 
2014). 
Emerging data about the prevalence of AT and about the complexity of translation 
patterns, coupled with the new findings of frequent binding of miRNAs to 5’UTR and 
CDS regions of mRNAs suggest that, as we demonstrated for C/EBPβ mRNA and miR-
142-3p, the miRNA binding to alternatively translated target mRNAs can interfere with 
AT regulation.  
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Hypothesis: miRNAs binding to mRNAs can 
interfere with alternative translation regulation in 
different ways 
miRNA binding to either mRNA 5’UTR or to CDS may: 
• Interfere with ribosome scanning of mRNAs, thus impacting on TIS 
recognition efficiency; 
• Perturb the equilibrium among the efficiency of translation of in frame or out 
of frame AT ORFs; 
• Reduce uORF translation, thus secondarily affecting the translation efficiency 
of downstream ORFs whose translation depends on re-initiation; 
• Reduce the translation of uORFs inhibitory of downstream ORFs translation, 
ultimately increasing its translation efficiency. 
As previously said, N-terminal proteomics and ribosome profiling data showed that 
alternative translation is highly prevalent in mammals. TISDdb reports that in average 1.4 
and 2 translation initiation sites per mRNA are used in human and mice, respectively, 
considering only one cell type per species (Wan and Qian, 2014). According to 
Vanderperre et al. 2013, the majority (88%) of mRNAs present alternative ORFs (3.8 per 
mRNA in average) and alternative proteins represent the 55% of the proteome. Many 
eukaryotic proteins show N-terminal heterogeneity presumably due to AT (Liu and Qian, 
2014) and, as previously discussed, studies on several genes, as C/EBP factors, Ora1 
genes, PTEN, PrP and OCT4 isoforms, state that AT is has particularly relevant 
biological roles. In Figure 1 we exemplify possible multi ORF mRNAs structures and 
propose how miRNA interactions with different TISs can produce diverse regulatory 
effects, under different scenarios. Conceivably, the miRNA binding over a TIS can 
directly induce ribosome stalling and/or interact with secondary structures in the mRNA, 
and ultimately modulate the TIS recognition efficiency. miRNAs binding to the main TIS 
(aTIS) can interfere with ribosomal scanning (Figure 1A). In mRNA with multiple in 
frame, interdependent ORFs the miRNA can recognize and bind the aTIS, reduce the 
aTIS recognition efficiency and favor the usage of dTIS, perturbing the ratio of long and 
N-truncated isoforms. If the different ORFs are out of frame, the miRNA binding can act 
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as a switch and trigger the production of protein products with completely different 
sequence and properties.  
It has been estimated that about 50% of mammalian transcripts contain at least one uORF 
(Calvo et al. 2009). In the same study, uORF-mediated translational regulation has been 
experimentally validated for one hundred eukaryotic transcripts, including around 30 
human transcripts. uORFs can positively or negatively influence the translation of the 
following ORF(s) with different mechanisms, briefly reviewed above. The binding of a 
miRNA to a 5’TIS in an inhibitory uORF can affect downstream TIS usage (Figure 1 B): 
the miRNA-induced inhibition of uORF translation can stimulate the downstream aTIS 
usage. This example can fit either uORF whose translation is inhibitory of aTIS usage and 
uORF encoding peptides inhibitory of aTIS usage. If instead the translation starting from 
the 5’TIS increases the efficiency of the downstream TIS usage by the so-called re-
initiation mechanism, the miRNA-induced inhibition of the uORF translation can 
decrease also the aTIS usage (Figure 1C). 
Many mRNAs display both uORFs, multiple in frame (and/or out of frame) ORFs, and 
also ORFs located in the 3’UTR regions (defined according to the position on the main 
ORF). Figure 1 C sketches a more complex structure of mRNAs. The translation of these 
ORFs can be interdependently regulated and the binding of a miRNA to one of the TISs 
can produce different regulatory effects, according to the involved ORF types, and to 
their regulatory relations. 
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Figure 1. Examples of possible regulatory effects due to interactions between miRNAs and different multi 
ORF mRNAs structures, under the assumption that the miRNA binding over a TIS can induce either 
ribosome stalling or interact with secondary structures in the mRNA, and ultimately modulate the TIS 
recognition efficiency. A) miRNAs interference with ribosomal scanning. The pre-initiation complex scans 
the 5’ UTR of the mRNA until it encounters a start codon: normally the first TIS is used. In mRNA with two 
alternative TISs, the miRNA binding to the most 5’ TIS (annotated TIS, aTIS) can reduce its usage in favor 
of the downstream one (dTIS), thus perturbing the ratio between long and truncated protein isoforms. If the 
different ORFs are out of frame, the miRNA binding can trigger the production of a protein product with 
completely different sequence and properties. Many mRNAs present uORFs in the 5’UTR, which can affect 
the main TIS usage. B) Generally, 5’ ORFs are inhibitory: in this case the miRNA binding to the 5’TIS can 
reduce uORF translation and thus stimulate the downstream aTIS usage. C) In other cases, the translation of 
the uORF starting from the 5’TIS is able to increase the efficiency of the downstream TIS usage, by the 
socalled re-initiation mechanism. The miRNA binding to the 5’TIS in mRNAs presenting re-initiation can 
decrease the aTIS usage. D) As known for several genes, mRNAs may present complex structures, including 
5’ and 3’TIS, along with one or more dTIS in addition to the aTIS: the translation of multiple ORFs can be 
interdependently regulated. In these cases, the binding of a miRNA to one of the TISs can produce different 
regulatory effects, according to the involved ORF types, and to their regulatory relations. 
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Experimentally determined miRNA binding sites overlap with 
active TISs in human mRNAs  
We considered the information about 6,693 genes with at least one proven active TIS, 
according to GTI-seq experiments, and merged these data with results on miRNA binding 
to human RNAs (belonging to 6,957 genes) experimentally determined using clash 
technique, obtaining a group of 3,624 unique genes and 4,064 mRNAs in the merged 
dataset. As done before, and following the study by Lee et al (2012) providing the 
original translation initiation data, the position of the main ORF as reference defined the 
aTIS. We thus tagged as 5’TIS the TIS upstream the aTIS, dTIS the TIS downstream the 
aTIS (i.e. included in the main ORF), and 3’TIS the TIS associated to ORFs starting after 
the end of the main ORF and located in the 3’UTR (Figure 2A). It is worth notice that, in 
the considered group of genes, the majority (2,164, 59.7%) is associated with 2 or more 
different active TISs (Figure 2B). The ring plot in the same figure shows the proportions 
of different types of TISs in the considered merged datasets (Figure 2C).  
 
 
Figure 2. A) Schematization of the different types of TIS considered: the annotated TIS (aTIS) was defined 
by the position of the main annotated ORF, as in Lee et al (2012); 5’TIS are upstream the aTIS; dTISs are 
located downstream the aTIS but they are included in the main ORF; 3’TISs are located after the end of the 
main ORF, (i.e. in the mRNA region annotated as 3’UTR). B) Distribution of number of genes according to 
the number of experimentally determined TISs per gene. C) Proportions of different types of TISs in the 
4,064 considered mRNAs. 
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We believe that the observation of numerous genes with multiple TISs can be only in 
minimal part due to the existence of several mRNAs belonging to the same gene, since 
our data include 1.2 mRNAs per gene, in average. Anyway, the following results are all 
based on analyses considering the correct data granularity, i.e. mRNA positions of TIS 
and miRNA binding sites.  
We considered 10,775 mRNAs with at least one active TIS and 7,388 mRNAs that can 
bind a miRNA, for a total of 396 different miRNAs represented. The first data integration 
focused on the identification of the subset of mRNAs in which the miRNA binding site is 
overlapping an active TIS (i.e. at least one nt in the start codon is included in the miRNA 
binding region), found 264 possible interactions between 96 unique miRNAs (28.1% of 
the 342 unique miRNAs in the merged dataset) and active TISs. Involved TISs are 
located into 197 mRNAs, belonging to 197 unique genes, accounting for 5.4% of the 
3,624 unique genes in the merged dataset.  
Many genes with roles in translation and chromatin structure regulation are involved in 
possible miRNA-TIS interactions. The group of mRNAs in which at least one TIS is 
bound by a miRNA include many histone proteins, proteins involved in nucleosome and 
chromatin assembly and/or in DNA conformation change, ribosomal proteins, and other 
proteins involved in translation and translation regulation. We wondered whether the 
observed gene types could be biased due to the set of 3,624 genes included in the 
“merged dataset”, restricted to genes represented both in the Lee et al (2012) GTI-seq 
dataset and in the Helwak et al., 2013 CLASH dataset. Thus we analysed the GO terms 
and Reactome pathways enrichment of the 197 genes involved in possible miRNA-TIS 
interactions using as background the whole set of genes in the “merged dataset”. In this 
way, we exclude that the enriched categories were due to a bias in the composition of the 
dataset. Table 1 shows a selection of non-redundant GO categories and pathways 
significantly enriched (p-value <0.0001) in the set of 197 genes perhaps involved in 
miRNA-TIS interactions.  
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Functiona
l 
Category 
Type 
ID Term P value 
Odds 
Ratio 
Gene 
Cou
nt 
GO BP 
GO:0006414 translational elongation 9.45E-23 15.87 33 
GO:0000184 
nuclear-transcribed mRNA catabolic 
process, nonsense-mediated decay 
3.47E-22 14.07 34 
GO:0006415 translational termination 5.71E-22 16.72 31 
GO:0006614 
SRP-dependent cotranslational 
protein targeting to membrane 
4.00E-20 12.80 32 
GO:0006413 translational initiation 5.97E-19 10.23 34 
GO:0006612 protein targeting to membrane 2.43E-18 9.64 34 
GO:0000956 
nuclear-transcribed mRNA catabolic 
process 
6.92E-18 8.84 35 
GO:0016071 mRNA metabolic process 1.36E-12 3.84 53 
GO:0006886 intracellular protein transport 1.28E-09 3.36 45 
GO:0046907 intracellular transport 1.85E-09 2.85 61 
GO:0006334 nucleosome assembly 2.40E-07 7.17 14 
GO:0034728 nucleosome organization 5.99E-07 5.99 15 
GO:0090304 nucleic acid metabolic process 3.06E-05 1.88 100 
GO:0006323 DNA packaging 4.62E-05 4.14 14 
GO CC 
GO:0005840 Ribosome 7.93E-18 8.39 36 
GO:0030529 ribonucleoprotein complex 6.64E-18 4.99 59 
GO:0065010 
extracellular membrane-bounded 
organelle 
9.57E-09 2.68 61 
GO:0005829 Cytosol 9.92E-09 2.41 87 
GO:0000786 nucleosome 2.37E-08 11.95 12 
GO:0044815 DNA packaging complex 1.23E-07 9.76 12 
GO MF 
GO:0003735 structural constituent of ribosome 8.38E-19 10.57 33 
GO:0003723 RNA binding 3.67E-11 2.88 82 
GO:0003676 nucleic acid binding 2.01E-08 2.36 103 
GO:0097159 organic cyclic compound binding 2.96E-05 1.90 117 
GO:1901363 heterocyclic compound binding 4.28E-05 1.87 116 
Reactome 
156842 Eukaryotic Translation Elongation 3.12E-20 14.16 33 
975956 
Nonsense Mediated Decay (NMD) 
independent of the Exon Junction 
3.12E-20 14.16 33 
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Complex (EJC) 
72764 Eukaryotic Translation Termination 3.14E-19 14.29 31 
975957 
Nonsense Mediated Decay (NMD) 
enhanced by the Exon Junction 
Complex (EJC) 
3.49E-19 11.93 34 
157279 
3' -UTR-mediated translational 
regulation 
1.57E-18 11.13 34 
156827 
L13a-mediated translational 
silencing of Ceruloplasmin 
expression 
1.57E-18 11.13 34 
72689 
Formation of a pool of free 40S 
subunits 
2.22E-18 12.17 32 
72737 
Cap-dependent Translation 
Initiation 
1.60E-17 10.00 34 
72613 Eukaryotic Translation Initiation 1.60E-17 10.00 34 
72706 
GTP hydrolysis and joining of the 
60S ribosomal subunit 
2.70E-17 10.24 33 
72766 Translation 5.80E-16 7.62 37 
74160 Gene Expression 1.04E-10 3.30 70 
1643685 Disease 1.67E-10 3.36 62 
72702 
Ribosomal scanning and start codon 
recognition 
5.68E-07 7.12 14 
212300 PRC2 methylates histones and DNA 3.91E-07 7.42 14 
4839726 Chromatin organization 4.44E-07 5.06 19 
171306 Packaging Of Telomere Ends 8.57E-06 8.25 10 
2559580 
Oxidative Stress Induced 
Senescence 
1.83E-05 4.52 15 
774815 Nucleosome assembly 2.30E-05 6.21 11 
606279 
Deposition of new CENPA-
containing nucleosomes at the 
centromere 
2.30E-05 6.21 11 
157579 Telomere Maintenance 4.32E-05 5.68 11 
Table 1. GO terms and Reactome pathways significantly enriched in the set of genes with active TISs 
overlapping miRNA-binding sites. 
 
Interestingly, these genes are highly enriched in genes encoding for ribosomal proteins or 
for playing roles in translational initiation, elongation and termination, in the post-
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transcriptional regulation of gene expression and in non-sense-mediated decay. Genes 
involved in possible miRNA-TIS interactions are also enriched in histone genes 
(nucleosome CC, nucleic acid binding MF, and DNA packaging BP), which are 
intronless, as mentioned above and other genes involved in gene expression regulation, as 
SET, encoding a protein that inhibits nucleosomes acetylation. At least 62 of the 
considered genes are known to be involved in one “disease” pathway, 70 in gene 
expression pathway, 15 in oxidative stress induced senescence and 11 in telomere 
maintenance and in nucleosome assembly.  
Characterization of miRNA-TIS interactions 
Position relative to TISs 
In considered miRNA-TIS interactions, the overlap between miRNA-binding sites and 
TIS positions shows a slight but significant propensity for microRNA binding sites to lie 
more frequently downstream the TIS (11.1 and 13.4 Nt respectively in the region 5’ and 
3’ to the TIS; binomial two sided test p-value=0.002).  
 
Evolutionary conservation of miRNA footprints 
We evaluated the conservation of miRNA binding sites in coding regions of mRNAs, 
using PhyloP 100 Vertebrate conservation as local basewise conservation score. Very 
interestingly, we found that the third (wobble) base conservation scores were significantly 
higher (11% more conserved) in miRNA binding sites than in the rest of coding sequence 
(t-test p-value = 0.002), suggesting that miRNA binding sites are under evolutionary 
selection.  
 
Possible meddling in the mRNA folding 
We investigated if miRNA binding sites tend to fall in regions that appear particularly 
important for the stabilization on the mRNA structure. To answer this question, for each 
mRNA, we predicted the minimum free energy (mfe) structure of the whole sequence, 
using RNAfold. We considered the part of the RNAfold "dot plot" base pairing matrix, 
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that gives pairing in the minimum free energy structure and compared it with the miRNA 
binding sites.  
We observed that in 215/264 (81.4%) interactions at least one continuous stretch of 5 or 
more paired nucleotides is included in the miRNA binding region. In 72/264 (27.3%) 
interactions at least one stretch of 10 or more paired nucleotides is included in the 
miRNA binding region. In these cases, the miRNA attachment is predicted to perturb the 
folding. Panel C of the figure in Supplementary File 2 shows, for each miRNA-mRNA 
interaction (in abscissa), the boxplot of the distribution of the length of continuous 
stretches (1 or more nt) of paired nucleotides in the minimum free energy structure of the 
considered mRNA. For comparison, the longest stretch of paired nucleotides overlapping 
with the miRNA binding site is shown as red dot. Red dots fall over the median and over 
the third quartile value in respectively 82.6 and 57.6% of interactions. Since when the 
miRNA footprint contains two or more continuous stretches near each other we counted 
only the longest one, we probably underestimated the number of paired nucleotides 
involved in miRNA-binding that could interfere with mRNA 3D structure. We can 
conclude that miRNA binding regions tend to fall in regions stabilizing the RNA folding. 
miRNA-TIS interactions classified by TIS type 
The identified 264 putative miRNA-TIS interactions involve 64 5’TIS, 68 aTIS, 128 dTIS 
and 4 3’TIS (Figure 3A). Figure 3B reports the numbers of unique miRNAs according to 
the category of the TIS overlapping the miRNA-binding site. A specific miRNA can bind 
more than one position in the mRNA and thus the miRNA-binding sites can overlap 
several TISs of different categories, in the same or in different mRNAs. The Venn 
diagram in Figure 3C shows that some miRNAs have binding sites overlapping only one 
TIS category (we observed 27 miRNAs whose binding sites overlap only dTISs), whereas 
other groups of miRNA-binding sites overlap to two or more TIS categories.  
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Figure 3. A total of 264 putative miRNA-TIS interactions were identified. A) Proportions 
of TISs types included in the set of active TISs overlapping miRNA-binding sites. B) 
Number of different miRNAs putatively interacting with each TIS type. C) Intersections 
of miRNA sets interacting with considered TIS types. 
Only miR-92a-3p has experimentally determined binding sites that overlap all the four 
TIS types. Interestingly, many miRNAs can potentially interact with a few TISs in 
specific mRNAs, whereas others exhibit more pervasive potential interactions with many 
TISs, as miR-615-3p that overlaps 17 different TISs (Figure 4).  
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Figure 4. For each miRNA, the number of putative miRNA-TIS interactions are 
shown, with colour code indicating the TIS type.  
 
According to our data, miR-92a-3p binding sites overlap with 15 different TIS (in 14 
mRNAs) including 2 5'TISs, 4 aTIS and 8 dTIS and 1 3’TIS. On the other hand, we 
observed that 44 mRNAs have two or more miRNAs with a binding site overlapping a 
TIS. Of them, specific mRNAs, as those encoding HIST1H2BK and HIST1H3B can 
potentially interact with up to 6 different miRNAs (Table 2).  
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Gene symbol mRNA refseq miRNAs 
Names N 
HIST1H2BK NM_080593 hsa-miR-15a-5p, hsa-miR-16-5p, hsa-miR-320a, hsa-miR-
424-5p,  
hsa-miR-423-5p, hsa-miR-1180 
6 
HIST1H3B NM_003537 hsa-let-7b-5p, hsa-miR-320a, hsa-miR-330-3p, hsa-miR-
193b-3p, 
hsa-miR-652-3p, hsa-miR-877-5p 
6 
RPS16 NM_001020 hsa-miR-17-3p, hsa-miR-24-3p, hsa-miR-149-5p, hsa-miR-
1296, 
hsa-miR-1303 
5 
HIST1H4C NM_003542 hsa-miR-17-5p, hsa-miR-100-5p, hsa-miR-425-3p, hsa-
miR-874 
4 
RPS9 NM_001013 hsa-miR-342-3p, hsa-miR-423-5p, hsa-miR-935, hsa-miR-
1296 
4 
EEF1G NM_001404 hsa-miR-17-5p, hsa-miR-193a-3p, hsa-miR-18a-3p 3 
HIST1H2BO NM_003527 hsa-miR-320a, hsa-miR-296-3p, hsa-miR-92b-5p 3 
RPL31 NM_000993 hsa-miR-100-5p, hsa-miR-18a-3p, hsa-miR-615-3p 3 
RPL36A NM_021029 hsa-miR-331-3p, hsa-miR-1226-3p, hsa-miR-1260b 3 
RPS17 NM_001021 hsa-miR-222-3p, hsa-miR-320a, hsa-miR-615-3p 3 
ASCC3 NM_006828 hsa-miR-425-5p, hsa-miR-1226-3p 2 
ASNS NM_001673 hsa-miR-17-5p, hsa-miR-23a-3p 2 
CHCHD2 NM_016139 hsa-miR-221-3p, hsa-miR-1229-3p 2 
DLST NM_001933 hsa-miR-503-5p, hsa-miR-92b-5p 2 
EIF4G1 NM_182917 hsa-miR-615-3p, hsa-miR-455-3p 2 
GHITM NM_014394 hsa-miR-92a-3p, hsa-miR-484 2 
GNB2L1 NM_006098 hsa-miR-29b-3p, hsa-miR-183-5p 2 
HIST1H3H NM_003536 hsa-miR-320a, hsa-miR-378a-3p 2 
HIST2H2BF NM_001024599 hsa-miR-18a-3p, hsa-miR-760 2 
LARS NM_020117 hsa-miR-92a-3p, hsa-miR-92b-3p 2 
NDUFA2 NM_002488 hsa-miR-99a-5p, hsa-miR-100-5p 2 
NPM1 NM_002520 hsa-miR-320a, hsa-miR-296-3p 2 
RPL12 NM_000976 hsa-let-7b-5p, hsa-miR-222-3p 2 
RPL13A NM_012423 hsa-miR-26a-5p, hsa-miR-92a-3p 2 
RPL27 NM_000988 hsa-miR-92a-3p, hsa-miR-324-5p 2 
RPL32 NM_001007074 hsa-miR-186-5p, hsa-miR-769-3p 2 
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RPL9 NM_000661 hsa-let-7a-5p, hsa-miR-18a-5p 2 
RPLP1 NM_001003 hsa-miR-877-5p, hsa-miR-1180 2 
RPS10 NM_001204091 hsa-miR-1296, hsa-miR-3176 2 
RPS12 NM_001016 hsa-miR-30c-5p, hsa-miR-181b-5p 2 
RPS23 NM_001025 hsa-miR-92a-3p, hsa-miR-1915-5p 2 
RRM2 NM_001165931 hsa-miR-26a-5p, hsa-miR-30c-5p 2 
TMX2 NM_015959 hsa-miR-196a-5p, hsa-miR-296-3p 2 
Table 2. List of genes and mRNAs with binding sites for two or more different miRNAs overlapping with active 
TISs. 
As shown in Table 3 A the mRNA of the intronless gene HIST1H4C, encoding a member 
of the histone H4 family, includes an active aTIS and 12 dTISs, three of which overlap 
the binding sites of four different miRNAs.  
 
Gene 
Symbol 
Gene 
ID 
Gene 
descriptio
n 
RefSe
q 
mRN
A 
TIS 
type 
TIS 
posi
tion 
in 
mR
NA 
Positio
n 
relative
ly to 
aTIS 
Fr
a
me 
OR
F 
leng
th 
Star
t 
cod
on 
overlapping 
miRNAs 
A) mRNA possibly interacting with multiple miRNAs 
HIST1H4
C 
8364 
Histone 
cluster 1, 
H4c 
NM_
00354
2 
aTIS 1 1 1 104 
AT
G 
- 
dTIS 85 85 1 76 
GG
C 
hsa-miR-874 
dTIS 146 146 1 15 
GT
C 
hsa-miR-100-
5p, hsa-miR-
425-3p 
dTIS 241 241 1 7 
CT
G 
hsa-miR-17-5p 
B) Active 5' TIS overlapping miRNA binding sites 
ASNS 440 
Asparagin
e 
Synthetase 
NM_
00110
1 
5'TIS 150 -102 0 30 
CT
G 
miR-23A-3p 
5'TIS 210 -42 0 10 
CT
G 
miR17-5p 
aTIS 252 1 0 562 
AT
G 
- 
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C) Active aTIS, overlappping miRNA-binding sites and followed by active dTIS(s) 
TRAP1 10131 
TNF 
Receptor-
Associated 
Protein 1 
NM_
01629
2 
aTIS 90 1 1 705 
AT
G 
miR-149-5p 
dTIS 
133
8 
124
9 
1 289 
GT
T 
- 
D) Not active aTIS, overlapping miRNA-binding sites and followed by active dTIS(s) 
SRSF9 8683 
Serine/argi
nine-rich 
splicing 
factor 9 
NM_
00376
9 
aTIS 147 1 1 221 
AT
G 
miR-935 
dTIS 549 403 1 88 
GG
G 
miR-30d-5p 
E) Active dTISs overlapping with miRNA-binding sites 
VMP1 81671 
Vacuole 
Membrane 
Protein 1 
NM_
03093
8 
aTIS 274 1 1 407 
AT
G 
- 
dTIS 316 43 1 393 
AT
G 
miR-25-3p 
Table 3. Selected examples of genes with miRNA-mRNA interactions involving TISs. In the table we report 
active TISs overlapping miRNA-binding sites, plus the reference aTIS (main ORF) position also if non active 
and/or non overlapping miRNA binding sites. A) The mRNA of the HIST1H4C presents 12 different active 
dTIS (data not shown) and 3 of them overlap with the binding site of a miRNA. B) In the ASNS mRNA, two 
miRNAs can interact with two active 5’TISs. C) In the TRAP1 mRNA the active aTIS overlaps the miR-149-
5p binding site and it is followed by at least one active dTIS. D) SRSF9 is an example of mRNA presenting a 
miRNA binding site overlapping an inactive aTIS, which is followed by active dTIS(s). E) VMP1 mRNA 
presents two active dTIS (data not shown), one of which, in frame with the aTIS. possibly interacts with a hsa-
miR-25-3p.*The aTIS (main ORF) is reported for reference also if it is non-active and/or non-overlapping 
miRNA binding sites.  
miRNA binding sites overlapping active 5’ TISs 
We identified 43 miRNAs whose binding sites overlap one of 64 TISs located in the 
5’UTR of one of 55 different mRNAs. Supplementary Files 3 and 4 report details 
regarding 55 involved genes and the results of functional enrichments. This group 
comprises genes encoding proteins regulating translation and involved in RNA splicing. 
Enriched Reactome pathways comprise Gap junction trafficking and regulation, Gap 
junction degradation, as well as Cell-extracellular matrix interactions, Adherens junctions 
interactions, Deadenylation-dependent mRNA decay, and Nonsense-Mediated Decay 
(NMD). 
An interesting example of mRNA in which a 5’ TISs can interact with miRNAs is ASNS, 
encoding Asparagine Synthetase (Table 3 B). hsa-miR-23a-3p and hsa-miR-17-5p 
binding sites overlap two different 5’TISs, directing the translation of uORFs. 
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miRNA binding sites overlapping active aTISs 
As said before, aTIS in 58 mRNAs (58 genes) are overlapping binding sites of 45 
different miRNAs, for a total of 68 possible interactions. Of these aTIS, 33 (48.5%) are 
associated to one or more additional active TIS included in the main ORF (dTIS). Figure 
5 shows that the majority of dTIS (22, 66.7% of mRNAs with active aTIS and dTIS(s) are 
in frame with the aTIS, and thus encode proteins differing for the N-terminal region from 
the main isoform. In 14 mRNAs we observed multiple dTIS in frame with the aTIS. The 
remaining cases are out of frame and encode totally different proteins, 7 with single dTIS 
out of frame and 4 mRNAs presenting more than one dTIS out of frame. In total, 18 
mRNAs present multiple dTISs active after an active aTIS (Figure 5)..  
 
 
 
Figure 5. Among mRNAs with aTIS putatively interacting with miRNAs in our dataset, one half are 
associated to active dTIS. The majority of dTIS are in frame with the aTIS, and thus encode proteins 
differing for the N-terminal region from the main isoform. In 23 mRNAs we observed multiple active dTIS 
in frame with the aTIS. The remaining cases are out of frame and encode totally different proteins, partly 
with a single dTIS out of frame and partly presenting more than one dTIS out of frame. Moreover, 28 
mRNAs present multiple dTISs active after an active aTIS. 
The enrichment results regarding genes with aTISs putatively interacting with miRNAs 
are similar to those obtained considering the whole set of genes. The most represented 
elements are constituent of the ribosome and proteins involved in either DNA packaging 
or in non-sense mediated RNA decay (Supplementary Files 3 and 4). Among possible 
miRNA-aTIS interactions we considered the example of TRAP1 (Table 3 C). This gene 
encodes for TNF Receptor Associated Protein 1, a mitochondrial chaperone (member of 
the heat shock protein 90 family), with ATPase activity that interacts with tumor necrosis 
factor type I and may  regulate cellular stress responses. hsa-miR-149-5p overlaps the 
TRAP1 main ORF start codon, that is followed by an active dTIS in frame with the main 
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ORF (705 amino acids), from which a N-term truncated peptide of 289 amino acids may 
be produced 
 
miRNA binding sites overlapping not active aTISs followed by 
active dTIS(s) 
We then considered those mRNAs with inactive aTISs followed by active dTIS (CDS). 
These case are of special interest since we can hypothesize that they represent mRNAs in 
which the aTIS was found inactive by GTI-seq experiments due to the binding of a 
miRNA covering the canonical aTIS. We found two genes in which the inactive aTIS is 
overlapping a miRNA-binding site and it is followed by one or more active dTIS: SRSF9 
(serine/arginine-rich splicing factor 9) and COG4 (component of oligomeric golgi 
complex 4), respectively interacting with hsa-miR-935 and hsa-miR-615-3p. SRSF9 
mRNA in an interesting example of a complex combination of ORFs: the same mRNA 
hosts, in addition to the aTIS one 5’TIS and three dTIS. According to data, the aTIS 
encoding a 221 residues peptide and overlapping hsa-miR-935 binding site is inactive, 
whereas the other TISs are active. In particular, among dTISs, two encode short (91 and 
64 residues) peptides and are out of frame respectively to the main ORF, whereas the 
third dTIS is in frame with the aTIS, corresponds to a 88 amino acids ORF and overlaps 
the binding site for hsa-miR-30d-5p. 
 
miRNA binding sites overlapping active dTISs 
Many considered mRNAs present ORFs included in the main annotated ORF, starting 
with dTISs. Among them, 93 mRNAs present one or more dTISs overlapped by the 
binding site one of 66 different miRNAs. Also in this group of genes we found many 
ribosomal proteins and histone genes, as well a few genes involved in cellular responses 
to stress (Supplementary Files 3 and 4).  
Table 3 E shows, as an example, that in the VMP1 mRNA, presenting two active dTISs, 
the second one, in frame with the main ORF (aTIS) overlaps hsa-miR-25-3p binding site. 
The main VMP1 ORF encodes the (multi-pass) vacuolar Membrane protein 1, a stress-
induced protein that plays a role in the initial stages of the autophagic process. When 
overexpressed, VMP1 promotes formation of intracellular vacuoles followed by cell 
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death. The alternative dTIS overlapping with hsa-miR-25-3p binding site hypothetically 
encodes a VMP1 isoform lacking the 14 N-terminal residues. 
 
Direct experimental evidence of functional 
miRNA-TIS interactions 
To further test the robustness of our hypothesis, we selected 10 putative miRNA-TIS 
interactions for experimental investigation using luciferase reporter assay. Selected 
interactions included 9 miRNA footprints putatively interacting with one of three 
different miRNAs (hsa-miR-23a-3p, hsa-miR-615-3p and has-miR-1226-3p) and 
overlapping different types of TISs (3 5’ TISs, 1 aTISs, and 6 dTISs) according to the 
above-described set of interactions. 
Moreover, we also considered JUNB (Jun B proto-oncogene, alias AP1) gene, in which 
the hsa-miR-1226-3p binding site (positions 32-49 in the mRNA, covering 18 nt) is only 
one nucleotide far from a 5’ TIS (positions 51-53 in the mRNA). As previously 
explained, the gene was not included in previous results since we used stringent criteria 
for the definition of putative miRNA-TIS interactions strictly focusing on cases in which 
the TIS is comprised in the stretch of nucleotides pairing with the miRNA. Since miR-
1226-3p is 26 nt long, we reasoned that the occupancy due to miRNA binding could 
anyhow influence the TIS usage. JunB plays key biological roles, since it regulates gene 
activity following the primary growth factor response. It is also associated with many 
diseases, including anaplastic large cell lymphoma, and it is related to key pathways, as 
mucin expression in cystic fibrosis via IL-6, IL-17 signaling pathways and G-protein 
signaling Ras family GTPases in kinase cascades. Moreover, a recent study about human 
endothelial cells activation (Schmid et al. 2013) reported evidence of translational control 
of JunB expression, and demonstrated that the variations of protein expression following 
activation are not attributable to transcriptional control through TFs. Due to the 
importance of JunB, and since this putative miRNA-TIS interaction represented an 
“extreme” case, we thought that it deserved experimental investigation.  
Supplementary File 5 contains detailed materials and methods regarding the validation 
experiments. In brief, for seven mRNAs (ASNS, EIF3B, EIF4G1, PPIA, RPS17, 
TAGLN2 and UQCC1) wild type miRNA footprint regions of around 100 nt were 
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obtained by PCR amplification of the HEK293T cells cDNA. For other three mRNAs 
(BAG66, JUNB, and RPL5), by annealing of synthetic oligonucleotides, both wild type 
and mutated miRNA footprint regions were obtained. Footprint regions were cloned in 
Dual-Luciferase miRNA Target Expression Vector. Each construct was co-transfected 
both with miRNA mimics and with scramble miRNA. All experiments were done in 
triplicate. 
The comparison of luciferase activity observed in mimics and scramble RNA co-
transfections showed a reduction of luciferase expression in 9 out of 10 tested wild type 
footprint sequences. In 6 cases, the difference is statistically significant with p-value < 
0.05 (Figure 6 A-B). These results indicate that all tested TIS (originally belonging to 
annotated, 5’ or downstream ORFs) are active and that in 60% of them the tested miRNA 
really binds to the footprint region suppressing the protein expression. 
 
Figure 6. Validations by Luciferase reporter assay of miRNA-mRNA interactions involving miRNA 
binding sites overlapping TISs. Panel A reports relative luciferase activity measurements (average and 
standard error) for co-transfections with miRNA mimics and with scramble miRNA (CTRL) of constructs 
containing, for each gene, the wild type miRNA footprint region overlapping the TIS. Below the gene name 
the type of TIS tested is indicated, whereas tested miRNAs are indicated on the top. Asterisks indicate 
statistically significant reductions of reporter expression (t-test p-value <0.05 *;  <0.01 **,  <0.001 ***). 
Panel B reports relative luciferase activity measurements for co-transfections with miRNA mimics and with 
scramble miRNA (CTRL) of constructs containing, for each gene, the wild type and the mutated (MM) 
miRNA footprint region overlapping the TIS, providing a rescue experiment for tested interactions. 
 
Moreover, rescue experiments, carried out for BAG66, JUNB, and RPL5, showed a 
complete restoration of expression when the miRNA mimics was co-transfected with 
constructs containing the mutated footprints. For the two interactions (RPL5/miR-615-3p 
and JUNB/miR-1226-3p) in which the mimics-induced silencing was statistically 
significant this result is particularly relevant. Experimental evidence demonstrates that 
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tested footprint regions are directly responsible for the miRNA-mRNA interaction 
probably interfering with protein synthesis. 
In summary, the validation experiments provided direct functional evidence of miRNA-
TIS interactions in 60% of tested cases, giving further support to the hypothesis that 
miRNA binding in regions overlapping with TISs can interfere with protein expression. 
 
Outlook 
The hypothesis that miRNAs could regulate alternative translation of many mRNAs is 
indirectly supported both by GTI-seq data providing information about the frequency of 
multiple and non-canonical active ORFs in human mRNAs and by the commonness of 
miRNA-mRNA binding outside 3’UTRs. The integration of the two types of evidence 
allowed us to identify many genes in which one or more miRNAs could interfere with 
translation of main annotated ORF or with ORFs located in the 5’ UTR respectively to 
the annotated ORF, or even downstream it. We demonstrated that miRNA-binding 
regions overlapping TISs are evolutionary conserved and that the miRNA footprints tend 
to overlap mRNA regions involved in RNA fold stabilization. We displayed how the 
binding of a miRNA to one of the TISs can produce different regulatory effects, 
according to the involved ORF types co(existing) in mRNAs, and to their regulatory 
relations. For each ORF type, we selected a few genes for which we provided 
experimental evidence of TIS activity. We obtained direct evidence of miRNA-TIS 
interaction causing suppression of protein expression in 60% of tested cases. Both in the 
experimentally investigated set of genes and in the largest group of putative interactions 
collected in this study, many interesting genes and miRNAs are represented that surely 
deserve further investigation, to better characterize the mechanisms of AT regulation by 
miRNAs. These studies will tell us if and how the miRNA-based regulation of mRNA 
alternative translation impact on cell processes and on disease.   
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Conclusions 
In this work we have extensively characterized miRNAs and other small RNAs under 
diverse points of view. 
We expanded the knowledge of miRNAs and moRNAs expressed by CD34+ cells and 
identified and validated a few elements that can contribute to PMF pathogenesis. We 
considered small RNA sequencing data of CD34+ cells of healthy subjects and PMF 
patients. In addition to 784 miRNAs annotated in miRBase, our in-house pipeline 
miR&moRe let us discover 34 new miRNAs expressed in our samples. Most miRNAs 
were expressed in their isoform variants, not as the annotated sequence. We also detected 
in CD34+ sequences aligning to hairpins outside known and novel miRNAs that 
correspond to expressed microRNA-offset RNAs, called moRNAs. Myeloproliferative 
disorders are clonal hematopoietic stem cell neoplasias, miRNAs and moRNAs 
deregulation can be implied in tumor physiopathology. We then looked for differentially 
expressed small RNAs in PMF CD34+ samples respect to control samples recognizing 37 
sRNAs with significant differentially expression (DE). Noteworthy, among them 2 
moRNAs are included and one was highly expressed in normal CD34+ cells but not 
detected at all in considered PMF samples. Very likely, moRNAs can function as 
miRNAs but biological roles and mechanisms of function still deserve investigation. We 
validated the differential expression of six selected DE on PMF granulocytes samples. 
Target predictions of these validated small RNA and functional enrichment analysis 
showed that miRNA targets are enriched in many interesting pathways involved in tumor 
development and progression, as signaling by FGFR, DAP12 signaling and Oncogene 
Induced Senescence. Hopefully identified and validated elements can help in the 
understanding the mechanisms that contribute to PMF pathogenesis and in formulating 
new targeted therapies. 
In order to have more awareness in applying normalization methods when managing 
RNA-seq data of small RNA dataset, we evaluated the performance of normalization 
algorithms formulated for long RNAs, applied to human small RNA datasets. We 
simulated multiple matrixes with a controlled number of differentially expressed 
elements. We chose five normalization methods among the most cited and widespread, 
implemented in R packages. Each algorithm is based on different hypothesis on statistical 
shape and characteristics of data and we tested their impact on the downstream analysis in 
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a differential expression test. To quantify normalization algorithms performances we 
calculated ROC curves and AUC curves. ROC curves showed that algorithms do not 
perform significantly differently applied to the same simulated scenarios and we are not 
able to definitively prefer a normalization algorithm as the best. All the algorithms 
produced a high false positive rate and AUC curves showed us only small differences in 
the performances. We are far from reaching the consensus on the best normalization 
algorithm and there is still room to improve normalization methods for RNA-seq analysis. 
We were later interested in studying whether different intracellular amounts of FHC 
might affect miRNA and gene expression profiles. As first step toward the dissection of 
the molecular basis of FHC-modulated gene expression, we performed an integrated 
analysis of miRNA and mRNA expression patterns in K562 FHC-silenced cells. By using 
a microRNA PCR Panel, we found that 4 out of 84 analysed miRNAs were consistently 
and significantly up-regulated in FHC-silenced cells. 
The profile of the four up-regulated miRNAs has been integrated with the transcriptome 
analysis by combining data obtained from the microRNA targets prediction software with 
a correlation-based approach. This analysis led to the identification of 91 down-regulated 
targets. IPA revealed that the highest scored pathways in which these genes are involved 
are: “Cell Death and Survival, Hematological System Development and Function, 
Hematopoiesis” and “DNA Replication, Recombination and Repair, Cell Cycle, Cancer”. 
It is interesting to note that, among the common pathways, “Cell Death and Survival” and 
“Hematological System Development and Function” rely on the ERK1/2 activation that 
our results demonstrate to be severely affected by FHC modulation. In conclusion, we 
believe that the identification of FHC-dependent miRNA/mRNA networks implies that 
different amounts of the ferritin subunit contribute, in K562 cells, to the remodelling of 
gene expression taking place during these cellular processes through the action of let-7g, 
let-7f, let-7i and miR-125b 
The hypothesis that miRNAs could regulate alternative translation of many mRNAs is 
indirectly supported by the integration of the two types of evidence: the multiple and non-
canonical active ORFs in human mRNAs, provided by GTI-seq data, and miRNA-mRNA 
binding outside 3’UTRs using CLASH technique data. Looking for overlapping regions 
in both the experimental evidences, we identified many genes in which one or more 
miRNAs could interfere with translation of ORF. These regions are evolutionary 
conserved and the miRNA footprints tend to overlap mRNA regions involved in RNA 
fold stabilization. We selected most significant genes and we provided experimental 
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evidence of miRNA-TIS interaction causing suppression of RNA expression in 60% of 
tested cases. This non canonical miRNA function surely deserve further investigation, to 
better characterize the mechanisms of AT regulation.  
miRNAs appear key modulators of information and understanding the interplay of 
miRNAs and DNA, coding RNA or other targeted elements is crucial. Although a general 
picture of miRNAs-mediated pathway is emerging, many questions remain. Further 
studies need to be performed to elucidate post-transcriptional and transcriptional role of 
miRNAs in different processes and diseases. 
 
